Document:

Exhibit 10.1

 Exhibit 10.1 
 EXECUTION COPY 
 U.S. $250,000,000 

TERM LOAN AGREEMENT 
 Dated as of September 18, 2012 
 among 

COMPUTER SCIENCES CORPORATION 
 as Borrower 
 and 

THE BANKS NAMED HEREIN 
 as Lenders 
 and 

THE BANK OF TOKYO-MITSUBISHI UFJ, LTD. 
 as Administrative Agent 
 BANK OF AMERICA, N.A. 

as Syndication Agent 
 THE BANK OF TOKYO-MITSUBISHI UFJ, LTD. 
 MERRILL LYNCH, PIERCE,
FENNER & SMITH INCORPORATED 
 as Joint Lead Arrangers and Joint Bookrunners 

 Table of Contents 

 

							
	 	    	 	  	Page	 
		
	ARTICLE I DEFINITIONS AND ACCOUNTING TERMS	  	 	1	  
			
	 Section 1.01
	    	Certain Defined Terms	  	 	1	  
			
	 Section 1.02
	    	Computation of Time Periods	  	 	12	  
			
	 Section 1.03
	    	Accounting Terms	  	 	12	  
		
	ARTICLE II AMOUNTS AND TERMS OF THE ADVANCES	  	 	13	  
			
	 Section 2.01
	    	The Advances	  	 	13	  
			
	 Section 2.02
	    	Making the Advances	  	 	13	  
			
	 Section 2.03
	    	[Reserved]	  	 	16	  
			
	 Section 2.04
	    	Fees	  	 	16	  
			
	 Section 2.05
	    	Optional Reduction of the Commitments	  	 	16	  
			
	 Section 2.06
	    	Repayment and Prepayment of Advances	  	 	16	  
			
	 Section 2.07
	    	Interest on Advances	  	 	17	  
			
	 Section 2.08
	    	Interest Rate Determination	  	 	18	  
			
	 Section 2.09
	    	Voluntary Conversion or Continuation of Advances	  	 	18	  
			
	 Section 2.10
	    	Increased Costs	  	 	19	  
			
	 Section 2.11
	    	Payments and Computations	  	 	20	  
			
	 Section 2.12
	    	Taxes	  	 	21	  
			
	 Section 2.13
	    	Sharing of Payments, Etc.	  	 	25	  
			
	 Section 2.14
	    	Evidence of Debt	  	 	25	  
			
	 Section 2.15
	    	Use of Proceeds	  	 	26	  
			
	 Section 2.16
	    	Increased Commitments; Additional Lenders	  	 	26	  
			
	 Section 2.17
	    	Substitution of Lenders	  	 	27	  
			
	 Section 2.18
	    	Defaulting Lenders	  	 	28	  
			
	 Section 2.19
	    	Special Purpose Funding Vehicles	  	 	29	  
		
	ARTICLE III CONDITIONS OF LENDING	  	 	30	  
			
	 Section 3.01
	    	Condition Precedent to Effective Date	  	 	30	  
			
	 Section 3.02
	    	Conditions Precedent to Each Borrowing	  	 	30	  
		
	ARTICLE IV REPRESENTATIONS AND WARRANTIES	  	 	31	  
			
	 Section 4.01
	    	Representations and Warranties of the Borrower	  	 	31	  
		
	ARTICLE V COVENANTS	  	 	34	  
			
	 Section 5.01
	    	Affirmative Covenants of the Borrower	  	 	34	  

  
 1 

							
			
	 Section 5.02
	    	Negative Covenants of the Borrower	  	 	37	  
		
	ARTICLE VI EVENTS OF DEFAULT	  	 	39	  
			
	 Section 6.01
	    	Events of Default	  	 	39	  
		
	ARTICLE VII THE AGENT	  	 	42	  
			
	 Section 7.01
	    	Authorization and Authority	  	 	42	  
			
	 Section 7.02
	    	Agent Individually	  	 	42	  
			
	 Section 7.03
	    	Duties of Agent; Exculpatory Provisions	  	 	43	  
			
	 Section 7.04
	    	Reliance by Agent	  	 	44	  
			
	 Section 7.05
	    	Indemnification	  	 	44	  
			
	 Section 7.06
	    	Resignation of Agent	  	 	45	  
			
	 Section 7.07
	    	Delegation of Duties	  	 	45	  
			
	 Section 7.08
	    	Non-Reliance on Agent and Other Lenders	  	 	46	  
			
	 Section 7.09
	    	Other Agents	  	 	47	  
		
	ARTICLE VIII MISCELLANEOUS	  	 	47	  
			
	 Section 8.01
	    	Amendments, Etc.	  	 	47	  
			
	 Section 8.02
	    	Notices, Etc.	  	 	47	  
			
	 Section 8.03
	    	No Waiver; Remedies	  	 	49	  
			
	 Section 8.04
	    	Costs, Expenses and Indemnification	  	 	49	  
			
	 Section 8.05
	    	Right of Set-off	  	 	50	  
			
	 Section 8.06
	    	Binding Effect	  	 	51	  
			
	 Section 8.07
	    	Assignments and Participations	  	 	51	  
			
	 Section 8.08
	    	Governing Law	  	 	53	  
			
	 Section 8.09
	    	Execution in Counterparts	  	 	53	  
			
	 Section 8.10
	    	Consent to Jurisdiction; Waiver of Immunities	  	 	53	  
			
	 Section 8.11
	    	Waiver of Trial by Jury	  	 	54	  
			
	 Section 8.12
	    	Survival of Warranties	  	 	54	  
			
	 Section 8.13
	    	Severability	  	 	54	  
			
	 Section 8.14
	    	Headings	  	 	54	  
			
	 Section 8.15
	    	Website Communications	  	 	55	  
			
	 Section 8.16
	    	USA PATRIOT Act Notice	  	 	56	  
			
	 Section 8.17
	    	Confidentiality	  	 	56	  
			
	 Section 8.18
	    	No Fiduciary Duty	  	 	57	  

  
 2 

							
	SCHEDULES	  			
	 Schedule I
	 	List of Applicable Lending Offices	  	 	I-1	  
	 Schedule II
	 	Lenders’ Commitments	  	 	II-1	  
			
	EXHIBITS	 		  			
			
	 Exhibit A
	 	Form of Notice of Borrowing	  	 	A-1-1	  
	 Exhibit B
	 	Form of Assignment and Acceptance	  	 	B-1	  
	 Exhibit C
	 	Form of Opinion of M. Louise Turilli, Esq., Counsel for the Borrower	  	 	C-1	  

  
 3 

 TERM LOAN AGREEMENT 

Dated as of September 18, 2012 
 This TERM LOAN AGREEMENT is entered into as of September 18, 2012, among Computer Sciences Corporation, a Nevada corporation (the “Borrower”), the financial institutions (the
“Banks”) listed on Schedule II hereof, and The Bank of Tokyo-Mitsubishi UFJ, Ltd. (“BTMU”), as administrative agent (the “Agent”) for the Lenders hereunder. 

In consideration of the premises and the agreements, provisions and covenants herein contained, the Borrower, the Lenders and the Agent
agree as follows: 
 ARTICLE I 
 DEFINITIONS AND ACCOUNTING TERMS 
 Section 1.01
Certain Defined Terms. As used in this Agreement, the following terms shall have the following meanings (such meanings to be equally applicable to both the singular and plural forms of the terms defined): 

“Advance” means an advance by a Lender to the Borrower as part of a Borrowing and refers to a Base Rate
Advance or a Eurodollar Rate Advance, each of which shall be a “Type” of Advance. 

“Affiliate” means, as to any Person, any other Person that, directly or indirectly, controls, is
controlled by or is under common control with such Person or is a director or executive officer (as such term is used in Regulation S-K promulgated under the Securities Act of 1933, as amended) of such Person. 

“Agreement” means this Term Loan Agreement, as this Term Loan Agreement may be amended, supplemented or
otherwise modified from time to time. 
 “Applicable Lending Office” means, with respect to each
Lender, such Lender’s Domestic Lending Office in the case of a Base Rate Advance, and such Lender’s Eurodollar Lending Office in the case of a Eurodollar Rate Advance. 

“Applicable Margin” means, for any period for which any interest payment is to be made with respect to
any Advance, the interest rate per annum derived by dividing (i) the sum of the Daily Margins for each of the days included in such period by (ii) the number of days included in such period. 

“Assignment and Acceptance” means an assignment and acceptance entered into by a Lender and an Eligible
Assignee, and accepted by the Agent, in substantially the form of Exhibit B hereto. 
 “Availability
Termination Date” means February 16, 2013 (or if such date is not a Business Day, the immediately preceding Business Day). 

  
 1 

 “Banks” means the Banks listed on Schedule II hereof.

 “Base Rate” means, for any period, a fluctuating interest rate per annum as shall be in
effect from time to time which rate per annum shall at all times be equal to the highest of: 
 (a) the Prime
Rate; 
 (b) 1/2 of one percent per annum above the Federal Funds Rate; and 

(c) the rate equal to the Eurodollar Rate based on an Interest Period of one month determined for each day that a Base
Rate Advance is outstanding (and in respect of any day that is not a London Banking Day, such rate as in effect on the immediately preceding London Banking Day) plus 1.00% per annum. 

“Base Rate Advance” means an Advance which bears interest as provided in Section 2.07(a).

 “Borrower” means Computer Sciences Corporation, a Nevada corporation. 

“Borrowing” means a borrowing consisting of Advances of the same Type made by each of the Lenders
pursuant to Section 2.01 on the same day to the Borrower pursuant to the same Notice of Borrowing. 

“BTMU” means The Bank of Tokyo-Mitsubishi UFJ, Ltd. 

“Business Day” means a day of the year on which banks are not required or authorized to close in New York
City and, if the applicable Business Day relates to any Eurodollar Rate Advances, on which dealings are carried on in the London interbank market. 
 “Capital Lease” means, with respect to any Person, any lease of any property by that Person as lessee which would, in conformity with GAAP, be required to be accounted for as a capital
lease on the balance sheet of that Person. 
 “Code” means the Internal Revenue Code of 1986, as
amended. 
 “Commitment” means, as to each Lender, the amount set opposite such Lender’s
name on Schedule II hereto or, if such Lender has entered into any Assignment and Acceptance, set forth for such Lender in the Register maintained by the Agent pursuant to Section 8.07(c), as such amount may be reduced pursuant to
Section 2.05 or increased pursuant to Section 2.16. 
 “Consolidated EBITDA” means,
for any period the sum of (a) net income, plus (b) taxes on income, plus (c) Consolidated Interest Expense, plus (d) depreciation expense, plus (e) amortization expense of goodwill, financing
costs and other intangibles, plus (f) extraordinary losses, plus (g) other non-cash charges to the extent deducted from net income, minus extraordinary gains. 

  
 2 

 “Consolidated Interest Expense” means, for any period,
total interest expense (including that portion attributable to Capital Leases in accordance with GAAP and capitalized interest) of the Borrower and its Subsidiaries on a consolidated basis with respect to all outstanding Debt of the Borrower and its
Subsidiaries, including all commissions, discounts and other fees and charges owed with respect to letters of credit and bankers’ acceptance financing, net costs under Interest Rate Agreements and amounts referred to in Section 2.04
payable to the Agent and the Lenders that are considered interest expense in accordance with GAAP, but excluding, however, any such amounts referred to in Section 2.04 payable on or before the Effective Date. 

“Consolidated Total Debt” means, as of any date of determination, all Debt (excluding Equity-linked Debt)
of the Borrower and its Subsidiaries on a consolidated basis. 
 “Convert,”
“Conversion” and “Converted” each refers to a conversion of Advances of one Type into Advances of another Type pursuant to Section 2.09. 

“Customary Permitted Liens” means, with respect to any Person, any of the following Liens: 

(a) Liens with respect to the payment of taxes, assessments or governmental charges in each case that are not yet due or
that are being contested in good faith by appropriate proceedings and with respect to which adequate reserves or other appropriate provisions are being maintained to the extent required by GAAP; 

(b) Liens of landlords arising by statute or lease contracts entered into in the ordinary course, inchoate, statutory or
construction liens, and liens of suppliers, mechanics, carriers, materialmen, warehousemen, producers, operators or workmen and other liens imposed by law created in the ordinary course of business for amounts not yet due or that are being contested
in good faith by appropriate proceedings and with respect to which adequate reserves or other appropriate provisions are being maintained to the extent required by GAAP; 

(c) liens, pledges or deposits made in the ordinary course of business in connection with workers’ compensation,
unemployment insurance or other types of social security benefits, taxes, assessments, statutory obligations or other similar charges or to secure the performance of bids, tenders, sales, leases, contracts (other than for the repayment of borrowed
money) or in connection with surety, appeal, customs or performance bonds or other similar instruments; 
 (d)
encumbrances arising by reason of zoning restrictions, easements, licenses, reservations, covenants, rights-of-way, utility easements, building restrictions and other similar encumbrances on the use of real property not materially detracting from
the value of such real property and not materially interfering with the ordinary conduct of the business conducted at such real property; 

  
 3 

 (e) encumbrances arising under leases or subleases of real property that do
not, individually or in the aggregate, materially detract from the value of such real property or materially interfere with the ordinary conduct of the business conducted at such real property; and 

(f) financing statements with respect to a lessor’s rights in and to personal property leased to such Person in the
ordinary course of such Person’s business. 
 “Daily Margin” means, for any date of
determination, the interest rate per annum set forth in the table below that corresponds to (i) the Level applicable to the Borrower in respect of its Rating established by S&P and Moody’s as set forth below for such date of
determination and (ii) the Type of Advance: 
  

					
	 	  	Daily Margin for Eurodollar Rate
Advances	 	Daily Margin for Base
Rate Advances
	 Level 1
	  	1.250%	 	0.250%
	 Level 2
	  	1.500%	 	0.500%
	 Level 3
	  	1.875%	 	0.875%
	 Level 4
	  	2.250%	 	1.250%
	 Level 5
	  	2.500%	 	1.500%

 For purposes of this definition, (a) if any change in the Rating established by
S&P or Moody’s shall result in a change in the Level, the change in the Daily Margin shall be effective as of the date on which such rating change is publicly announced by S&P or Moody’s, as the case may be, (b) if Ratings are
available from only one of S&P or Moody’s, then the applicable Level shall be set by reference to this one Rating, (c) if Ratings are available from each of S&P and Moody’s and such Ratings fall within two different Levels,
then the higher of such Ratings shall apply, unless there is a split in such Ratings of more than one Level, in which case the Level that is one Level higher than the Level of the lower Rating shall apply, (d) if Ratings are unavailable from
S&P and Moody’s for any reason other than such agencies cease providing public debt ratings generally for any day, then the applicable Level for such day shall be deemed to be Level 5; and (e) if either of S&P or Moody’s
change the basis on which their ratings are established and or described, each reference in this Agreement to a Rating announced by S&P or Moody’s, as the case may be, shall be deemed to refer to the then equivalent rating established by
S&P or Moody’s. 
 “Debt” means, with respect to any Person, (a) indebtedness of
such Person for borrowed money, (b) obligations of such Person evidenced by bonds, debentures, notes or other similar instruments and (c) obligations of such Person as lessee under Capital Leases; provided that “Debt”
shall not include borrowings against the cash surrender value of life insurance policies covering employees of the Borrower or its Affiliates and 

  
 4 

 
owned by the Borrower so long as (i) recourse for such borrowings is limited to such policies and the proceeds thereof and (ii) any value assigned to such policies on the consolidated
financial statements of the Borrower and its Subsidiaries is net of the amount of such borrowings. 

“Defaulting Lender” means at any time, subject to Section 2.18(c), (i) any Lender that has
failed for three or more Business Days to comply with its obligations under this Agreement to make an Advance, unless such Lender has notified the Agent and the Borrower in writing that such failure is the result of such Lender’s determination
that one or more conditions precedent to funding has not been satisfied (which conditions precedent, together with the applicable default, if any, will be specifically identified in such writing), (ii) any Lender that has notified the Agent or
the Borrower in writing, or has stated publicly, that it does not intend to comply with its funding obligations hereunder, (iii) any Lender that has defaulted on its funding obligations under other loan agreements or credit agreements generally
under which it has commitments to extend credit or that has notified, or whose Parent Company has notified, the Agent or the Borrower in writing, or has stated publicly, that it does not intend to comply with its funding obligations under loan
agreements or credit agreements generally, (iv) any Lender that has, for three or more Business Days after written request of the Agent or the Borrower, failed to confirm in writing to the Agent and the Borrower that it will comply with its
prospective funding obligations hereunder (provided that such Lender will cease to be a Defaulting Lender pursuant to this clause (iv) upon the Agent’s and the Borrower’s receipt of such written confirmation), or (v) any Lender
with respect to which a Lender Insolvency Event has occurred and is continuing with respect to such Lender or its Parent Company; provided that a Lender Insolvency event shall not be deemed to occur with respect to a Lender or its Parent
Company solely as a result of the acquisition or maintenance of an ownership interest in such Lender or Parent Company by a governmental authority or instrumentality thereof. Any determination by the Agent that a Lender is a Defaulting Lender
under any of clauses (i) through (v) above will be conclusive and binding absent manifest error, and such Lender will be deemed to be a Defaulting Lender (subject to Section 2.18(c)) upon notification of such determination by the
Agent to the Borrower and the Lenders. 
 “Domestic Lending Office” means, with respect to any
Lender, the office of such Lender specified as its “Domestic Lending Office” opposite its name on Schedule I hereto or in the Assignment and Acceptance pursuant to which it became a Lender, or such other office of such Lender as such
Lender may from time to time specify to the Borrower and the Agent. 
 “Effective Date” means
September 18, 2012, so long as the conditions precedent set forth in Section 3.01 have been satisfied or waived by the Banks and the Agent. 
 “Eligible Assignee” means any financial institution or entity engaged in the business of extending revolving credit approved in writing by the Borrower (so long as no Potential Event of
Default or Event of Default then exists and is continuing) and the Agent as an Eligible Assignee for purposes of this Agreement; provided that (i) the Borrower shall be deemed to have approved an assignment unless it shall have objected

  
 5 

 
to such assignment within five Business Days after having notice thereof, and (ii) the Borrower’s and the Agent’s approval shall not be unreasonably withheld or delayed;
provided further that no such approval shall be required in the case of an assignment by a Lender to an Affiliate of such Lender or to another Lender; provided further that notwithstanding the foregoing,
“Eligible Assignee” shall not include the Borrower or any of the Borrower’s Affiliates or Subsidiaries. 
 “Employee Benefit Plan” means any “employee benefit plan” as defined in Section 3(3) of ERISA which is or was maintained or contributed to by the Borrower, its Subsidiaries
or any of its ERISA Affiliates. 
 “Environmental Law” means any and all statutes, laws,
regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or other governmental restrictions of any federal, state or local governmental authority within the United States or any State
or territory thereof and which relate to the pollution or protection of the environment or the release of any hazardous materials into the environment. 
 “Equity-linked Debt” means Debt that is required to be converted at, or prior to, maturity into equity securities of the Borrower. 

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time to time, and the
regulations promulgated and rulings issued thereunder. 
 “ERISA Affiliate” means any Person
who for purposes of Title IV of ERISA is a member of the Borrower’s controlled group, or under common control with the Borrower, within the meaning of Section 414 of the Code and the regulations promulgated and rulings issued
thereunder. Any former ERISA Affiliate of the Borrower or its Subsidiaries shall continue to be considered an ERISA Affiliate within the meaning of this definition with respect to the period such entity was an ERISA Affiliate of the Borrower or its
Subsidiaries and with respect to liabilities arising after such period for which the Borrower or its Subsidiaries could be liable under the Code or ERISA. 
 “ERISA Event” means (a) the occurrence of a reportable event, within the meaning of Section 4043 of ERISA, unless the 30-day notice requirement with respect thereto has been
waived by the PBGC; (b) the provision by the administrator of any Pension Plan of a notice of intent to terminate such Pension Plan pursuant to Section 4041(a)(2) of ERISA (including any such notice with respect to a plan amendment
referred to in Section 4041(e) of ERISA); (c) the cessation of operations at a facility in the circumstances described in Section 4062(e) of ERISA; (d) the withdrawal by the Borrower or an ERISA Affiliate from a Multiple Employer
Plan during a plan year for which it was a substantial employer, as defined in Section 4001(a)(2) of ERISA; (e) the failure by the Borrower or any ERISA Affiliate to make a payment to a Pension Plan required under Section 303(k) of
ERISA, which Section imposes a lien for failure to make required payments; (f) the institution by the PBGC of proceedings to terminate a Pension Plan, pursuant to Section 4042 of ERISA, or the occurrence of any event or condition
which, in the reasonable judgment of the Borrower, might constitute grounds 

  
 6 

 
under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, a Pension Plan; (g) the withdrawal by the Borrower or any ERISA Affiliate from any
Multiemployer Plan or the termination of such Multiemployer Plan resulting in liability pursuant to Title IV of ERISA; or (h) a determination that any Pension Plan is, or is expected to be, in “at-risk” status (within the meaning of
Section 303(i)(4)(A) of ERISA or Section 430(i)(4)(A) of the Code). 
 “Eurocurrency
Liabilities” has the meaning assigned to that term in Regulation D of the Board of Governors of the Federal Reserve System, as in effect from time to time. 

“Eurodollar Lending Office” means, with respect to any Lender, the office of such Lender specified as its
“Eurodollar Lending Office” opposite its name on Schedule I hereto or in the Assignment and Acceptance pursuant to which it became a Lender (or, if no such office is specified, its Domestic Lending Office), or such other office of such
Lender as such Lender may from time to time specify to the Borrower and the Agent. 
 “Eurodollar
Rate” means, for any Interest Period for each Eurodollar Rate Advance comprising part of the same Borrowing, an interest rate per annum equal to (a) the rate determined by the Agent to be the offered rate that appears on the page of
the Reuters screen that displays an average British Bankers Association Interest Settlement Rate for deposits in U.S. dollars (for delivery on the first day of such Interest Period) with a term equivalent to such Interest Period, determined as of
approximately 11:00 a.m. (London time) on the date two Business Days prior to the commencement of such Interest Period; (b) in the event the rate referenced in the preceding clause (a) does not appear on such page or service or such
page or service shall cease to be available, the rate per annum equal to the rate determined by the Agent to be the offered rate on such other page or other service that displays an average British Bankers Association Interest Settlement Rate for
deposits in U.S. dollars (for delivery on the first day of such Interest Period) with a term equivalent to such Interest Period, determined as of approximately 11:00 a.m. (London time) on the date two Business Days prior to the commencement of such
Interest Period, or (c) in the event the rates referenced in the preceding clauses (a) and (b) are not available, the rate per annum determined by the Agent as the rate of interest (rounded upward to the next 1/100th of 1%) at which
deposits in U.S. dollars for delivery on the first day of such Interest Period in same day funds in the approximate amount of the Eurodollar Rate Advance being made, continued or converted by BTMU and with a term equivalent to such Interest Period
would be offered by BTMU to major banks in the London interbank market at their request at approximately 11:00 a.m. (London time) on the date two Business Days prior to the commencement of such Interest Period. 

“Eurodollar Rate Advance” means an Advance which bears interest as provided in Section 2.07(b).

 “Eurodollar Rate Reserve Percentage” of any Lender for any Interest Period for any Eurodollar
Rate Advance means the reserve percentage applicable during such Interest Period (or if more than one such percentage shall be so applicable, the daily average of such percentages for those days in such Interest Period during which any such
percentage shall be so applicable) under regulations issued from time to time by the 

  
 7 

 
Board of Governors of the Federal Reserve System (or any successor) for determining the maximum reserve requirements (including, without limitation, any emergency, supplemental or other marginal
reserve requirement) for such Lender with respect to liabilities or assets consisting of or including Eurocurrency Liabilities having a term equal to such Interest Period. 

“Events of Default” has the meaning specified in Section 6.01. 

“Exchange Act Report” means, collectively, the Annual Reports of the Borrower on Form 10-K, from time to
time, and Quarterly Reports on Form 10-Q, from time to time, and Reports on Form 8-K of the Borrower filed with or furnished to the SEC from time to time. 
 “Excluded Taxes” has the meaning specified in Section 2.12. 
 “FATCA” means Sections 1471 though 1474 of the Code, as of the date hereof, and any Treasury regulations promulgated with respect thereto and official interpretations thereof. 

“Federal Funds Rate” means, for any period, a fluctuating interest rate per annum equal for each day
during such period to the weighted average of the rates on overnight Federal funds transactions with members of the Federal Reserve System arranged by Federal funds brokers, as published for such day (or, if such day is not a Business Day, for the
next preceding Business Day) by the Federal Reserve Bank of New York, or, if such rate is not so published for any day which is a Business Day, the average of the quotations for such day on such transactions received by the Agent from three Federal
funds brokers of recognized standing selected by it. 
 “GAAP” means generally accepted
accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such
other statements by such other entity as may be approved by a significant segment of the accounting profession, which are applicable to the circumstances as of the date of determination. 

“Granting Lender” has the meaning specified in Section 2.19. 

“Indemnified Taxes” has the meaning specified in Section 2.12. 

“Increase Effective Date” has the meaning specified in Section 2.16(c). 

“Insufficiency” means, with respect to any Pension Plan, the amount, if any, of its unfunded benefit
liabilities, as defined in Section 4001(a)(18) of ERISA. 
 “Interest Period” means, for
each Eurodollar Rate Advance comprising part of the same Borrowing, the period commencing on the date of such Eurodollar Rate Advance, or on the date of continuation of such Advance as a Eurodollar Rate Advance upon expiration of successive Interest
Periods applicable thereto, or on the date of Conversion 

  
 8 

 
of a Base Rate Advance into a Eurodollar Rate Advance, and ending on the last day of the period selected by the Borrower pursuant to the provisions hereof. The duration of each such Interest
Period shall be one, two, three or six months, as the Borrower may select in the Notice of Borrowing or the Notice of Conversion/Continuation for such Advance; provided, however, that: 

(a) the Borrower may not select any Interest Period which ends after the Maturity Date; 

(b) Interest Periods commencing on the same date for Advances comprising part of the same Borrowing shall be of the same
duration; and 
 (c) whenever the last day of any Interest Period would otherwise occur on a day other than a
Business Day, the last day of such Interest Period shall be extended to occur on the next succeeding Business Day, provided, that if such extension would cause the last day of such Interest Period to occur in the next following calendar
month, the last day of such Interest Period shall occur on the next preceding Business Day. 
 “Interest
Rate Agreement” means any interest rate swap agreement, interest rate cap agreement, interest rate collar agreement or other similar agreement or arrangement to which the Borrower or any of its Subsidiaries is a party. 

“Lender Insolvency Event” means that (i) a Lender or its Parent Company is insolvent, or is
generally unable to pay its debts as they become due, or admits in writing its inability to pay its debts as they become due, or makes a general assignment for the benefit of its creditors, or (ii) such Lender or its Parent Company is the
subject of a bankruptcy, insolvency, reorganization, liquidation or similar proceeding, or a receiver, trustee, conservator, intervenor or sequestrator or the like has been appointed for such Lender or its Parent Company, or such Lender or its
Parent Company has taken any action in furtherance of or indicating its consent to or acquiescence in any such proceeding or appointment. 
 “Lenders” means the Banks listed on Schedule II hereof and each Eligible Assignee that shall become a party hereto pursuant to Section 8.07. 

“Level” means Level 1, Level 2, Level 3, Level 4 or Level 5, as the case may be. 

“Level 1” means that, as of any date of determination, the applicable Rating is equal to or better than
A- (in the case of a Rating from S&P) or A3 (in the case of a Rating from Moody’s), as applicable, as of such date of determination. 
 “Level 2” means that, as of any date of determination, the applicable Rating is equal to BBB+ (in the case of a Rating from S&P) or Baa1 (in the case of a Rating from Moody’s),
as applicable, as of such date of determination. 

  
 9 

 “Level 3” means that, as of any date of determination, the
applicable Rating is equal to BBB (in the case of a Rating from S&P) or Baa2 (in the case of a Rating from Moody’s), as applicable, as of such date of determination. 

“Level 4” means that, as of any date of determination, the applicable Rating is equal to BBB- (in the
case of a Rating from S&P) or Baa3 (in the case of a Rating from Moody’s), as applicable, as of such date of determination. 
 “Level 5” means that, as of any date of determination, the applicable Rating is equal to or below BB+ (in the case of a Rating from S&P) or, Ba1 (in the case of a Rating from
Moody’s), as applicable, as of such date of determination, or the only Rating is a private rating and the Borrower will not authorize the applicable rating agency to make such Rating available to the Agent and the Lenders. 

“Lien” means any lien, mortgage, pledge, security interest, charge or encumbrance of any kind (including
any interest of a vendor or lessor under any conditional sale or other title retention agreement and any lease in the nature thereof). 
 “Long-Term Debt” means senior, unsecured, non-credit enhanced, long-term debt securities of the Borrower. 

“Majority Lenders” means at any time Lenders holding greater than 50% of the then aggregate unpaid
principal amount of the Advances held by all Lenders, or, if no such principal amount is then outstanding, Lenders having greater than 50% of the all of the Commitments (provided that, for purposes hereof, neither the Borrower, nor any of its
Affiliates, if a Lender, nor any Defaulting Lender, shall be included in (a) the Lenders holding such amount of the Advances or having such amount of the Commitments or (b) determining the aggregate unpaid principal amount of the Advances
or the total Commitments). 
 “Maturity Date” means September 18, 2016 (or if such date is not a
Business Day, the immediately preceding Business Day). 
 “Moody’s” means Moody’s
Investors Service, Inc. and any successor thereto. 
 “Multiemployer Plan” means a
“multiemployer plan” as defined in Section 4001(a)(3) of ERISA to which the Borrower or any ERISA Affiliate of the Borrower is making, or is obligated to make, contributions or has within any of the preceding six plan years been
obligated to make or accrue contributions. 
 “Multiple Employer Plan” means a single employer
plan, as defined in Section 4001(a)(15) of ERISA, which (a) is maintained for employees of the Borrower or an ERISA Affiliate and at least one Person other than the Borrower and its ERISA Affiliates or (b) was so maintained and in
respect of which the Borrower or an ERISA Affiliate could have liability under Section 4063, 4064 or 4069 of ERISA in the event such plan has been or were to be terminated. 

  
 10 

 “Non-Consenting Lender” means any Lender that does not
approve any consent, waiver or amendment that (i) requires the approval of all affected Lenders in accordance with the terms of Section 8.01 and (ii) has been approved by the Majority Lenders. 

“Non-Defaulting Lender” means, at any time, a Lender that is not a Defaulting Lender. 

“Notice of Borrowing” has the meaning specified in Section 2.02(a). 

“Notice of Conversion/Continuation” has the meaning specified in Section 2.09. 

“Parent Company” means, with respect to a Lender, the bank holding company (as defined in Federal Reserve
Board Regulation Y), if any, of such Lender, or if such Lender does not have a bank holding company, then any corporation, association, partnership or other business entity owning, beneficially or of record, directly or indirectly, a majority of the
shares of such Lender. 
 “PBGC” means the U.S. Pension Benefit Guaranty Corporation.

 “Pension Act” means the Pension Protection Act of 2006, as amended. 

“Pension Plan” means a Single Employer Plan or a Multiple Employer Plan or both. 

“Person” means an individual, partnership, corporation, business trust, joint stock company, trust,
unincorporated association, joint venture or other entity, or a government or any political subdivision or agency thereof. 
 “Potential Event of Default” means a condition or event which, after notice or lapse of time or both, would constitute an Event of Default if that condition or event were not cured or
removed within any applicable grace or cure period. 
 “Prime Rate” means the rate of interest
quoted in The Wall Street Journal, Money Rates Section as the prime rate, as in effect from time to time. If the Wall Street Journal ceases publication of such rate, then the Prime Rate means such rate listed in a publication or service and selected
by BTMU in its reasonable judgment as most nearly approximates the foregoing (which rate is not intended to be the lowest rate of interest charged by BTMU in connection with extensions of credit to debtors). 

“Rating” means as of any date, the public rating that has been most recently announced by any of S&P
or Moody’s, as the case may be, with respect to the Long-Term Debt, or if any such rating agency shall have issued more than one such public rating, the lowest such public rating issued by such rating agency. 

“Register” has the meaning specified in Section 8.07(c). 

  
 11 

 “Related Parties” means, with respect to any Person, such
Person’s Affiliates and the partners, directors, officers, employees, agents and advisors of such Person and of such Person’s Affiliates. 
 “S&P” means Standard & Poor’s Ratings Group and any successor thereto. 
 “SEC” means the Securities and Exchange Commission and any successor agency. 
 “Significant Subsidiary” means, at any time, any Subsidiary of the Borrower which accounts for more than 5% of consolidated total assets or 5% of consolidated revenue of the Borrower
determined in accordance with GAAP. 
 “Single Employer Plan” means a single employer plan, as
defined in Section 4001(a)(15) of ERISA, which (a) is maintained for employees of the Borrower or any ERISA Affiliate and no Person other than the Borrower and its ERISA Affiliates or (b) was so maintained and in respect of which the
Borrower or an ERISA Affiliate could have liability under Section 4062 or 4069 of ERISA in the event such plan has been or were to be terminated. 
 “SPC” has the meaning specified in Section 2.19. 
 “Subsidiary” of any Person means any corporation, association, partnership or other business entity of which at least 50% of the total voting power of shares of stock or other securities
entitled to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of that Person or a combination thereof. Unless otherwise
specified, all references herein to a “Subsidiary” or to “Subsidiaries” shall refer to a Subsidiary or Subsidiaries of the Borrower. 
 “Taxes” has the meaning specified in Section 2.12. 
 “Type” means, with reference to an Advance, a Base Rate Advance or a Eurodollar Rate Advance. 
 “Withdrawal Liability” has the meaning given such term under Part I of Subtitle E of Title IV of ERISA. 

Section 1.02 Computation of Time Periods. In this Agreement in the computation of periods of time from a
specified date to a later specified date, the word “from” means “from and including” and the words “to” and “until” each means “to but excluding”. 

Section 1.03 Accounting Terms. All accounting terms not specifically defined herein shall be construed
in accordance with GAAP consistent with those applied in the preparation of the financial statements referred to in Section 4.01(e). All computations determining compliance with financial covenants or terms, including definitions used therein,
shall be prepared in accordance with generally accepted accounting principles in effect at the time of the preparation of, and in conformity with those used to prepare, the historical financial

  
 12 

 
statements delivered to the Lenders pursuant to Section 4.01(e). If at any time the computations for determining compliance with financial covenants or provisions relating thereto utilize
generally accepted accounting principles different than those then being utilized in the financial statements being delivered to the Lenders, such financial statements shall be accompanied by a reconciliation statement. If at any time any change in
GAAP or the required adoption by the Borrower of international financial reporting standards would affect the computation of any financial ratio or requirement set forth in this Agreement, and either the Borrower or the Majority Lenders shall so
request, the Agent, the Lenders and the Borrower shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP or the adoption of such international financial reporting
standards (subject to the approval of the Majority Lenders); provided that, until so amended, (i) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein or the adoption of such international
financial reporting standards and (ii) the Borrower shall provide to the Agent and the Lenders financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between
calculations of such ratio or requirement made before and after giving effect to such change in GAAP or the adoption of such international financial reporting standards. 
 ARTICLE II 
 AMOUNTS AND TERMS OF THE ADVANCES 

Section 2.01 The Advances. Each Lender severally agrees, on the terms and conditions hereinafter set forth, to
make Advances to the Borrower from time to time on any Business Day during the period from the Effective Date until the Availability Termination Date if such Lender has any unused Commitment on any such date, and, thereafter, on each Increase
Effective Date and, in respect of any Increase Effective Date, within 3 Business Days after such Increase Effective Date, in each case, in an aggregate amount not to exceed at any time outstanding such Lender’s Commitment at such time. Each
Borrowing shall be in an aggregate amount not less than $5,000,000 or an integral multiple of $1,000,000 in excess thereof and shall consist of Advances of the same Type made on the same day to the Borrower by the Lenders ratably according to their
respective unused Commitments. Amounts borrowed under this Section 2.01 and prepaid or repaid may not be reborrowed. 

Section 2.02 Making the Advances. 

(a) Each Borrowing shall be made on notice, given not later than (x) 10:00 A.M. (New York City time) on the date of a
proposed Borrowing consisting of Base Rate Advances and (y) 12:00 noon (New York City time) on the third Business Day prior to the date of a proposed Borrowing consisting of Eurodollar Rate Advances, in each case by the Borrower to the Agent,
which shall give to each Lender prompt notice thereof by telecopier or e-mail. Each such notice of a Borrowing (a “Notice of Borrowing”) shall be by e-mail or telephone, confirmed immediately in writing by hand delivery or e-mail,
in substantially the form of Exhibit A hereto, specifying therein the requested (i) date of such Borrowing, (ii) Type of Advances comprising such Borrowing, (iii) aggregate amount of such Borrowing, and (iv) in the case of a
Borrowing comprised of Eurodollar Rate Advances, the initial Interest Period for each such Advance. The Borrower may, 

  
 13 

 
subject to the conditions herein provided, borrow more than one Borrowing on any Business Day. Each Lender shall, before 1:00 P.M. (New York City time) in the case of a Borrowing consisting of
Base Rate Advances and before 11:00 A.M. (New York City time) in the case of a Borrowing consisting of Eurodollar Rate Advances, in each case on the requested date of such Borrowing, make available for the account of its Applicable Lending Office to
the Agent at its address referred to in Section 8.02, in same day funds, such Lender’s ratable portion of such Borrowing. Upon fulfillment of the applicable conditions set forth in Section 3.02, the Agent will make such funds
available to the Borrower in like funds as received by the Agent either by (i) crediting the account of the Borrower on the books of the Agent with the amount of such funds or (ii) wire transfer of such funds, in each case in accordance
with instructions provided to (and reasonably acceptable to) the Agent by the Borrower. 
 (b) Anything in
subsection (a) above to the contrary notwithstanding, 
 (i) the Borrower may not select Eurodollar Rate
Advances for any Borrowing or with respect to the Conversion or continuance of any Borrowing if the aggregate amount of such Borrowing or such Conversion or continuance is less than $5,000,000; 

(ii) there shall be no more than five Interest Periods relating to Eurodollar Rate Advances outstanding at any time;

 (iii) if any Lender shall notify the Agent that the introduction of or any change in or in the interpretation
of any law or regulation makes it unlawful, or that any central bank or other governmental authority asserts that it is unlawful, for such Lender or its Eurodollar Lending Office to perform its obligations hereunder to make Eurodollar Rate Advances
or to fund or maintain Eurodollar Rate Advances hereunder, the Commitment of such Lender to make Eurodollar Rate Advances or to Convert all or any portion of Base Rate Advances shall forthwith be suspended until the Agent shall notify the Borrower
that such Lender has determined that the circumstances causing such suspension no longer exist and such Lender’s then outstanding Eurodollar Rate Advances, if any, shall be Base Rate Advances; to the extent that such affected Eurodollar Rate
Advances become Base Rate Advances, all payments of principal that would have been otherwise applied to such Eurodollar Rate Advances shall be applied instead to such Lender’s Base Rate Advances; provided that if Majority Lenders are
subject to the same illegality or assertion of illegality, then the right of the Borrower to select Eurodollar Rate Advances for such Borrowing or any subsequent Borrowing or to Convert all or any portion of Base Rate Advances shall forthwith be
suspended until the Agent shall notify the Borrower that the circumstances causing such suspension no longer exist, and each Advance comprising such Borrowing shall be a Base Rate Advance; provided further that if, at any time after a Lender gives
notice under this Section 2.02(b)(iii), such Lender determines that it may lawfully make Eurodollar Rate Advances, such Lender shall promptly give notice of that determination to the Borrower and the Agent, and the Agent shall promptly transmit
the notice to each other Lender. The Borrower’s right to request, and such Lender’s obligation, if any, to make Eurodollar Rate Advances shall thereupon be restored; and 

  
 14 

 (iv) if the Majority Lenders shall notify the Agent that (A) the
Eurodollar Rate for Eurodollar Rate Advances comprising such Borrowing will not adequately reflect the cost to such Majority Lenders of making, funding or maintaining their respective Eurodollar Rate Advances for such Borrowing or (B) dollar
deposits are not being offered to banks in the London interbank market for the applicable amount and Interest Period of such Borrowing or (C) reasonable and adequate means do not exist for ascertaining the Eurodollar Rate for such Interest
Period, the right of the Borrower to select Eurodollar Rate Advances for such Borrowing or any subsequent Borrowing shall be suspended until the Agent shall notify the Borrower and the Lenders that the circumstances causing such suspension no longer
exist, and each Advance comprising such Borrowing shall be made as a Base Rate Advance. 
 (c) Each Notice of
Borrowing shall be irrevocable and binding on the Borrower. In the case of any Borrowing which the related Notice of Borrowing specifies is to be comprised of Eurodollar Rate Advances, the Borrower shall indemnify each Lender against any loss, cost
or expense incurred by such Lender by reason of the liquidation or reemployment of deposits or other funds acquired by such Lender to fund the Advance to be made by such Lender as part of such Borrowing or by reason of the termination of hedging or
other similar arrangements, in each case when such Advance is not made on such date, including without limitation, as a result of any failure to fulfill on or before the date specified in such Notice of Borrowing for such Borrowing the applicable
conditions set forth in Article III. The Lender making demand for such indemnification shall deliver to the Borrower concurrently with such demand a written statement as to such losses, expenses and liabilities, and this statement shall be
conclusive as to the amount of compensation due to such Lender, absent manifest error. 
 (d) Unless the Agent
shall have received notice from a Lender prior to any Borrowing that such Lender will not make available to the Agent such Lender’s ratable portion of such Borrowing, the Agent may assume that such Lender has made such portion available to the
Agent on the date of such Borrowing in accordance with subsection (a) of this Section 2.02 and the Agent may, in reliance upon such assumption, make available to the Borrower on such date a corresponding amount. If and to the extent that
such Lender shall not have so made such ratable portion available to the Agent, such Lender and the Borrower severally agrees to repay to the Agent forthwith on demand such corresponding amount together with interest thereon, for each day from the
date such amount is made available to the Borrower until the date such amount is repaid to the Agent, at (i) in the case of the Borrower, the interest rate applicable at the time to Advances comprising such Borrowing and (ii) in the case
of such Lender, the Federal Funds Rate. If such Lender shall repay to the Agent such corresponding amount, such amount so repaid shall constitute such Lender’s Advance as part of such Borrowing for purposes of this Agreement. 

(e) The failure of any Lender to make the Advance to be made by it as part of any Borrowing shall not relieve any other
Lender of its obligation, if any, hereunder to make its Advance on the date of such Borrowing, but no Lender shall be responsible for the failure of any other Lender to make the Advance to be made by such other Lender on the date of any Borrowing.

  
 15 

 Section 2.03 [Reserved]. 

Section 2.04 Fees. 

(a) Commitment Fees. The Borrower agrees to pay to the Agent for the account of each Lender a commitment fee on the
amount of such Lender’s unused Commitment from the Effective Date, in the case of each Bank, and, to the extent not paid by the Borrower to any other Lender in respect of the same Commitment for the same period, from the effective date
specified in the Assignment and Acceptance pursuant to which a successor to any Bank or other Lender becomes a Lender hereunder, in each case until the Availability Termination Date, payable in arrears on the last day of each March, June, September
and December, commencing September 30, 2012, and on the Availability Termination Date, in an amount equal to the product of (i) the average daily amount of such Lender’s unused Commitment in effect during the period for which such
payment that is to be made times (ii) 0.250% per annum, provided that no Defaulting Lender shall be entitled to receive any commitment fee in respect of its unused Commitment for any period during which that Lender is a Defaulting
Lender (and the Borrower shall not be required to pay such fee that otherwise would have been required to have been paid to that Defaulting Lender). 
 (b) Agents’ Fees. The Borrower agrees to pay to the Agent the fees payable pursuant to the fee letter dated as of September 6, 2012 between the Borrower and BTMU, in the amounts and at
the times specified in such letter. 
 Section 2.05 Optional Reduction of the Commitments.

 The Borrower shall have the right, upon at least three Business Days’ notice to the Agent by the Borrower, such notice to
be received by the Agent not later than 12:00 noon (New York City time), to terminate in whole or permanently reduce ratably in part the unused portions of the respective Commitments of the Lenders, provided that the aggregate amount of the
Commitments of the Lenders shall not be reduced to an amount which is less than the aggregate principal amount of the Advances then outstanding, and provided, further, that each partial reduction shall be in the aggregate amount of
$5,000,000 or an integral multiple of $1,000,000 in excess thereof. 
 Section 2.06 Repayment and Prepayment
of Advances. 
 (a) Scheduled Repayments. The Borrower shall repay the aggregate principal
amount of Advances outstanding on the following dates in the respective amounts set opposite such dates: 
  

					
	 Date
	  	Percentage of Aggregate
Advances
Outstanding
(without giving effect to any
prepayments)	 
	 December 31, 2013
	  	 	2.50	% 
	 March 31, 2014
	  	 	2.50	% 
	 June 30, 2014
	  	 	2.50	% 
	 September 30, 2014
	  	 	2.50	% 
	 December 31, 2014
	  	 	2.50	% 
	 March 31, 2015
	  	 	2.50	% 
	 June 30, 2015
	  	 	2.50	% 
	 September 30, 2015
	  	 	2.50	% 
	 December 31, 2015
	  	 	2.50	% 
	 March 31, 2016
	  	 	2.50	% 
	 June 30, 2016
	  	 	2.50	% 

  
 16 

 (b) Mandatory Repayment on Maturity Date. The Borrower shall repay
the outstanding principal amount of each Lender’s Advances on the Maturity Date. 
 (c) Voluntary
Prepayments of Borrowings. The Borrower shall not have any right to prepay any principal amount of any Advances other than as provided in this subsection (c). The Borrower may, on any Business Day, upon notice to the Agent not later than
9:00 A.M. (New York City time) on such Business Day, in the case of Base Rate Advances, and at least three Business Days’ notice to the Agent, in the case of Eurodollar Rate Advances, in each case stating the proposed date and aggregate
principal amount of the prepayment, and if such notice is given the Borrower shall prepay such stated amount; provided, however, that (i) each partial prepayment shall be in an aggregate principal amount not less than $5,000,000
and integral multiples of $1,000,000 in excess thereof and (ii) in the case of any such prepayment of any Eurodollar Rate Advance, the Borrower shall pay all accrued interest to the date of such prepayment on the portion of such Eurodollar Rate
Advance being prepaid and shall be obligated to reimburse the Lenders in respect thereof pursuant to Section 8.04(b). 

Section 2.07 Interest on Advances. The Borrower shall pay interest accrued on the principal amount of
each Advance outstanding from time to time from the date of such Advance until such principal amount shall be paid in full, at the following rates per annum: 
 (a) Base Rate Advances. If such Advance is a Base Rate Advance, a rate per annum equal at all times to the sum of the Base Rate in effect from time to time plus the Applicable Margin, payable in
arrears on the last day of each March, June, September and December during the term of this Agreement, commencing December 31, 2012, and on the Maturity Date; provided that the Agent may, upon the request of the Majority Lenders, require
that the Borrower pay interest (“Base Default Interest”) on any amount of principal, interest, fees and other amounts payable under this Agreement (including, without limitation, the principal amount of Base Rate Advances, but
excluding the principal amount of Eurodollar Rate Advances) which is not paid when due (whether at stated maturity, by acceleration or otherwise) from the date on which such amount is due until such amount is paid in full, payable on demand, at a
rate per annum equal at all times to 2% per annum above the Base Rate in effect from time to time; provided, however, that following the making of the request or the granting of the consent specified by Section 6.01 to
authorize the Agent to declare the Advances due and payable pursuant to the provisions of Section 6.01, and upon acceleration of the Advances, Base Default Interest shall accrue and be payable hereunder whether or not previously required by the
Majority Lenders. 

  
 17 

 (b) Eurodollar Rate Advances. If such Advance is a Eurodollar Rate
Advance, a rate per annum equal at all times during the Interest Period for such Advance to the sum of the Eurodollar Rate for such Interest Period plus the Applicable Margin, payable in arrears on the last day of such Interest Period and, if such
Interest Period has a duration of more than three months, on the day which occurs during such Interest Period three months from the first day of such Interest Period; provided that the Agent may, upon the request of the Majority Lenders,
require that the Borrower pay interest (“Eurodollar Default Interest”) on any principal amount of any Eurodollar Rate Advance which is not paid when due (whether at stated maturity, by acceleration or otherwise) from the date on
which such amount is due until such amount is paid in full, payable on demand, at a rate per annum equal at all times to (A) during the Interest Period applicable to such Eurodollar Rate Advance, the greater of (x) 2% per annum above the
Base Rate in effect from time to time and (y) 2% per annum above the rate per annum required to be paid on such amount immediately prior to the date on which such amount became due and (B) after the expiration of such Interest Period,
2% per annum above the Base Rate in effect from time to time; provided, however, that following the making of the request or the granting of the consent specified by Section 6.01 to authorize the Agent to declare the Advances
due and payable pursuant to the provisions of Section 6.01, and upon acceleration of the Advances, Eurodollar Default Interest shall accrue and be payable hereunder whether or not previously required by the Majority Lenders. 

(c) Reserves on Eurodollar Rate Advances. The Borrower shall pay to each Lender, as long as such Lender shall be
required to maintain reserves with respect to liabilities or assets consisting of or including Eurocurrency funds or deposits (currently known as “Eurocurrency liabilities”), additional interest on the unpaid principal amount of each
Eurodollar Rate Advance equal to the actual costs of such reserves allocated to such Advance by such Lender (as determined by such Lender in good faith, which determination shall be conclusive), which shall be due and payable on each date on which
interest is payable on such Advance, provided the Borrower shall have received at least 10 days’ prior notice (with a copy to the Agent) of such additional interest from such Lender. If a Lender fails to give notice 10 days prior to the
relevant Interest Payment Date, such additional interest shall be due and payable 10 days from receipt of such notice. 

Section 2.08 Interest Rate Determination. The Agent shall give prompt notice to the Borrower and the
Lenders of the applicable interest rate determined by the Agent for purposes of Section 2.07(a) or 2.07(b). 

Section 2.09 Voluntary Conversion or Continuation of Advances. 

(a) The Borrower may on any Business Day, upon notice given to the Agent not later than 12:00 noon (New York City time) on
the third Business Day prior to the date of the proposed Conversion or continuance (a “Notice of Conversion/Continuation”) and subject to the provisions of Section 2.02(b), (i) Convert Advances of one Type comprising the
same Borrowing into Advances of another Type and (ii) upon the expiration of any Interest Period applicable to Advances which are Eurodollar Rate Advances made to the Borrower, continue all (or, subject to Section 2.02(b), any portion

  
 18 

 
of) such Advances as Eurodollar Rate Advances and the succeeding Interest Period(s) of such continued Advances shall commence on the last day of the Interest Period of the Advances to be
continued; provided, however, that any Conversion of any Eurodollar Rate Advances into Base Rate Advances shall be made on, and only on, the last day of an Interest Period for such Eurodollar Rate Advances. Each such Notice of
Conversion/Continuation shall, within the restrictions specified above, specify (A) the date of such continuation or Conversion, (B) the Advances (or, subject to Section 2.02(b), any portion thereof) to be continued or Converted,
(C) if such continuation is of, or such Conversion is into, Eurodollar Rate Advances, the duration of the Interest Period for each such Advance and (D) that no Potential Event of Default or Event of Default has occurred and is continuing.
The Borrower may elect different options with respect to different portions of the affected Borrowing, in which case each such portion shall be allocated ratably among the Lenders holding the Advances comprising such Borrowing, and the Advances
comprising each such portion shall be considered a separate Borrowing. 
 (b) If upon the expiration of the then
existing Interest Period applicable to any Advance which is a Eurodollar Rate Advance made to the Borrower, the Borrower shall not have delivered a Notice of Conversion/Continuation in accordance with this Section 2.09, then such Advance shall
upon such expiration automatically be Converted to a Base Rate Advance. 
 (c) After the occurrence of and during
the continuance of a Potential Event of Default or an Event of Default, the Borrower may not elect to have an Advance be made or continued as, or Converted into, a Eurodollar Rate Advance after the expiration of any Interest Rate then in effect for
that Advance. 
 Section 2.10 Increased Costs. 

(a) If, due to either (i) the introduction of or any change (other than any change by way of imposition or increase
of reserve requirements in the case of Eurodollar Rate Advances included in the Eurodollar Rate Reserve Percentage) in or in the interpretation of any law or regulation or (ii) the compliance with any guideline or request from any central bank
or other governmental authority (whether or not having the force of law), there shall be any increase in the cost (other than with respect to Taxes) to any Lender of agreeing to make or making, funding or maintaining Eurodollar Rate Advances made to
the Borrower, then the Borrower shall from time to time, upon demand by such Lender (with a copy of such demand to the Agent), pay to the Agent for the account of such Lender additional amounts sufficient to compensate such Lender for such increased
cost. A reasonably detailed certificate as to the amount and manner of calculation of such increased cost, submitted to the Borrower and the Agent by such Lender, shall be conclusive and binding for all purposes, absent manifest error. 

(b) If any Lender determines that compliance with any law or regulation or any guideline or request from any central bank
or other governmental authority (whether or not having the force of law) affects or would affect the amount of capital or liquidity required or expected to be maintained by such Lender or any corporation controlling such

  
 19 

 
Lender and that the amount of such capital or liquidity is increased by or based upon the existence of such Lender’s commitment to lend hereunder and other commitments of this type, then,
upon demand by such Lender (with a copy of such demand to the Agent), the Borrower shall immediately pay to the Agent for the account of such Lender, from time to time as specified by such Lender, additional amounts sufficient to compensate such
Lender or such corporation in the light of such circumstances, to the extent that such Lender reasonably determines such increase in capital or liquidity to be allocable to the existence of such Lender’s commitment to lend hereunder. A
reasonably detailed certificate as to such amounts and the manner of calculation thereof submitted to the Borrower and the Agent by such Lender shall be conclusive and binding for all purposes, absent manifest error. For the avoidance of doubt, this
Section 2.10(b) shall apply to all requests, rules, guidelines or directives concerning capital adequacy issued in connection with the Dodd-Frank Wall Street Reform and Consumer Protection Act, regardless of the date adopted, issued,
promulgated or implemented and this Section 2.10(b) shall apply to all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar
authority) or the United States regulatory authorities, in each case pursuant to Basel III, regardless of the date enacted, adopted or issued or implemented. 
 (c) If a Lender shall change its Applicable Lending Office, such Lender shall not be entitled to receive any greater payment under Sections 2.10 and 2.12 than the amount such Lender would have been
entitled to receive if it had not changed its Applicable Lending Office, unless such change was made at the request of the Borrower or at a time when the circumstances giving rise to such greater payment did not exist. 

(d) If any Lender requests compensation under this Section 2.10, or if the Borrower is required to pay additional
amounts with respect to a Lender pursuant to Section 2.12(a), such Lender shall use reasonable efforts to designate another lending office for funding or booking its Advances hereunder or to assign its rights and obligations hereunder to
another of its offices, branches or Affiliates if, in the judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 2.10 or Section 2.12(a), as the case may be, in the
future and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. 
 Section 2.11 Payments and Computations. 
 (a) The Borrower shall make each payment hereunder not later than 1:00 P.M. (New York City time) on the day when due in U.S. dollars to the Agent at its address referred to in Section 8.02 in same
day funds, without setoff, deduction or counterclaim. Subject to the immediately succeeding sentence, the Agent will promptly thereafter cause to be distributed like funds relating to the payment of principal or interest or commitment fees ratably
(other than amounts payable pursuant to Section 2.10 or 2.12) to the Lenders for the account of their respective Applicable Lending Offices, and like funds relating to the payment of any other amount payable to any Lender to such Lender for the
account of its Applicable Lending Office, in each case to be applied in accordance with the terms of this Agreement. Upon receipt of principal or interest paid after an Event of Default and 

  
 20 

 
an acceleration or a deemed acceleration of amounts due hereunder, the Agent will promptly thereafter cause to be distributed like funds relating to the payment of principal or interest ratably
in accordance with each Lender’s outstanding Advances (other than amounts payable pursuant to Section 2.10 or 2.12) to the Lenders for the account of their respective Applicable Lending Offices. Upon its acceptance of an Assignment and
Acceptance and recording of the information contained therein in the Register pursuant to Section 8.07(c), from and after the effective date specified in such Assignment and Acceptance, the Agent shall make all payments hereunder in respect of
the interest assigned thereby to the Lender assignee thereunder, and the parties to such Assignment and Acceptance shall make all appropriate adjustments in such payments for periods prior to such effective date directly between themselves.

 (b) All computations of interest based on the Base Rate shall be made by the Agent on the basis of a year of
365 or 366 days, as the case may be, and all computations of interest based on the Eurodollar Rate or the Federal Funds Rate and of commitment fees shall be made by the Agent on the basis of a year of 360 days, in each case for the actual number of
days (including the first day but excluding the last day) occurring in the period for which such interest or such fees are payable. Each determination by the Agent of an interest rate hereunder shall be conclusive and binding for all purposes,
absent manifest error. 
 (c) Whenever any payment hereunder shall be stated to be due on a day other than a
Business Day, such payment shall be made on the next succeeding Business Day, and such extension of time shall in such case be included in the computation of payment of interest or commitment fee, as the case may be; provided, however,
if such extension would cause payment of interest on or principal of Eurodollar Rate Advances to be made in the next following calendar month, such payment shall be made on the next preceding Business Day. 

(d) Unless the Agent shall have received notice from the Borrower prior to the date on which any payment is due to the
Lenders hereunder that the Borrower will not make such payment in full, the Agent may assume that the Borrower has made such payment in full to the Agent on such date and the Agent may, in reliance upon such assumption, cause to be distributed to
each Lender on such due date an amount equal to the amount then due such Lender. If and to the extent that the Borrower shall not have so made such payment in full to the Agent, each Lender shall repay to the Agent forthwith on demand such amount
distributed to such Lender together with interest thereon, for each day from the date such amount is distributed to such Lender until the date such Lender repays such amount to the Agent, at the Federal Funds Rate. 

Section 2.12 Taxes. 

(a) Any and all payments by the Borrower hereunder shall be made, in accordance with Section 2.11, free and clear of
and without deduction for any and all present or future taxes, levies, imposts, deductions, charges or withholdings imposed by a governmental authority, and all interest, additions to tax and penalties with respect thereto (hereinafter referred to
as “Taxes”), excluding, in the case of each Lender, SPC 

  
 21 

 
and the Agent, (i) Taxes imposed on (or measured by) its income or gross margin, and franchise and branch profits or similar taxes imposed on it, by the jurisdiction under the laws of which
such Lender, SPC or the Agent (as the case may be) is organized or any political subdivision thereof or in which its principal office is located, (ii) Taxes imposed on (or measured by) its income, and franchise and branch profits or similar
taxes imposed on it, by the jurisdiction of such Lender’s Applicable Lending Office or such SPC’s lending office or any political subdivision thereof, (iii) Taxes imposed upon or measured by all or a part of the net income or gross
margin of such Lender, SPC or the Agent, and branch profits or similar taxes imposed on such Lender, SPC or the Agent, by the United States or any political subdivision or taxing authority thereof or therein, (iv) United States income Taxes
(including withholding taxes with respect to payments hereunder) payable with respect to payments hereunder under laws (including without limitation any statute, treaty, ruling, determination or regulation) in effect on the date hereof in the case
of each Bank and on the effective date of the Assignment and Acceptance pursuant to which it became a Lender in the case of each other Lender and on the date that it funded its first Advance hereunder in the case of an SPC, or, in the case of any
Lender or SPC, on the date such Lender or SPC designated a new lending office, except to the extent that such Lender or SPC (or its assignor, if any) was entitled, at the time of designation of an Applicable Lending Office (or assignment), to
receive additional amounts from the Borrower with respect to such Taxes pursuant to this Section 2.12, and (v) any United States federal withholding tax to the extent imposed as a result of a failure to satisfy the applicable requirements
of FATCA (that are necessary to avoid withholding) after December 31, 2012, or such later date on which the requirements become effective (all such non-excluded Taxes being hereafter referred to as “Indemnified Taxes”; and all
such excluded Taxes being hereinafter referred to as “Excluded Taxes”). Notwithstanding the preceding sentence, if the Borrower shall be required by law to deduct any Taxes from or in respect of any sum payable hereunder to any
Lender, any SPC or the Agent, (i) unless such Taxes are Excluded Taxes, the sum payable shall be increased as may be necessary so that after making all required deductions (including deductions applicable to additional sums payable under this
Section 2.12) such Lender, SPC or the Agent (as the case may be) receives an amount equal to the sum it would have received had no such deductions been made, (ii) the Borrower shall make such deductions and (iii) the Borrower shall
pay the full amount deducted to the relevant taxation authority or other authority in accordance with applicable law. 
 (b) In addition, the Borrower agrees to pay any present or future stamp or documentary taxes or any other excise or property taxes, charges or similar levies which arise from the execution, delivery or
registration of, or otherwise with respect to, this Agreement (hereinafter referred to as “Other Taxes”). 
 (c) The Borrower will indemnify each Lender and the Agent for the full amount of Indemnified Taxes or Other Taxes, in each case with respect to this Agreement or payments hereunder (including, without
limitation, any Indemnified Taxes or Other Taxes imposed by any jurisdiction on amounts payable under this Section 2.12), and in each case paid by such Lender or the Agent (as the case may be) and any liability (including penalties, interest
and reasonable expenses) arising therefrom or with respect thereto, whether or not such Indemnified Taxes or Other Taxes were correctly or legally 

  
 22 

 
asserted. This indemnification shall be made within 30 days from the date such Lender or the Agent (as the case may be) makes written demand therefor and provides the Borrower with a certificate
setting forth, in reasonable detail (without disclosing any confidential information), the calculation of the amount of such payment or liability. 
 (d) Within 30 days after the date of any payment by the Borrower of Taxes pursuant to Section 2.12(a), 2.12(b) or 2.12(c), the Borrower will furnish to the Agent, at its address referred to in
Section 8.02, the original or a certified copy of a receipt evidencing payment thereof, a copy of any return required by law or regulation to report such payment or other evidence of such payment reasonably satisfactory to the Agent.

 (e) (i) Each Lender organized under the laws of a jurisdiction outside the United States, on or prior to the
date of its execution and delivery of this Agreement in the case of each Bank and on the date of the Assignment and Acceptance pursuant to which it becomes a Lender in the case of each other Lender, and from time to time thereafter if requested in
writing by the Borrower (but only so long as such Lender remains lawfully able to do so), shall provide the Borrower with either (A) two (2) duly completed and executed originals of Internal Revenue Service form W-8BEN or W-8ECI, as
appropriate, or any successor form prescribed by the Internal Revenue Service, to establish that such Lender is not subject to, or is subject to a reduced rate of, United States withholding Tax with respect to any payments to such Lender of interest
payable under this Agreement or (B) if such Lender claims the benefits of the exemption for portfolio interest under section 881(c) of the Code, (1) a certificate to the effect that such Lender is not (x) a “bank” within the
meaning of section 881(c)(3)(A) of the Code, (y) a “10 percent shareholder” of the Borrower within the meaning of section 881(c)(3)(B) of the Code, or (z) a “controlled foreign corporation” described in section
881(c)(3)(C) of the Code and two (2) duly completed and executed originals of Internal Revenue Service Form W-8BEN. 
 (ii) If a payment made to a Lender would be subject to United States federal withholding tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA
(including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower, at the time or times prescribed by law and at such time or times reasonably requested in writing by the Borrower,
such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested in writing by the Borrower as may be necessary for the Borrower to comply
with its obligations under FATCA, to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. 

(iii) In addition, each Lender organized under the laws of a jurisdiction outside the United States, to the extent it does
not act or ceases to act for its own account with respect to any portion of any sums paid or payable to such Lender under this Agreement (for example, in the case of a typical participation by such Lender), on or prior to the date of its execution
and delivery of this Agreement in 

  
 23 

 
the case of each Bank and on the date of the Assignment and Acceptance pursuant to which it becomes a Lender in the case of each other Lender, on or prior to such later date when such Lender
ceases to act for its own account with respect to any portion of any such sums paid or payable, and from time to time thereafter if requested in writing by the Borrower (but only so long as such Lender remains lawfully able to do so), shall provide
the Borrower with two (2) duly completed and executed originals of Internal Revenue Service form W-8IMY, or any successor form prescribed by the Internal Revenue Service, together with any information, if any, such Lender chooses to transmit
with such form, and any other certificate or statement of exemption required under the Code or the regulations thereunder, to establish that such Lender is not acting for its own account with respect to a portion of any such sums payable to such
Lender. 
 (iv) Each Lender that is a U.S. person, on or prior to the date of its execution and delivery of this
Agreement in the case of each Bank and on the date of the Assignment and Acceptance pursuant to which it becomes a Lender in the case of each other Lender, and from time to time thereafter if requested in writing by the Borrower, shall provide the
Borrower with two (2) duly completed and executed originals of Internal Revenue Service Form W-9, certifying that such Lender is exempt from U.S. backup withholding tax. 

(f) For any period during which any Tax is required to be deducted or withheld (i) on the basis of the information,
certificates or statements of exemption a Lender chooses to transmit with an Internal Revenue Service Form W-8IMY pursuant to subsection 2.12(e)(iii), or (ii) due solely to a Lender’s failure to provide the Borrower with the appropriate
form described in Section 2.12(e) (other than if such failure is due to a change in law occurring subsequent to the date on which a form originally was required to be provided and except to the extent that such Lender (or its assignor, if any)
was entitled, at the time of designation of a new Applicable Lending Office (or assignment), to receive additional amounts from the Borrower with respect to such withholding taxes pursuant to Section 2.12(a) above), such Tax shall be considered
an Excluded Tax for purposes of Section 2.12(a); provided, however, that should a Lender become subject to Taxes because of its failure to deliver a form required hereunder, the Borrower shall, at the expense of such Lender, take
such steps as the Lender shall reasonably request to assist the Lender to recover such Taxes. 
 (g) If any
Person determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 2.12 (including by means of additional amounts paid pursuant to
Section 2.12(a)), it shall pay to the Borrower an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, under this Section 2.12 with respect to the Taxes giving rise to such refund),
net of all out-of-pocket expenses (including any Taxes) of such indemnified Person with respect to such refund and without interest (other than any interest paid by the relevant governmental authority with respect to such refund). Upon reasonable
written request of such indemnified Person, the Borrower shall repay to such indemnified Person the amount paid to the Borrower by such indemnified Person pursuant to the previous sentence to the extent such indemnified

  
 24 

 
Person is required to repay such refund to such governmental authority. Notwithstanding anything to the contrary in this Section 2.12(g), in no event will any indemnified Person be required
to pay any amount to the Borrower pursuant to this Section 2.12(g) to the extent that such payment would place such indemnified Person in a less favorable position (on a net after-Tax basis) than such indemnified Person would have been in if
the indemnification payments or additional amounts giving rise to such refund had never been paid. This Section 2.12(g) shall not be construed to require any indemnified Person to make available its Tax returns (or any other information
relating to its Taxes which it deems confidential) to the Borrower. 
 (h) Notwithstanding anything to the
contrary in this Agreement, the Borrower shall not be required to indemnify any Person for Excluded Taxes. 
 (i)
Without prejudice to the survival of any other agreement hereunder, the agreements and obligations of the Borrower contained in this Section 2.12, and the agreements and obligations of all Persons under Section 2.12(g), shall survive the
payment in full of principal and interest hereunder. 
 Section 2.13 Sharing of Payments, Etc. If any
Lender shall obtain any payment (whether voluntary, involuntary, through the exercise of any right of set-off, or otherwise) on account of the Advances made by it (other than pursuant to Section 2.10 or 2.12) in excess of its ratable share of
payments on account of the Advances obtained by all the Lenders, such Lender shall forthwith purchase from the other Lenders such participations in the Advances made by them as shall be necessary to cause such purchasing Lender to share the excess
payment ratably with each of them, provided, however, that if all or any portion of such excess payment is thereafter recovered from such purchasing Lender, such purchase from each Lender shall be rescinded and such Lender shall repay
to the purchasing Lender the purchase price to the extent of such recovery together with an amount equal to such Lender’s ratable share (according to the proportion of (a) the amount of such Lender’s required repayment to (b) the
total amount so recovered from the purchasing Lender) of any interest or other amount paid or payable by the purchasing Lender in respect of the total amount so recovered. The Borrower agrees that any Lender so purchasing a participation from
another Lender pursuant to this Section 2.13 may, to the fullest extent permitted by law, exercise all its rights of payment (including the right of set-off) with respect to such participation as fully as if such Lender were the direct creditor
of the Borrower in the amount of such participation. 
 Section 2.14 Evidence of Debt.

 (a) Each Lender shall maintain in accordance with its usual practice an account or accounts evidencing the
indebtedness of the Borrower to such Lender resulting from each Advance owing to such Lender from time to time, including the amounts of principal and interest payable and paid to such Lender from time to time hereunder. The Borrower agrees that
upon notice by any Lender to the Borrower (with a copy of such notice to the Agent) to the effect that a promissory note or other evidence of indebtedness is required or appropriate in order for such Lender to evidence (whether for purposes of
pledge, enforcement or otherwise) the Advances owing to, or to be made by, such Lender, the Borrower shall promptly execute and deliver to such Lender promissory 

  
 25 

 
notes or other evidence of such indebtedness, in form and substance reasonably satisfactory to the Borrower and such Lender, payable to the order of such Lender in a principal amount equal, in
the case of the Advances, to the aggregate principal amount of the Commitment of such Lender; provided, however, that the execution and delivery of such promissory note or other evidence of indebtedness shall not be a condition precedent to
the making of any Advance under this Agreement. 
 (b) The Register maintained by the Agent pursuant to
Section 8.07(c) shall include a control account, and a subsidiary account for each Lender, in which accounts (taken together) shall be recorded (i) the date, amount and tenor, as applicable, of each Borrowing, the Borrower that received
the proceeds of such Borrowing, the Type of Advances comprising such Borrowing and the Interest Period applicable thereto, (ii) the terms of each Assignment and Acceptance delivered to and accepted by it, if any, (iii) the amount of any
principal or interest due and payable or to become due and payable from the Borrower to each Lender hereunder, and (iv) the amount of any sum received by the Agent from the Borrower hereunder and each Lender’s share thereof. 

(c) The entries made in the Register shall be conclusive and binding for all purposes, absent manifest error. 

Section 2.15 Use of Proceeds. 

(a) Advances shall be used by the Borrower for refinancing of existing Debt and for general corporate purposes.

 (b) No portion of the proceeds of any Advances under this Agreement shall be used by the Borrower or any of
its Subsidiaries in any manner which might cause the Advances or the application of such proceeds to violate, or require any Lender to make any filing or take any other action under, Regulation T, Regulation U or Regulation X of the Board of
Governors of the Federal Reserve System or any other regulation of such Board or to violate the Securities Exchange Act of 1934, in each case as in effect on the date or dates of such Advances and such use of proceeds. 

Section 2.16 Increased Commitments; Additional Lenders. 

(a) No more than three separate times, the Borrower may, upon at least thirty (30) days notice to the Agent (which
shall promptly provide a copy of such notice to the Lenders), propose to increase the aggregate amount of the Commitments in increments of $10,000,000, the total amount of all such increases not to exceed $350,000,000 (the amount of any such
increase, the “Increased Commitments”); provided that at the time of and after giving effect to any increase in the Commitments (and the delivery of the applicable commitment increase notice shall constitute a representation
and warranty by the Borrower that on the effective date of such increase such statements are true) (i) the representations and warranties of the Borrower contained in Article IV are correct on and as of the date of such increase, before
and after giving effect to such increase, as though made on and as of such date, except to the extent that any such representation or warranty expressly relates only to an earlier date, in which case they were correct as of such earlier date; and
(ii) no Event of Default exists and is continuing. Each Lender party to this 

  
 26 

 
Agreement at such time shall have the right (but no obligation), for a period of fifteen (15) days following receipt of such notice, to elect by notice to the Borrower and the Agent to
increase its Commitment by a principal amount which bears the same ratio to the Increased Commitments as its then Commitment bears to the aggregate Commitments then existing. 

(b) If any Lender party to this Agreement shall not elect to increase its Commitment pursuant to subsection (a) of
this Section, the Borrower may designate another lender or other lenders (which may be, but need not be, one or more of the existing Lenders) which at the time agree to (i) in the case of any such lender that is an existing Lender, increase its
Commitment and (ii) in the case of any other such lender (an “Additional Lender”), become a party to this Agreement. The sum of the increases in the Commitments of the existing Lenders pursuant to this subsection (b) plus
the Commitments of the Additional Lenders shall not in the aggregate exceed the unsubscribed amount of the Increased Commitments. 
 (c) An increase in the aggregate amount of the Commitments pursuant to this Section 2.16 shall become effective (the “Increase Effective Date”) upon the receipt by the Agent of an
agreement in form and substance satisfactory to the Agent signed by the Borrower, by each Additional Lender and by each other Lender whose Commitment is to be increased, setting forth the new Commitments of such Lenders and Additional Lenders on a
revised Schedule II to this Agreement and setting forth the agreement of each Additional Lender to become a party to this Agreement and to be bound by all the terms and provisions hereof, together with such evidence of appropriate corporate
authorization on the part of the Borrower with respect to the Increased Commitments and such opinions of counsel for the Borrower with respect to the Increased Commitments as the Agent may reasonably request. 

Section 2.17 Substitution of Lenders. If any Lender requests compensation from the Borrower under
Section 2.10(a) or (b), if the Borrower is required to pay any additional amounts with respect to any Lender or SPC under Section 2.12(a), or if any Lender shall become a Defaulting Lender or a Non-Consenting Lender, the Borrower shall
have the right, with the assistance of the Agent, to seek one or more substitute banks or financial institutions (which may be one or more of the Lenders) reasonably satisfactory to the Agent and the Borrower to purchase the Advances and assume the
Commitments of such Lender or SPC, as applicable, and the Borrower, the Agent, such Lender or such SPC, as applicable, and such substitute banks or financial institutions shall execute and deliver an appropriately completed Assignment and Acceptance
pursuant to Section 8.07(a) hereof to effect the assignment of rights to and the assumption of obligations by such substitute banks or financial institutions; provided that (a) any such Lender or SPC, as applicable, shall be
entitled to (i) if requesting compensation from the Borrower under Section 2.10(a) or (b), compensation under Section 2.10 for any costs incurred by it prior to its replacement, (ii) payment of all Advances of such Lender then
outstanding and all interest and fees accrued to the date of such payment, and (iii) if any Eurodollar Rate Advances of such Lender are then outstanding, any reimbursement which would be payable under Section 8.04(b) in connection with a
prepayment of such Eurodollar Rate Advances on such date, (b) in the case of any assignment resulting from a Lender becoming a Non-Consenting Lender, the applicable assignee shall have consented to the applicable amendment, waiver or consent
and (c) no Event of Default shall then exist and be continuing. 

  
 27 

 Section 2.18 Defaulting Lenders. 

(a) Notwithstanding anything to the contrary herein, any payment of principal, interest, fees or other amounts received by
the Agent for the account of any Defaulting Lender under this Agreement (whether voluntary or mandatory, at maturity, pursuant to Article VI or otherwise) by the Borrower for the account of a Defaulting Lender under this Agreement will not be
required to be paid or distributed to such Defaulting Lender, but will instead be applied at such time or times as may be determined by the Agent as follows: first, to the payment of any amounts owing by such Defaulting Lender to the Agent
under this Agreement; second, to the funding of any Advance in respect of which such Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Agent; third, if so determined by the
Agent and the Borrower, held in such account as cash collateral for future funding obligations of the Defaulting Lender in respect of any Advances under this Agreement. If such Lender is still a Defaulting Lender and any amounts remain in such
account on the date that the Commitments are terminated and all payment obligations of the Borrower hereunder are paid in full, then such amounts will be applied by the Agent to the making of payments in the following order of priority:
first, to the payment of any amounts owing by such Defaulting Lender to the Agent hereunder; second, to the payment of any amounts owing to the Lenders as a result of any judgment of a court of competent jurisdiction obtained by any
Lender against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; third, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent
jurisdiction obtained by such Borrower against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; and, fourth, to pay amounts owing under this Agreement to such Defaulting
Lender or as a court of competent jurisdiction may otherwise direct; provided that any amounts held as cash collateral for funding obligations of a Defaulting Lender shall be returned to such Defaulting Lender upon the termination of this
Agreement and the satisfaction of such Defaulting Lender’s obligations hereunder. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or to post
cash collateral pursuant to this Section 2.18 shall be deemed paid to and redirected by such Defaulting Lender, and each Lender irrevocably consents hereto. 

(b) No Commitment of any Lender shall be increased or otherwise affected, and, except as otherwise expressly provided in
this Section 2.18, performance by the Borrower of its obligations shall not be excused or otherwise modified as a result of the operation of this Section 2.18. The rights and remedies against a Defaulting Lender under this
Section 2.18 are in addition to any other rights and remedies which the Borrower, the Agent or any Lender may have against such Defaulting Lender. 
 (c) If the Borrower and the Agent agree in writing in their reasonable determination that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, the Agent will so notify the parties
hereto, whereupon as of the effective date 

  
 28 

 
specified in such notice and subject to any conditions set forth therein (which may include arrangements with respect to any cash collateral), that Lender will, to the extent applicable, purchase
that portion of outstanding Advances of the other Lenders or take such other actions as the Agent may determine to be necessary to cause the Advances and funded and held on a pro rata basis by the Lenders in accordance with their pro rata share,
whereupon such Lender will cease to be a Defaulting Lender; provided that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender; and
provided, further, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from
such Lender’s having been a Defaulting Lender. 
 Section 2.19 Special Purpose Funding Vehicles.

 (a) Notwithstanding anything to the contrary contained herein, any Lender, (a “Granting
Lender”) may grant to a special purpose funding vehicle (an “SPC”) the option to fund all or any part of any Advance that such Granting Lender would otherwise be obligated to fund pursuant to this Agreement;
provided, that (i) nothing herein shall constitute a commitment by an SPC to fund any Advance, and (ii) if an SPC elects not to exercise such option or otherwise fails to fund all or any part of such Advance, the Granting Lender
shall be obligated to fund such Advance pursuant to the terms hereof. The funding of an Advance by an SPC hereunder shall utilize the Commitment of the Granting Lender to the same extent, and as if, such Advance were funded by such Granting Lender.
Each party hereto hereby agrees that no SPC shall be liable for any indemnity or payment under this Agreement for which a Lender would otherwise be liable for so long as, and to the extent, the Granting Lender provides such indemnity or makes such
payment. Notwithstanding anything to the contrary contained in this Agreement, any SPC may disclose on a confidential basis any non-public information relating to its funding of Advances to any rating agency, commercial paper dealer or provider of
any surety or guarantee to such SPC. 
 (b) Each Granting Lender, acting solely for this purpose on the
Borrower’s behalf, shall maintain a register comparable to the Register maintained by the Agent pursuant to Section 8.07(c) for purpose of recording the funding of Advances by SPCs. 

(c) Assignments of and participations in Advances funded by SPCs shall be subject to the provisions of Section 8.07.

 (d) Notwithstanding anything to the contrary in this Agreement, (i) the Borrower shall not be required to
pay any amount under Sections 2.10, 2.12 or 2.17 that is greater than the amount which the Borrower would have been required to pay had such SPC not provided the Borrower with any part of any Advance of such Granting Lender and (ii) an SPC
shall not be entitled to any benefits under Section 2.12 unless such SPC agrees to be subject to the provisions of Sections 2.10(d), 2.12(e), 2.12(f), 2.12(g) and 2.17 as if it were an assignee (as of the date it funds its first Advance
hereunder) under Section 8.07. 

  
 29 

 ARTICLE III 
 CONDITIONS OF LENDING 
 Section 3.01 Condition
Precedent to Effective Date. The effectiveness of this Agreement and the obligation of each Lender to make its initial Advance hereunder on and after the Effective Date are subject to the conditions precedent that (x) the Borrower shall
have paid all documented accrued fees required by this Agreement and reasonable and documented out-of-pocket expenses of the Agent and the Lenders (including the reasonable and documented accrued fees and out-of-pocket expenses of counsel to the
Agent) and (y) the Agent receive on or before the Effective Date the following, each dated the Effective Date, and each in form and substance satisfactory to the Agent and in sufficient copies for each Lender: 

(a) This Agreement, executed by the Borrower, the Agent and each Lender listed on Schedule II attached hereto; 

(b) Copies of (i) the resolutions of the Board of Directors of the Borrower, approving this Agreement, and
(ii) of all documents evidencing other necessary corporate action and governmental approvals, if any, with respect to this Agreement, in each case certified by the Secretary or an Assistant Secretary of the Borrower; 

(c) A certificate of the Secretary or an Assistant Secretary of the Borrower certifying the names and true signatures of
the officers of the Borrower authorized to sign this Agreement and the other documents to be delivered by the Borrower hereunder; 
 (d) A certificate of the Secretary or Assistant Secretary of the Borrower, dated the Effective Date, certifying the correctness and completeness of the copies of Borrower’s Certificate of
Incorporation and Bylaws previously delivered to the Agent, together with good standing certificates from the state of its incorporation, each to be dated a recent date prior to the Effective Date; 

(e) A favorable opinion of M Louise Turilli, Esq., Vice President, Deputy General Counsel and Assistant Secretary of the
Borrower, substantially in the form of Exhibit C hereto; and 
 (f) A certificate of an authorized officer of the
Borrower, stating that the representations and warranties of the Borrower contained in Article IV are correct on and as of the Effective Date. 
 Section 3.02 Conditions Precedent to Each Borrowing. The obligation of each Lender to make an Advance on the occasion of each Borrowing (including the initial Borrowing)
shall be subject to the further conditions precedent that (i) the Agent shall have received a Notice of Borrowing with respect thereto in accordance with Section 2.02 and (ii) on the date of such Borrowing the following statements
shall be true (and each of the giving of the applicable Notice of Borrowing and the acceptance by the Borrower of the proceeds of such Borrowing shall constitute a representation and warranty by the Borrower that on the date of such Borrowing such
statements are true): 

  
 30 

 (a) The representations and warranties of the Borrower contained in
Article IV are correct on and as of the date of such Borrowing, before and immediately after giving effect to such Borrowing and to the application of the proceeds therefrom, as though made on and as of such date, except to the extent that any
such representation or warranty expressly relates only to an earlier date, in which case they were correct as of such earlier date; and 
 (b) No event has occurred and is continuing, or would result from such Borrowing or from the application of the proceeds therefrom, which constitutes an Event of Default or a Potential Event of Default.

 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES 
 Section 4.01
Representations and Warranties of the Borrower. The Borrower represents and warrants as follows: 
 (a) Due Organization, etc. The Borrower is a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of organization. The Borrower is duly qualified to
do business as a foreign corporation in good standing in all other jurisdictions which require such qualification, except to the extent that failure to so qualify would not have a material adverse effect on the business, financial condition or
operations of the Borrower and the Subsidiaries, taken as a whole. Each Significant Subsidiary of the Borrower is duly organized and validly existing under the laws of the jurisdiction of its incorporation or formation. Each such Subsidiary is duly
qualified to do business in all other jurisdictions which require such qualification, except to the extent that failure to so qualify would not have a material adverse effect on the business, financial condition or operations of the Borrower and the
Subsidiaries, taken as a whole. 
 (b) Due Authorization, etc. The execution, delivery and performance by
the Borrower of this Agreement are within the Borrower’s corporate powers, have been duly authorized by all necessary corporate action, and do not contravene (i) the Borrower’s certificate of incorporation or bylaws or (ii) law
or any material contractual restriction binding on or affecting the Borrower. 
 (c) Governmental Consent.
No authorization or approval or other action by, and no notice to or filing with, any governmental authority or regulatory body is required for the due execution, delivery and performance by the Borrower of this Agreement except for those which have
been obtained prior to the Effective Date and remain in full force and effect. 
 (d) Validity. This
Agreement is the legal, valid and binding obligation of the Borrower enforceable against the Borrower in accordance with its terms, subject to the effect of applicable bankruptcy, insolvency, arrangement, moratorium and other similar laws affecting
creditors’ rights generally and to the application of general principles of equity. 

  
 31 

 (e) Condition of the Borrower. The consolidated balance sheet of the
Borrower as at March 30, 2012, and the related consolidated statements of income and stockholders’ equity of the Borrower for the fiscal year then ended, copies of which have been furnished to each Bank, fairly present the consolidated
financial condition of the Borrower as at such date and the consolidated results of the operations of the Borrower for the fiscal year ended on such date, all in accordance with GAAP consistently applied. There has been no material adverse change in
the business, financial condition or operations of the Borrower and the Subsidiaries, taken as a whole, since March 30, 2012. 
 (f) Litigation. There is no pending or (to the knowledge of the Borrower) threatened investigation, action or proceeding against the Borrower or any of its Subsidiaries before any court,
governmental agency or arbitrator which (i) except as disclosed to the Lenders in the Exchange Act Reports filed prior to the Effective Date, would, if adversely determined, reasonably be expected to have a material adverse affect on the
business, financial condition or operations of the Borrower and the Subsidiaries, taken as a whole, or (ii) purports to affect the legality, validity or enforceability of this Agreement. 

(g) Margin Regulations. The Borrower is not engaged in the business of extending credit for the purpose of
purchasing or carrying margin stock (within the meaning of Regulation U issued by the Board of Governors of the Federal Reserve System), and no proceeds of any Advance will be used to purchase or carry any margin stock or to extend credit to others
for the purpose of purchasing or carrying any margin stock in any manner that violates or would cause a violation of Regulation T, Regulation U or Regulation X. 
 (h) Payment of Taxes. Except as disclosed in the Exchange Act Reports prior to the Effective Date, the Borrower and each of its Significant Subsidiaries have filed or caused to be filed all Tax
returns (federal, state, local and foreign) required to be filed and paid all amounts of Taxes shown thereon to be due, including interest and penalties, except (i) for such Taxes as are being contested in good faith and by proper proceedings
and with respect to which appropriate reserves are being maintained by the Borrower or any such Subsidiary, as the case may be and (ii) to the extent that the failure to file such returns or pay such Taxes would not reasonably be expected to
have a material adverse effect on the business, financial condition or operations of the Borrower and the Subsidiaries, taken as a whole. 
 (i) Governmental Regulation. The Borrower is not subject to regulation under the Federal Power Act, the Interstate Commerce Act or the Investment Company Act of 1940, each as amended, or to any
Federal or state statute or regulation limiting its ability to incur indebtedness for money borrowed. 
 (j)
ERISA. 
 (i) No ERISA Event has occurred or is reasonably expected to occur (other than for premiums payable
under Title IV of ERISA), that would reasonably be expected to result in a liability to the Borrower or its ERISA Affiliates of more than $125,000,000 over the amount previously reflected for any such liabilities, in accordance with GAAP, on the
financial statements delivered pursuant to Section 4.01(e). 

  
 32 

 (ii) Schedule B (Actuarial Information) to the most recently completed
annual report (Form 5500 Series) for each Pension Plan, copies of which have been filed with the Internal Revenue Service and furnished to the Agent, is complete and, to the best knowledge of the Borrower, accurate, and since the date of such
Schedule B there has been no change in the funding status of any such Pension Plan except any change that would not reasonably be expected to have a material adverse effect on the business, financial condition or operations of the Borrower and the
Subsidiaries, taken as a whole. 
 (iii) As of the most recent valuation date for each Multiemployer Plan for
which the actuarial report is available, the potential liability to the Borrower or any of its ERISA Affiliates for a complete withdrawal from such Multiemployer Plan, when aggregated with such potential liability for a complete withdrawal for all
Multiemployer Plans, based on information available pursuant to Section 4221(e) of ERISA, does not exceed $125,000,000. 
 (iv) The Borrower and each of its ERISA Affiliates are in compliance with all applicable provisions and requirements of ERISA and the regulations and published interpretations thereunder with respect to
each Employee Benefit Plan, and have performed all their obligations under each Employee Benefit Plan except for any suchfailure to perform or comply that would not reasonably be expected to have a material adverse effect on the business, financial
condition or operations of the Borrower and the Subsidiaries, taken as a whole. Each Employee Benefit Plan that is intended to qualify under Section 401(a) of the Code has received a determination letter from the Internal Revenue Service that
the Employee Benefit Plan is so qualified (or a timely application for such a determination letter is pending), and to the best of the Borrower’s knowledge, the Employee Benefit Plan has not been operated in any way that would result in the
Employee Benefit Plan no longer being so qualified except as would not reasonably be expected to have a material adverse effect on the business, financial condition or operations of the Borrower and the Subsidiaries, taken as a whole. 

(v) Neither the Borrower nor any ERISA Affiliate has been notified by the sponsor of a Multiemployer Plan that such
Multiemployer Plan is insolvent, in reorganization or has been terminated or has been determined to be in “endangered” or “critical” status, within the meaning of Title IV of ERISA, and, to the best knowledge of the Borrower, no
Multiemployer Plan is reasonably expected to be insolvent, in reorganization or to be terminated or to be determined to be in “endangered” or “critical” status within the meaning of Title IV of ERISA, in each case, resulting in a
liability to the Borrower or its ERISA Affiliates of more than $125,000,000. 
 (k) Disclosure. No
representation or warranty of the Borrower contained in this Agreement (including any Schedule furnished in connection herewith) contains any untrue statement of a material fact. No other document, certificate or written statement furnished to the
Agent or any Lender by or, as authorized by the Borrower, on behalf of the Borrower for use in connection with the transactions contemplated in this Agreement, 

  
 33 

 
taken as a whole with other documents, certificates or written statements furnished contemporaneously therewith, contains any untrue statement of fact or omits to state a material fact (known to
the Borrower in the case of any documents, certificates or written statements not furnished by it) necessary in order to make the statements contained therein not misleading in light of the circumstances under which the same were made. 

(l) Insurance. The Borrower and its Significant Subsidiaries (i) maintain insurance with responsible and
reputable insurance companies or associations in such amounts and covering such risks as are usually insured by companies engaged in similar businesses or (ii) maintain a plan or plans of self-insurance to such extent and covering such risks as
is usual for companies of comparable size engaged in the same or similar business, which plans shall include, among other things, adequate reserves for the risks that are self-insured. 

(m) Environmental Matters. (i) The Borrower and each of its Subsidiaries is in compliance with all
Environmental Laws except to the extent any non-compliance would not reasonably be expected to have a material adverse effect on the business, financial condition or operations of the Borrower and the Subsidiaries, taken as a whole, and
(ii) there has been no “release or threatened release of a hazardous substance” (as defined by the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, 42 U.S.C. § 9601 et
seq.) or any other release, emission or discharge into the environment of any hazardous or toxic substance, pollutant or other materials from the Borrower’s or its Subsidiaries’ property other than as permitted under applicable
Environmental Law and other than those which would not have a material adverse effect on the business, financial condition or operations of the Borrower and the Subsidiaries, taken as a whole. Other than disposals for which the Borrower has been
indemnified in full, all “hazardous waste” (as defined by the Resource Conservation and Recovery Act, 42 U.S.C. § 6901 et seq. (1976) and the regulations thereunder, 40 CFR Part 261 (“RCRA”))
generated at the Borrower’s or any Subsidiaries’ properties have in the past been and shall continue to be disposed of at sites which maintain valid permits under RCRA and any applicable state or local Environmental Law, except to the
extent where the failure to so dispose would not reasonably be expected have a material adverse effect on the business, financial condition or operations of the Borrower and the Subsidiaries, taken as a whole. 

ARTICLE V 

COVENANTS 

Section 5.01 Affirmative Covenants of the Borrower. The Borrower covenants and agrees that the Borrower
will, unless and until all of the Advances shall have been paid in full and all of the Commitments of the Lenders shall have terminated, unless Majority Lenders shall otherwise consent in writing: 

(a) Compliance with Laws, Etc. Comply, and cause each of its Subsidiaries to comply, with all applicable laws,
rules, regulations and orders, such compliance to include, without limitation, (i) complying with all Environmental Laws and (ii) paying 

  
 34 

 
before the same become delinquent all Taxes imposed upon it or upon its property except to the extent contested in good faith, except where failure to so comply would not reasonably be expected
to have a material adverse effect on the business, financial condition or operations of the Borrower and the Subsidiaries, taken as a whole. 
 (b) Reporting Requirements. Furnish to the Agent: 
 (i) as
soon as available and in any event within 60 days after the end of each of the first three fiscal quarters of each fiscal year of the Borrower, a copy of the quarterly report (x) for such quarter for the Borrower, containing a consolidated
balance sheet and consolidated statements of income and (x) for the period consisting of the fiscal year then elapsed, for the Borrower, containing consolidated statements of stockholders’ equity and cash flows; 

(ii) as soon as available and in any event within 120 days after the end of each fiscal year of the Borrower, a copy of
the consolidated annual audit report for such year for the Borrower, containing financial statements (including a consolidated balance sheet, consolidated statements of income, retained earnings and cash flows of the Borrower) for such year,
accompanied by an opinion of Deloitte & Touche or other nationally recognized independent public accountants. The opinion shall be unqualified (as to going concern, scope of audit and disagreements over the accounting or other treatment of
offsets) and shall state that such consolidated financial statements present fairly the consolidated financial position of the Borrower as at the dates indicated and the results of their operations and cash flow for the periods indicated in
conformity with GAAP applied on a basis consistent with prior years (except as stated therein) and that the examination by such accountants in connection with such consolidated financial statements has been made in accordance with generally accepted
auditing standards; 
 (iii) together with each delivery of the report of the Borrower pursuant to
clause (i) or clause (ii) above, a compliance certificate for the quarter or year, as applicable, executed by an authorized financial officer of the Borrower (A) stating, in the case of the financial statements delivered under
Section 5.01(b)(i) for such quarter, that such financial statements fairly present the consolidated financial condition of the Borrower and its Subsidiaries, taken as a whole, as at the dates indicated and the consolidated results of operations
of the Borrower and its Subsidiaries, taken as a whole, and cash flow for the periods indicated in conformity with GAAP applied on a basis consistent with prior years (except as otherwise stated therein), subject to changes resulting from audit and
normal year-end adjustment, (B) stating that such authorized financial officer has reviewed the terms of this Agreement and has made, or caused to be made under his or her supervision, a review in reasonable detail of the transactions and
consolidated financial condition of the Borrower and its Subsidiaries, taken as a whole, during the accounting period covered by such financial statements and that such authorized financial officer does not have knowledge of the existence as at the
date of the compliance certificate, of any condition or event that constitutes an Event of Default or a Potential Event of Default or, if any such condition or event exists, specifying the nature thereof and what action the Borrower has taken, is
taking and proposes to take with respect thereto and (C) demonstrating in reasonable detail compliance at the end of such accounting periods with the restrictions contained in Section 5.02(c). 

  
 35 

 (iv) as soon as possible and in any event within five days after the
occurrence of each Event of Default and each Potential Event of Default, continuing on the date of such statement, a statement of an authorized financial officer of the Borrower setting forth details of such Event of Default or Potential Event of
Default and the action which the Borrower has taken and proposes to take with respect thereto; 
 (v) promptly
after the sending or filing thereof, copies of all proxy statements, financial statements and reports that the Borrower or any of its Subsidiaries sends to its stockholders generally, and copies of all regular, periodic and special reports, and all
registration statements, that the Borrower or any of its Subsidiaries files with the SEC or any governmental authority that may be substituted therefor, or with any national securities exchange; 

(vi) promptly after the commencement thereof, notice of all material actions, suits and proceedings before any court or
government department, commission, board, bureau, agency or instrumentality, domestic or foreign, affecting the Borrower or any of its Subsidiaries, of the type described in Section 4.01(f); 

(vii) promptly after the occurrence thereof, notice of (A) any event which makes any of the representations contained
in Section 4.01(m) inaccurate or (B) the receipt by the Borrower of any notice, order, directive or other communication from a governmental authority alleging violations of or noncompliance with any Environmental Law which could reasonably
be expected to have a material adverse effect on the business, financial condition or operations of the Borrower and the Subsidiaries, taken as a whole; 
 (viii) promptly after any change in any Rating, a notice of such change, which notice shall specify the new Rating, the date on which such change was publicly announced by S&P or Moody’s, as the
case may be, and such other information with respect to such change as any Lender through the Agent may reasonably request; and 
 (ix) such other information respecting the business, financial condition or operations of the Borrower and the Subsidiaries as any Lender through the Agent may from time to time reasonably request.

 In lieu of furnishing to the Agent paper copies of the documents required to be delivered pursuant to
Sections 5.01(b)(i), (ii), (v), (vi) and (ix), to the extent such documents are filed with the SEC, the Borrower shall notify the Agent when such documents are so filed and may make such documents available to the Agent and Lenders at its
Internet website located at http://www.csc.com and through the SEC’s EDGAR system. Notwithstanding the foregoing, the Borrower shall deliver paper copies of such documents to any Lender that requests the Borrower to deliver such paper copies.

 (c) Corporate Existence, Etc. The Borrower will, and will cause each of its Significant Subsidiaries
to, at all times maintain its fundamental business and preserve 

  
 36 

 
and keep in full force and effect its corporate existence and all material rights, franchises and licenses necessary or desirable in the normal conduct of its business, in each case as
applicable, except as permitted under Section 5.02(b) and except if, in the reasonable business judgment of the Borrower, it is in the business interest of the Borrower or such Subsidiary not to preserve and maintain such legal existence
(except with respect to the Borrower), rights (charter and statutory) and franchises, and such failure to preserve the same would not reasonably be expected to have a material adverse effect on the business, financial condition or operations of the
Borrower and the Subsidiaries, taken as a whole. 
 (d) Maintenance of Insurance. The Borrower will and
will cause each of its Significant Subsidiaries to maintain insurance with responsible and reputable insurance companies or associations in such amounts and covering such risks as are usually insured by companies engaged in similar businesses.
Notwithstanding the foregoing, the Borrower and such Subsidiaries may maintain a plan or plans of self-insurance to such extent and covering such risks as is usual for companies of comparable size engaged in the same or similar business, which plans
shall include, among other things, adequate reserves for the risks that are self-insured. On request the Borrower will advise the Agent and the Lenders concerning any such plan or plans for self-insurance. 

(e) Visitation Rights. At any reasonable time and from time to time during normal business hours and with
reasonable prior notice, permit the Agent or any of the Lenders or any agents or representatives thereof (at their sole cost and expense), to visit the properties of, the Borrower and any of its Subsidiaries, and to discuss the affairs, finances and
accounts of the Borrower and any of its Subsidiaries with any of their officers employees, or if an Event of Default is continuing, with their independent certified public accountants. 

(f) Keeping of Books. Keep, and will cause each of its Significant Subsidiaries to keep, in all material respects,
proper books of record and account in accordance with GAAP. 
 Section 5.02 Negative Covenants of the
Borrower. The Borrower covenants and agrees that, unless and until all of the Advances shall have been paid in full and the Commitments of all of the Lenders shall have terminated, unless Majority Lenders shall otherwise consent in writing:

 (a) Liens, Etc. The Borrower will not create or suffer to exist, or permit any of its Significant
Subsidiaries to create or suffer to exist, any Lien, upon or with respect to any of its properties, whether now owned or hereafter acquired, or assign, or permit any of such Subsidiaries to assign, any right to receive income, in each case to secure
or provide for the payment of any Debt of any Person, unless the Borrower’s obligations hereunder shall be secured equally and ratably with, or prior to, any such Debt; provided however that the foregoing restriction shall not
apply to the following Liens which are permitted: 
 (i) Customary Permitted Liens; 

  
 37 

 (ii) Liens in favor of the United States to secure amounts paid to the
Borrower or any of its Subsidiaries as advance or progress payments under government contracts entered into by it so long as such Liens cover only (x) special bank accounts into which only such advance or progress payments are deposited and
(y) supplies covered by such government contracts and material and other property acquired for or allocated to the performance of such government contracts; 

(iii) attachment, judgment and other similar Liens arising in connection with legal proceedings, provided that any
such judgment does not constitute an Event of Default; 
 (iv) Liens on accounts receivable resulting from the
sale of such accounts receivable; 
 (v) Liens on assets of any Significant Subsidiary of the Borrower existing
at the time such Person becomes a Significant Subsidiary or is merged into or consolidated with the Borrower or a Significant Subsidiary (other than any such Lien created in contemplation of becoming a Significant Subsidiary); 

(vi) purchase money Liens upon or in any asset acquired or held by the Borrower or any Significant Subsidiary (including
any capital interest in any Person) to secure the purchase price of such asset or to secure Debt incurred solely for the purpose of financing the acquisition of or construction of improvements on or with respect to any such asset (provided that the
amount of Debt secured by such Lien does not exceed 100% of the purchase price of such asset and transaction costs relating to such acquisition or the costs of such construction) and Liens existing on such asset at the time of its acquisition (other
than any such Lien created in contemplation of such acquisition); and the interest of the lessor thereof in any asset that is subject to a Capital Lease; 
 (vii) Liens, other than Liens described in clauses (i) through (vi) and in clause (ix), to secure Debt not in excess of an aggregate of $100,000,000 principal amount at any time
outstanding; 
 (viii) Liens resulting from any extension, renewal or replacement (or successive extensions,
renewals or replacements), in whole or in part, of any Debt secured by any Lien referred to in clauses (v) and (vi) so long as (x) the aggregate principal amount of any such Debt shall not increase as a result of any such extension,
renewal or replacement and (y) Liens resulting from any such extension, renewal or replacement shall cover only such property which secured the Debt that is being extended, renewed or replaced; and 

(ix) Liens securing Debt owing to the Borrower or any of the Subsidiaries. 

(b) Restrictions on Fundamental Changes. The Borrower will not, and will not permit any of its Significant
Subsidiaries to, merge or consolidate with or into, or convey, transfer, lease or otherwise dispose of (whether in one transaction or in a series of transactions) all or a substantial portion of its assets (whether now owned or hereafter

  
 38 

 
acquired) to any Person (other than the Borrower or any Subsidiary of the Borrower, so long as the Borrower, directly or indirectly, owns 80% or more of the voting stock thereof), or enter into
any partnership, joint venture, syndicate, pool or other combination, unless (a) no Event of Default or Potential Event of Default has occurred and is continuing or would result therefrom and (b) in the case of any consolidation or merger
involving the Borrower, either (i) the Borrower is the surviving entity or (ii) the Person surviving or resulting from such consolidation or merger shall have assumed the obligations of the Borrower hereunder in an agreement or instrument
reasonably satisfactory in form and substance to the Agent and such surviving corporation shall have delivered, for the benefit of the Lenders and the Agent, such other documents as may reasonably be requested, including, without limitation,
information in respect of “know your customer” and similar requirements, an incumbency certificate and an opinion of nationally recognized independent counsel, or other independent counsel reasonably satisfactory to the Majority Lenders,
to the effect that all agreements or instruments effecting such assumption are enforceable in accordance with their terms and comply with the terms hereof. 
 (c) Financial Covenants. 
 (i) Minimum Interest Coverage
Ratio. The Borrower will not permit at the end of any quarterly financial reporting period the ratio of Consolidated EBITDA to Consolidated Interest Expense for the period of four consecutive fiscal quarters ending on the last day of such
quarterly financial reporting period, taken as a single period, to be less than 3.00 to 1.00. 
 (ii)
Consolidated Total Debt to Consolidated EBITDA Ratio. The Borrower will not permit at the end of any quarterly financial reporting period the ratio of Consolidated Total Debt as of the last day of such quarterly financial reporting period to
Consolidated EBITDA for the period of four consecutive fiscal quarters ending on the last day of such quarterly financial reporting period, taken as a single period, to exceed 3.00 to 1.00. 

ARTICLE VI 

EVENTS OF DEFAULT 
 Section 6.01 Events of Default. If any of the following events (“Events of Default”) shall occur and be continuing: 

(a) The Borrower shall fail to pay any principal of any Advance when the same becomes due and payable or the Borrower
shall fail to pay any interest on any Advance or any fees or other amounts payable hereunder within five days after the date due; or 
 (b) Any representation or warranty made by the Borrower herein or in connection with this Agreement shall prove to have been incorrect in any material respect when made; or 

  
 39 

 (c) The Borrower shall fail to perform or observe (i) any term,
covenant or agreement contained in Section 5.01(c) or 5.02, or (ii) any other term, covenant or agreement contained in this Agreement on its part to be performed or observed if the failure to perform or observe such other term, covenant or
agreement shall remain unremedied for 30 days after the earlier to occur of (i) written notice thereof having been given to the Borrower by the Agent at the request of any Lender or (ii) actual knowledge thereof by the Borrower of such
failure; or 
 (d) The Borrower or any of its Significant Subsidiaries shall fail to pay any principal of or
premium or interest on any of its Debt or any payment obligations in respect of guarantees of the Borrower or any such Significant Subsidiary of Debt owed to any Person other than the Borrower and the Subsidiaries which is outstanding in a principal
amount of at least $125,000,000 in the aggregate (but excluding Debt arising under this Agreement), when the same becomes due and payable (whether by scheduled maturity, required prepayment, acceleration, demand or otherwise), and such failure shall
continue after the applicable grace period, if any, specified in the agreement or instrument relating to such Debt or guarantee; or any other event shall occur or condition shall exist under any agreement or instrument relating to any such Debt and
shall continue after the applicable grace period, if any, specified in such agreement or instrument, if the effect of such event or condition is to accelerate, or to permit the acceleration of, the maturity of such Debt; or any such Debt shall be
declared to be due and payable, or required to be prepaid (other than by a regularly scheduled required prepayment or by a required prepayment of insurance proceeds or by a required prepayment as a result of formulas based on asset sales or excess
cash flow), redeemed, purchased or defeased, or an offer to prepay, redeem, purchase or defease such Debt shall be required to be made, in each case prior to the stated maturity thereof; or 

(e) The Borrower or any of its Significant Subsidiaries shall generally not pay its debts as such debts become due, or
shall admit in writing its inability to pay its debts generally, or shall make a general assignment for the benefit of creditors; or any proceeding shall be instituted by or against the Borrower or any of its Significant Subsidiaries seeking to
adjudicate it a bankrupt or insolvent, or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief, or composition of it or its debts under any law relating to bankruptcy, insolvency or reorganization or relief of
debtors, or seeking the entry of an order for relief or the appointment of a receiver, trustee, custodian or other similar official for it or for substantial part of its property and, in the case of any such proceeding instituted against it (but not
instituted by it), either such proceeding shall remain undismissed or unstayed for a period of 60 days, or any of the actions sought in such proceeding (including, without limitation, the entry of an order for relief against, or the appointment of a
receiver, trustee, custodian or other similar official for, it or for any substantial part of its property) shall occur; or the Borrower or any of its Significant Subsidiaries shall take any corporate or partnership action to authorize any of the
actions set forth above in this subsection (e); or 
 (f) Any judgment or order for the payment of money in
excess of $125,000,000 shall be rendered against the Borrower or any of its Significant Subsidiaries and is not promptly paid by the Borrower or any of its Significant 

  
 40 

 
Subsidiaries and either (i) enforcement proceedings shall have been commenced by any creditor upon such judgment or order or (ii) there shall be any period of 10 consecutive days during
which a stay of enforcement of such judgment or order, by reason of a pending appeal or otherwise, shall not be in effect; or 
 (g) 
 (i) There occurs one or more ERISA Events which individually
or in the aggregate results in or might reasonably be expected to result in liability to the Borrower or any of its ERISA Affiliates in excess of $125,000,000 over the amount previously reflected for any such liabilities, in accordance with GAAP, on
the financial statements delivered pursuant to Section 4.01(e); or 
 (ii) The Borrower or any ERISA
Affiliate shall have been notified by the sponsor of a Multiemployer Plan that it has incurred an aggregate Withdrawal Liability for all years to such Multiemployer Plan in an amount that, when aggregated with all other amounts required to be paid
to Multiemployer Plans by the Borrower and its ERISA Affiliates as Withdrawal Liability (determined as of the date of such notification), exceeds $125,000,000; or 

(iii) The Borrower or any ERISA Affiliate shall have been notified by the sponsor of a Multiemployer Plan that such
Multiemployer Plan is insolvent, in reorganization or is being terminated or has been determined to be in “endangered” or “critical” status, within the meaning of Title IV or ERISA, if as a result of such event the aggregate
annual contributions of the Borrower and its ERISA Affiliates to all Multiemployer Plans that are then insolvent, in reorganization or being terminated or have been determined to be in endangered or critical status have been or will be increased
over the amounts contributed to such Multiemployer Plans for the plan year of such Multiemployer Plan immediately preceding the plan year in which the event occurs by an amount exceeding, in each case, resulting in a liability to the Borrower or its
ERISA Affiliates of more than $125,000,000; or 
 (h) Any Person or two or more Persons acting in concert shall
have acquired beneficial ownership (within the meaning of Rule 13d-3 of the SEC under the Securities Exchange Act of 1934, as amended), directly or indirectly, of securities of the Borrower (or other securities convertible into such securities)
representing 35% or more of the combined voting power of all securities of the Borrower entitled to vote in the election of directors, other than securities having such power only by reason of the happening of a contingency. 

then, and in any such event, the Agent (i) shall at the request, or may with the consent, of the Majority Lenders, by notice to the Borrower,
declare the obligation of each Lender to make Advances to be terminated, whereupon the same shall forthwith terminate, and (ii) shall at the request, or may with the consent, of the Majority Lenders, by notice to the Borrower, declare the
Advances, all interest thereon and all other amounts payable under this Agreement to be forthwith due and payable, whereupon the Advances, all such interest and all such amounts shall become and be forthwith due and payable, without presentment,
demand, protest or further notice of any kind, all of which are here expressly waived by the Borrower; provided, however, 

  
 41 

 
that in the event of an actual or deemed entry of an order for relief with respect to the Borrower or any of its Significant Subsidiaries under the Federal Bankruptcy Code, (A) the
obligation of each Lender to make Advances shall automatically be terminated and (B) the Advances, all such interest and all such amounts shall automatically become and be due and payable, without presentment, demand, protest or any notice of
any kind, all of which are hereby expressly waived by the Borrower. 
 ARTICLE VII 

THE AGENT 

Section 7.01 Authorization and Authority. Each Lender hereby irrevocably appoints BTMU to act on
its behalf as the Agent hereunder and authorizes the Agent to take such actions on its behalf and to exercise such powers as are delegated to the Agent by the terms hereof, together with such actions and powers as are reasonably incidental thereto.
The provisions of this Article are solely for the benefit of the Agent and the Lenders, and the Borrower shall have no rights as a third party beneficiary of any of such provisions. 

Section 7.02 Agent Individually. 

(a) The Person serving as the Agent hereunder shall have the same rights and powers in its capacity as a Lender as any
other Lender and may exercise the same as though it were not the Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the
Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with the Borrower or
any Subsidiary or other Affiliate thereof as if such Person were not the Agent hereunder and without any duty to account therefor to the Lenders. 
 (b) Each Lender understands that the Person serving as Agent, acting in its individual capacity, and its Affiliates (collectively, the “Agent’s Group”) are engaged in a wide range of
financial services and businesses (including investment management, financing, securities trading, corporate and investment banking and research) (such services and businesses are collectively referred to in this Section 7.02 as
“Activities”) and may engage in the Activities with or on behalf of the Borrower or its Affiliates. Furthermore, the Agent’s Group may, in undertaking the Activities, engage in trading in financial products or undertake other
investment businesses for its own account or on behalf of others (including the Borrower and its Affiliates and including holding, for its own account or on behalf of others, equity, debt and similar positions in the Borrower or its Affiliates),
including trading in or holding long, short or derivative positions in securities, loans or other financial products of one or more of the Borrower and its Affiliates. Each Lender understands and agrees that in engaging in the Activities, the
Agent’s Group may receive or otherwise obtain information concerning the Borrower and its Affiliates (including information concerning the ability of the Borrower to perform its obligations hereunder) which information may not be available to
any of the Lenders that are not members of the Agent’s Group. None of the Agent nor any member of the 

  
 42 

 
Agent’s Group shall have any duty to disclose to any Lender or use on behalf of the Lenders, and shall not be liable for the failure to so disclose or use, any information whatsoever about
or derived from the Activities or otherwise (including any information concerning the business, prospects, operations, property, financial and other condition or creditworthiness of the Borrower) or to account for any revenue or profits obtained in
connection with the Activities, except that the Agent shall deliver or otherwise make available to each Lender such documents as are expressly required by this Agreement to be transmitted by the Agent to the Lenders. 

(c) Each Lender further understands that there may be situations where members of the Agent’s Group or their
respective customers (including the Borrower and its Affiliates) either now have or may in the future have interests or take actions that may conflict with the interests of any one or more of the Lenders (including the interests of the Lenders
hereunder). Each Lender agrees that no member of the Agent’s Group is or shall be required to restrict its activities as a result of the Person serving as Agent being a member of the Agent’s Group, and that each member of the Agent’s
Group may undertake any Activities without further consultation with or notification to any Lender. None of (i) this Agreement, (ii) the receipt by the Agent’s Group of information (including Information) concerning the Borrower or
its Affiliates (including information concerning the ability of the Borrower to perform its obligations hereunder) nor (iii) any other matter shall give rise to any fiduciary, equitable or contractual duties (including without limitation any
duty of trust or confidence) owing by the Agent or any member of the Agent’s Group to any Lender including any such duty that would prevent or restrict the Agent’s Group from acting on behalf of customers (including the Borrower or its
Affiliates) or for its own account. 
 Section 7.03 Duties of Agent; Exculpatory Provisions.

 (a) The Agent’s duties hereunder are solely ministerial and administrative in nature and the Agent shall
not have any duties or obligations except those expressly set forth herein. Without limiting the generality of the foregoing, the Agent shall not have any duty to take any discretionary action or exercise any discretionary powers, but shall be
required to act or refrain from acting (and shall be fully protected in so acting or refraining from acting) upon the written direction of the Majority Lenders (or such other number or percentage of the Lenders as shall be expressly provided for
herein), provided that the Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Agent or any of its Affiliates to liability or that is contrary to this Agreement or applicable law.

 (b) The Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the
request of the Majority Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Agent shall believe in good faith shall be necessary, under the circumstances as provided in Sections 8.01 or 6.01) or
(ii) in the absence of its own gross negligence or willful misconduct. The Agent shall be deemed not to have knowledge of any Potential Event of Default or Event of Default or the event or events that give or may give rise to any Potential
Event of Default or Event of Default unless and until the Borrower or any Lender shall have given notice to the Agent describing such Potential Event of Default or Event of Default and such event or events. 

  
 43 

 (c) Neither the Agent nor any member of the Agent’s Group shall be
responsible for or have any duty to ascertain or inquire into (i) any statement, warranty, representation or other information made or supplied in or in connection with this Agreement, (ii) the contents of any certificate, report or other
document delivered hereunder or in connection herewith or the adequacy, accuracy and/or completeness of the information contained therein, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set
forth herein or therein or the occurrence of any Potential Event of Default or Event of Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement or any other agreement, instrument or document or the perfection
or priority of any Lien or security interest created or purported to be created hereby or (v) the satisfaction of any condition set forth in Article III or elsewhere herein, other than (but subject to the foregoing clause (ii)) to confirm
receipt of items expressly required to be delivered to the Agent. 
 (d) Nothing in this Agreement shall require
the Agent or any of its Related Parties to carry out any “know your customer” or other checks in relation to any person on behalf of any Lender and each Lender confirms to the Agent that it is solely responsible for any such checks it is
required to carry out and that it may not rely on any statement in relation to such checks made by the Agent or any of its Related Parties. 
 Section 7.04 Reliance by Agent. The Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent,
statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper
Person. The Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition
hereunder to the making of an Advance that by its terms must be fulfilled to the satisfaction of a Lender, the Agent may presume that such condition is satisfactory to such Lender unless an officer of the Agent responsible for the transactions
contemplated hereby shall have received notice to the contrary from such Lender prior to the making of such Advance, and such Lender shall not have made available to the Agent such Lender’s ratable portion of the applicable Borrowing. The Agent
may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel,
accountants or experts. 
 Section 7.05 Indemnification. The Lenders agree to indemnify the
Agent (to the extent the Borrower is required to reimburse the Agent pursuant to Section 8.04 and only to the extent not reimbursed by the Borrower), ratably according to the respective principal amounts of the Advances then held by each of
them (or if no Advances are at the time outstanding or if any Advances are held by Persons which are not Lenders, ratably according to the respective amounts of their Commitments), from and against any and all liabilities, obligations, losses,
damages, penalties, actions, judgments, suits, costs, expenses or 

  
 44 

 
disbursements of any kind or nature whatsoever which may be imposed on, incurred by, or asserted against the Agent in any way relating to or arising out of this Agreement or any action taken or
omitted by the Agent under this Agreement, provided that no Lender shall be liable for any portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements resulting from the
Agent’s gross negligence or willful misconduct. Without limitation of the foregoing, each Lender agrees to reimburse the Agent promptly upon demand for its ratable share of any out-of-pocket expenses (including counsel fees) incurred by the
Agent in connection with the preparation, execution, delivery, administration, syndication, modification, amendment or enforcement (whether through negotiations, legal proceedings or otherwise) of, or legal advice in respect of rights or
responsibilities under, this Agreement, to the extent that the Agent is not reimbursed for such expenses by the Borrower. 

Section 7.06 Resignation of Agent. The Agent may at any time give notice of its resignation to the
Lenders and the Borrower. Upon receipt or giving of any such notice of resignation, the Majority Lenders shall have the right, in consultation with the Borrower, to appoint a successor, which shall be a bank with an office in New York, New York, or
an Affiliate of any such bank with an office in New York, New York. If no such successor shall have been so appointed by the Majority Lenders and shall have accepted such appointment within 30 days after the retiring Agent gives notice of its
resignation (such 30-day period, the “Lender Appointment Period”), then the retiring Agent may on behalf of the Lenders, appoint a successor Agent meeting the qualifications set forth above. In addition and without any obligation on
the part of the retiring Agent to appoint, on behalf of the Lenders, a successor Agent, the retiring Agent may at any time upon or after the end of the Lender Appointment Period notify the Borrower and the Lenders that no qualifying Person has
accepted appointment as successor Agent and the effective date of such retiring Agent’s resignation. Upon the resignation effective date established in such notice and regardless of whether a successor Agent has been appointed and accepted such
appointment, the retiring Agent’s resignation shall nonetheless become effective and (i) the retiring Agent shall be discharged from its duties and obligations as Agent hereunder and (ii) all payments, communications and
determinations provided to be made by, to or through the Agent shall instead be made by or to each Lender directly and, during such period, the Borrower shall have no obligation to pay to any Person the fees described in Section 2.04(b), until
such time as the Majority Lenders appoint a successor Agent as provided for above in this paragraph. Upon the acceptance of a successor’s appointment as Agent hereunder, such successor shall succeed to and become vested with all of the rights,
powers, privileges and duties as Agent of the retiring (or retired) Agent, and the retiring Agent shall be discharged from all of its duties and obligations as Agent hereunder (if not already discharged therefrom as provided above in this
paragraph). The fees payable by the Borrower to a successor Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring Agent’s resignation hereunder, the
provisions of this Article and Section 8.04 shall continue in effect for the benefit of such retiring Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the
retiring Agent was acting as Agent. 
 Section 7.07 Delegation of Duties. The Agent may perform
any and all of its duties and exercise its rights and powers hereunder by or through any one or more sub-agents appointed by the Agent. The Agent and any such sub-agent may perform any and all of its duties

  
 45 

 
and exercise its rights and powers by or through their respective Related Parties. Each such sub-agent and the Related Parties of the Agent and each such sub-agent shall be entitled to the
benefits of all provisions of this Article VII and Section 8.04 (as though such sub-agents were the “Agent” hereunder) as if set forth in full herein with respect thereto. 

Section 7.08 Non-Reliance on Agent and Other Lenders. 

(a) Each Lender confirms to the Agent, each other Lender and each of their respective Related Parties that it
(i) possesses (individually or through its Related Parties) such knowledge and experience in financial and business matters that it is capable, without reliance on the Agent, any other Lender or any of their respective Related Parties, of
evaluating the merits and risks (including tax, legal, regulatory, credit, accounting and other financial matters) of (x) entering into this Agreement, (y) making Advances and other extensions of credit hereunder and (z) in taking or
not taking actions hereunder and thereunder, (ii) is financially able to bear such risks and (iii) has determined that entering into this Agreement and making Advances and other extensions of credit hereunder is suitable and appropriate
for it. 
 (b) Each Lender acknowledges that (i) it is solely responsible for making its own independent
appraisal and investigation of all risks arising under or in connection with this Agreement, (ii) that it has, independently and without reliance upon the Agent, any other Lender or any of their respective Related Parties, made its own
appraisal and investigation of all risks associated with, and its own credit analysis and decision to enter into, this Agreement based on such documents and information, as it has deemed appropriate and (iii) it will, independently and without
reliance upon the Agent, any other Lender or any of their respective Related Parties, continue to be solely responsible for making its own appraisal and investigation of all risks arising under or in connection with, and its own credit analysis and
decision to take or not take action under, this Agreement based on such documents and information as it shall from time to time deem appropriate, which may include, in each case: 

(i) the financial condition, status and capitalization of the Borrower; 

(ii) the legality, validity, effectiveness, adequacy or enforceability of this Agreement and any other agreement,
arrangement or document entered into, made or executed in anticipation of, under or in connection with this Agreement; 
 (iii) determining compliance or non-compliance with any condition hereunder to the making of an Advance and the form and substance of all evidence delivered in connection with establishing the
satisfaction of each such condition; 
 (iv) the adequacy, accuracy and/or completeness of the Information
Memorandum and any other information delivered by the Agent, any other Lender or by any of their respective Related Parties under or in connection with this Agreement, the transactions contemplated hereby and thereby or any other agreement,
arrangement or document entered into, made or executed in anticipation of, under or in connection with this Agreement. 

  
 46 

 Section 7.09 Other Agents. Each Lender hereby acknowledges
that neither the syndication agent, the documentation agents nor any other Lender designated as any “Agent” on the signature pages hereof (other than the Agent) has any liability hereunder other than in its capacity as a Lender.

 ARTICLE VIII 
 MISCELLANEOUS 
 Section 8.01 Amendments, Etc.

 No amendment or waiver of any provision of this Agreement, nor consent to any departure by the Borrower therefrom, shall in
any event be effective unless the same shall be in writing and signed by the Majority Lenders, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided,
however, that no amendment, waiver or consent shall, unless in writing and signed by all the Lenders, do any of the following: (a) waive any of the conditions specified in Section 3.01, (b) except pursuant to Section 2.16,
increase the Commitments of the Lenders or subject the Lenders to any additional obligations, (c) reduce the principal of, or interest on, the Advances or any fees or other amounts payable hereunder, (d) postpone any date fixed for any
payment of principal of, or interest on, the Advances or any fees or other amounts payable hereunder, (e) change the percentage of the Commitments or of the aggregate unpaid principal amount of the Advances, or the number of Lenders, which
shall be required for the Lenders or any of them to take any action hereunder, or (f) amend this Section 8.01; and provided, further, that no amendment, waiver or consent shall, unless in writing and signed by the Agent in
addition to the Lenders required above to take such action, affect the rights or duties of the Agent under this Agreement; and provided further that no amendment of Section 2.19 shall be effective without the written consent of
each Granting Lender, all or any part of whose outstanding Advances is being funded by an SPC at the time of such amendment. 

Section 8.02 Notices, Etc. 

(a) General. Unless otherwise expressly provided in this Agreement, all notices, requests, demands, directions and
other communications provided for hereunder shall be in writing (including by facsimile transmission). All such written notices shall be mailed, faxed or delivered to the applicable address, facsimile number or (subject to Section 8.15)
electronic mail address, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows: 

  
 47 

 (1) if to the Borrower or the Agent, to the address, facsimile number,
electronic mail address or telephone number set forth below, or to such other address, facsimile number, electronic mail address or telephone number as shall be designated by such party in a notice to the other parties: 

 

			
	Borrower:	  	Computer Sciences Corporation
		  	3170 Fairview Park Drive
		  	Falls Church, Virginia 22042
		  	Attention: Thomas R. Irvin
		  	Phone: (703) 641-3544
		  	Fax: (703) 641-3799
		  	Email: tirvin@csc.com
		
	Agent:	  	The Bank of Tokyo-Mitsubishi UFJ, Ltd.
		  	1251 Avenue of the Americas, New York NY 10020
		  	Attention: Lawrence Blat
		  	Phone: 212-782-4310 or 212-782-5777
		  	 Email: lblat@us.mufg.jp (with a copy to:
 AgencyDesk@us.mufg.jp)

 (2) if to any other Lender, to the address, facsimile number, electronic mail address or
telephone number of its Domestic Lending Office as may be specified opposite its name on Schedule I hereto (or in the Assignment and Acceptance pursuant to which it became a Lender), or to such other address, facsimile number, electronic mail
address or telephone number as shall be designated by such party in a notice to the Borrower and the Agent. 

(b) Timing. All such notices and other communications shall be deemed to be given or made upon the earlier to occur
of (i) actual receipt by the relevant party hereto during the recipient’s normal business hours (or if delivered after normal business hours shall be deemed to have been delivered on the next Business Day) and (ii) (A) if
delivered by hand or by courier, when signed for by or on behalf of the relevant party hereto; (B) if delivered by mail, four Business Days after deposit in the United States mail, postage prepaid; (C) if delivered by facsimile, when sent
and receipt has been confirmed by telephone; and (D) if delivered by electronic mail (subject to the provisions of Section 8.15(c)) when received; provided, however, that notices and other communications to the Agent pursuant
to Article II or VII shall not be effective until actually received by such Person. In no event shall a voicemail message be effective as a notice, communication or confirmation hereunder. 

(c) Effectiveness of Facsimile Documents and Signatures. This Agreement and, except as otherwise specified herein,
any documents delivered pursuant to or in connection with this Agreement may be transmitted and/or signed by facsimile or other electronic delivery. The effectiveness of any such documents and signatures shall, subject to applicable law, have the
same force and effect as manually-signed originals and shall be binding on the Borrower, the Agent and the Lenders. The Agent may also require that any such documents and signatures be confirmed by a manually-signed original thereof;
provided, however, that the failure to request or deliver the same shall not limit the effectiveness of any facsimile document or signature. 
 (d) Reliance by the Agent and Lenders. The Agent and the Lenders shall be entitled to rely and act upon any notices purportedly given by or on behalf of the Borrower even if (i) such notices
were not made in a manner specified herein, were 

  
 48 

 
incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The
Borrower shall indemnify each indemnified person from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of the Borrower. All telephonic notices to and other
communications with the Agent may be recorded by the Agent, and each of the parties hereto hereby consents to such recording. 

Section 8.03 No Waiver; Remedies. No failure on the part of any Lender or the Agent to exercise, and no
delay in exercising, any right hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided
are cumulative and not exclusive of any remedies provided by law. 
 Section 8.04 Costs, Expenses and
Indemnification. 
 (a) The Borrower agrees to pay promptly on demand all reasonable costs and
out-of-pocket expenses (other than Taxes, for which the provisions of Section 2.12 shall apply instead) of Agent (in its capacity as such) in connection with the preparation, execution, delivery, administration, syndication, modification and
amendment of this Agreement, and the other documents to be delivered hereunder or thereunder, including, without limitation, the reasonable fees and out-of-pocket expenses of a single counsel for the Agent with respect thereto and with respect to
advising the Agent as to its rights and responsibilities hereunder. The Borrower further agrees to pay promptly on demand all costs and expenses of the Agent and of each Lender, if any (including, without limitation, reasonable counsel fees and
out-of-pocket expenses), in connection with the enforcement (whether through negotiations, legal proceedings or otherwise) of this Agreement and the other documents to be delivered hereunder, including, without limitation, reasonable counsel fees
and out-of-pocket expenses in connection with the enforcement of rights under this Section 8.04(a). 
 (b)
If any payment of principal of any Eurodollar Rate Advance extended to the Borrower is made other than on the last day of the interest period for such Advance, as a result of a payment pursuant to Section 2.06 or acceleration of the maturity of
the Advances pursuant to Section 6.01 or for any other reason, the Borrower shall, upon demand by any Lender (with a copy of such demand to the Agent), pay to the Agent for the account of such Lender any amounts required to compensate such
Lender for any additional losses, costs or expenses which it may reasonably incur as a result of such payment, including, without limitation, any loss, cost or expense incurred by reason of the liquidation or reemployment of deposits or other funds
acquired by any Lender to fund or maintain such Advance. 
 (c) The Borrower agrees to indemnify and hold
harmless the Agent (in its capacity as such), each Lender and each director, officer, employee, agent, attorney and affiliate of the Agent and each Lender (each an “indemnified person”) in connection with any expenses, losses,
claims, damages or liabilities to which the Agent, a Lender or such indemnified persons may become subject (other than Taxes, for which the provisions of 

  
 49 

 
Section 2.12 shall apply instead), insofar as such expenses, losses, claims, damages or liabilities (or actions or other proceedings commenced or threatened in respect thereof) arise out of
the transactions referred to in this Agreement or arise from any use or intended use of the proceeds of the Advances, or in any way arise out of activities of the Borrower that violate Environmental Laws, and to reimburse the Agent, each Lender and
each indemnified person, upon their demand, for any reasonable legal or other out-of-pocket expenses incurred in connection with investigating, defending or participating in any such loss, claim, damage, liability, or action or other proceeding,
whether commenced or threatened (whether or not the Agent, such Lender or any such person is a party to any action or proceeding out of which any such expense arises); provided that nothing in this Section 8.04(c) shall obligate
the Borrower to pay the normal expenses of the Agent in the administration of this Agreement in the absence of pending or threatened litigation or other proceedings or the claims or threatened claims of others and then only to the extent arising
therefrom. Notwithstanding the foregoing, the Borrower shall have no obligation hereunder to an indemnified person with respect to indemnified liabilities which have resulted from the gross negligence, bad faith or willful misconduct of such
indemnified person, as determined by a final and nonappealable judgment by a count of competent jurisdiction, or which have resulted from a claim brought by the Borrower against an indemnified person for breach in bad faith of such indemnified
person’s obligations hereunder in which the Borrower has obtained a final and nonappealable judgment in its favor on such claim as determined by a court of competent jurisdiction. In the case of an investigation, litigation or proceeding to
which the indemnity in this paragraph applies, such indemnity shall be effective whether or not such investigation, litigation or proceeding is brought by the Borrower, any of the Borrower’s equity holders or creditors, an indemnified person or
any other person or entity, whether or not an indemnified person is otherwise a party thereto. 
 (d) To the
fullest extent permitted by applicable law, the Borrower shall not assert, and the Borrower hereby waives, any claim against any indemnified person, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to
direct or actual damages) arising out of, in connection with, or as a result of this Agreement, or any agreement or instrument contemplated hereby, the transactions contemplated hereby, any Advance or the use of the proceeds thereof. 

Section 8.05 Right of Set-off. Upon (i) the occurrence and during the continuance of any Event of
Default and (ii) the making of the request or the granting of the consent specified by Section 6.01 to authorize the Agent to declare the Advances due and payable pursuant to the provisions of Section 6.01, each Lender is hereby
authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all deposits (time or demand, provisional or final, or general, but not special) at any time held and other indebtedness at any time
owing by such Lender or any Affiliate thereof to or for the credit or the account of the Borrower against any and all of the obligations of the Borrower now or hereafter existing under this Agreement that are then due and payable, whether or not
such Lender shall have made any demand under this Agreement, and each such Affiliate is hereby irrevocably authorized to permit such setoff and application. Each Lender agrees promptly to notify the Borrower after any such set-off and application
made by such Lender, provided that the failure to give such notice shall not affect the validity of such set-off and application. The rights of each Lender under this Section are in addition to other rights and remedies (including, without
limitation, other rights of set-off) which such Lender may have. 

  
 50 

 Section 8.06 Binding Effect. This Agreement shall be deemed
to have been executed and delivered when it shall have been executed by the Borrower and the Agent and when the Agent shall have been notified by each Bank that such Bank has executed it and thereafter shall be binding upon and inure to the benefit
of the Borrower, the Agent and each Lender and their respective successors and permitted assigns, except that the Borrower shall not, except as permitted in Section 5.02(b), have the right to assign its rights or obligations hereunder or any
interest herein without the prior written consent of all Lenders. This Agreement and the fee letter referred to in Section 2.04(b) constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all
previous oral agreements and understandings relating to the subject matter hereof. 
 Section 8.07
Assignments and Participations. 
 (a) Each Lender may assign to one or more Eligible Assignees
all or a portion of its rights and obligations under this Agreement (including, without limitation, all or a portion of its Commitment and the Advances owing to it); provided, however, that (i) each such assignment shall be of a
constant, and not a varying, percentage of all rights and obligations under this Agreement, (ii) after giving effect to any such assignment, (1) the assigning Lender shall no longer have any Commitment or (2) the amount of the
Commitment of each of the assigning Lender and the Eligible Assignee party to such assignment (in each case determined as of the date of the Assignment and Acceptance with respect to such assignment) shall not be less than $5,000,000 and increments
of $1,000,000 in excess thereof (iii) each such assignment shall be to an Eligible Assignee, and (iv) the parties to each such assignment shall execute and deliver to the Agent, for its acceptance and recording in the Register, an
Assignment and Acceptance, and a processing and recordation fee of $3,500 (unless the assignor is a Lender and the assignee is an Affiliate such Lender, in which case no fee shall be required)). Upon such execution, delivery, acceptance and
recording, from and after the effective date specified in each Assignment and Acceptance, (x) the assignee thereunder shall be a party hereto and, to the extent that rights and obligations hereunder have been assigned to it pursuant to such
Assignment and Acceptance, have the rights and obligations of a Lender hereunder and (y) the Lender assignor thereunder shall, to the extent that rights and obligations hereunder have been assigned by it pursuant to such Assignment and
Acceptance, relinquish its rights and be released from its obligations under this Agreement (and, in the case of an Assignment and Acceptance covering all or the remaining portion of an assigning Lender’s rights and obligations under this
Agreement, such Lender shall cease to be a party hereto). Any Lender may at any time (i) upon notice to the Borrower and the Agent, assign all or any portion of its rights hereunder to an Affiliate of such Lender or to another Lender or
(ii) without notice to or consent of the Borrower or the Agent, pledge as security all or any portion of its rights hereunder, including to any Federal Reserve Bank; provided, that no such pledge or assignment shall release such Lender
from any of its obligations hereunder. 

  
 51 

 (b) By executing and delivering an Assignment and Acceptance, the Lender
assignor thereunder and the assignee thereunder confirm to and agree with each other and the other parties hereto as follows: (i) other than as provided in such Assignment and Acceptance, such assigning Lender makes no representation or
warranty and assumes no responsibility with respect to any statements, warranties or representations made in or in connection with this Agreement or the execution, legality, validity, enforceability, genuineness, sufficiency or value of this
Agreement or any other instrument or document furnished pursuant hereto; (ii) such assigning Lender makes no representation or warranty and assumes no responsibility with respect to the financial condition of the Borrower or the performance or
observance by the Borrower of any of its obligations under this Agreement or any other instrument or document furnished pursuant hereto; (iii) such assignee confirms that it has received a copy of this Agreement, together with copies of the
financial statements referred to in Section 4.01, and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into such Assignment and Acceptance; (iv) such assignee will,
independently and without reliance upon the Agent, such assigning Lender or any other Lender and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking
action under this Agreement; (v) such assignee confirms that it is an Eligible Assignee; (vi) such assignee appoints and authorizes the Agent to take such action as agent on its behalf and to exercise such powers under this Agreement as
are delegated to the Agent by the terms hereof, together with such powers as are reasonably incidental thereto; and (vii) such assignee agrees that it will perform in accordance with their terms all of the obligations which by the terms of this
Agreement are required to be performed by it as a Lender. 
 (c) The Agent, acting solely for this purpose on the
Borrower’s behalf, shall maintain at its address referred to in Section 8.02 a copy of each Assignment and Acceptance delivered to and accepted by it and a register for the recordation of the names and addresses of the Lenders and the
Commitment of, and, with respect to the Borrower, principal amount of the Advances owing to, each Lender from time to time (the “Register”). In addition, the Agent shall maintain on the Register information regarding the designation
and revocation of designation of any Lender as a Defaulting Lender. The entries in the Register shall be conclusive and binding for all purposes, absent manifest error, and the Borrower, the Agent and the Lenders may treat each Person whose name is
recorded in the Register as a Lender hereunder for all purposes of this Agreement. The Register shall be available for inspection by the Borrower or any Lender at any reasonable time and from time to time upon reasonable prior notice. 

Within five days of its receipt of an Assignment and Acceptance executed by an assigning Lender and an assignee representing that it is
an Eligible Assignee (together with a processing and recordation fee of $3,500 with respect thereto (unless the assignor is a Lender and the assignee is an Affiliate such Lender, in which case no fee shall be required)) and upon consent of the Agent
and, so long as no Potential Event of Default or Event of Default then exists and is continuing (and except for assignments to an Affiliate of the Lender or to another Lender), the Borrower thereto, which consents shall not be unreasonably withheld
or delayed, the Agent shall, if such Assignment and Acceptance has been completed and is in substantially the form of Exhibit B hereto, (1) accept such Assignment and Acceptance and (2) record the information contained therein in the
Register. All communications with the Borrower with respect to such consent of the Borrower shall be sent pursuant to Section 8.02. 

  
 52 

 (d) Each Lender may sell participations to one or more banks or other
entities in or to all or a portion of its rights and obligations under this Agreement (including, without limitation, all or a portion of its Commitment and the Advances owing to it; provided, however, that (i) such Lender’s
obligations under this Agreement (including, without limitation, its Commitment to the Borrower hereunder) shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such
obligations, (iii) such Lender shall remain the holder of any such Advance for all purposes of this Agreement, (iv) the Borrower, the Agent and the other Lenders shall continue to deal solely and directly with such Lender in connection
with such Lender’s rights and obligations under this Agreement, and (v) no Lender shall grant any participation under which the participant shall have rights to require such Lender to take or omit to take any action hereunder or approve
any amendment to or waiver of this Agreement, except to the extent such amendment or waiver would reduce the interest rate or the amount of principal or fees applicable to Advances or the Commitment in which such participant is participating.

 (e) Any Lender may, in connection with any assignment or participation or proposed assignment or participation
pursuant to this Section 8.07, disclose to the assignee or participant or proposed assignee or participant, any information relating to the Borrower furnished to such Lender by or on behalf of the Borrower; provided that, prior to any
such disclosure, the assignee or Participant or proposed assignee or participant shall agree to preserve the confidentiality of any confidential information relating to the Borrower received by it from such Lender. 

Section 8.08 Governing Law. This Agreement shall be governed by, and construed in accordance
with, the laws of the State of New York. 
 Section 8.09 Execution in Counterparts. This
Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same
agreement. 
 Section 8.10 Consent to Jurisdiction; Waiver of Immunities. The Borrower
irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or in tort or otherwise, against the Agent or any Lender, or any Related
Party of the foregoing in any way relating to this Agreement or the transactions relating hereto, in each case in any forum other than the courts of the State of New York sitting in New York County, and of the United States District Court of the
Southern District of New York, and any appellate court from any thereof and each of the parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of such courts and agrees that all claims in respect of any such action,
litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by applicable law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action,
litigation or proceeding shall be conclusive and may be enforced in 

  
 53 

 
other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement shall affect any right that the Agent or any Lender may otherwise have to bring
any action or proceeding relating to this Agreement against the Borrower or its properties in the courts of any jurisdiction. The Borrower irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any objection that
it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement in any court referred to in this Section. Each of the parties hereto hereby irrevocably waives, to the fullest extent
permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. Each party hereto irrevocably consents to service of process in the manner provided for notices in
Section 8.02. Nothing in this Agreement will affect the right of any party hereto to serve process in any other manner permitted by applicable law. 
 Section 8.11 Waiver of Trial by Jury. THE BORROWER, THE BANKS, THE AGENT AND, BY ITS ACCEPTANCE OF THE BENEFITS HEREOF, OTHER LENDERS EACH HEREBY AGREES TO WAIVE
ITS RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT. The scope of this waiver is intended to be all-encompassing of any and all disputes that may be filed in any court and that relate to
the subject matter of this transaction, including without limitation contract claims, tort claims, breach of duty claims and all other common law and statutory claims. The Borrower, the Banks, the Agent and, by its acceptance of the benefits hereof,
other Lenders each (i) acknowledges that this waiver is a material inducement for the Borrower, the Lenders and the Agent to enter into a business relationship, that the Borrower, the Lenders and the Agent have already relied on this waiver in
entering into this Agreement or accepting the benefits thereof, as the case may be, and that each will continue to rely on this waiver in their related future dealings and (ii) further warrants and represents that each has reviewed this waiver
with its legal counsel, and that each knowingly and voluntarily waives its jury trial rights following consultation with legal counsel. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THIS WAIVER
SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT. In the event of litigation, this Agreement may be filed as a written consent to a trial by the court. 

Section 8.12 Survival of Warranties. All agreements, representations and warranties made in this
Agreement shall survive the execution and delivery of this Agreement and any increase in the Commitments under this Agreement. 

Section 8.13 Severability. In case any provision in or obligation under this Agreement shall be invalid,
illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

 Section 8.14 Headings. Section and subsection headings in this Agreement are included herein
for convenience of reference only and shall not constitute a part of this Agreement for any other purpose or be given any substantive effect. 

  
 54 

 Section 8.15 Website Communications. 

(a) The Borrower hereby agrees that it will provide to the Agent all information, documents and other materials that it is
obligated to furnish to the Agent pursuant to this Agreement, including, without limitation, all notices, requests, financial statements, financial and other reports, certificates and other information materials, but excluding any such communication
that (i) relates to a request for a new, or a conversion of an existing, borrowing or other extension of credit (including any election of an interest rate or interest period relating thereto), (ii) relates to the payment of any principal
or other amount due under this Agreement prior to the scheduled date therefor, (iii) provides notice of any default or event of default under this Agreement or (iv) is required to be delivered to satisfy any condition precedent to the
effectiveness of this Agreement and/or any borrowing or other extension of credit thereunder (all such non-excluded communications being referred to herein collectively as “Communications”), by transmitting the Communications in an
electronic/soft medium in a format acceptable to the Agent to lblat@us.mufg.jp (with a copy to: AgencyDesk@us.mufg.jp) or as otherwise specified in Section 5.01(b). In addition, the Borrower agrees to continue to provide the Communications to
the Agent in the manner specified in this Agreement but only to the extent requested by the Agent. 
 (b) The
Borrower further agrees that the Agent may make the Communications available to the Lenders by posting the Communications on Intralinks or a substantially similar electronic transmission systems (the “Platform”). 

THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE”. THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY
OR COMPLETENESS OF THE COMMUNICATIONS, OR THE ADEQUACY OF THE PLATFORM AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS OR OMISSIONS IN THE COMMUNICATIONS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, WITHOUT LIMITATION, ANY
WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY THE AGENT PARTIES IN CONNECTION WITH THE COMMUNICATIONS OR THE PLATFORM. IN NO EVENT
SHALL THE AGENT OR ANY OF ITS AFFILIATES OR ANY OF THEIR RESPECTIVE OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, ADVISORS OR REPRESENTATIVES (COLLECTIVELY, “AGENT PARTIES”) HAVE ANY LIABILITY TO THE BORROWER, ANY LENDER OR ANY OTHER PERSON OR
ENTITY FOR DAMAGES OF ANY KIND, INCLUDING, WITHOUT LIMITATION, DIRECT OR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES (WHETHER IN TORT, CONTRACT OR OTHERWISE) ARISING OUT OF THE BORROWER’S OR THE AGENT’S
TRANSMISSION OF COMMUNICATIONS THROUGH THE INTERNET, EXCEPT TO THE EXTENT THE LIABILITY OF ANY AGENT PARTY IS FOUND IN A FINAL NON-APPEALABLE JUDGMENT BY A COURT OF COMPETENT JURISDICTION TO HAVE RESULTED PRIMARILY FROM SUCH AGENT PARTY’S GROSS
NEGLIGENCE OR WILLFUL MISCONDUCT. 

  
 55 

 (c) The Agent agrees that the receipt of the Communications by the Agent at
its e-mail address set forth above shall constitute effective delivery of the Communications to the Agent for purposes of this Agreement. Each Lender agrees that notice to it (as provided in the next sentence) specifying that the Communications have
been posted to the Platform shall constitute effective delivery of the Communications to such Lender for purposes of this Agreement. Each Lender agrees to notify the Agent in writing (including by electronic communication) from time to time of such
Lender’s e-mail address to which the foregoing notice may be sent by electronic transmission and that the foregoing notice may be sent to such e-mail address. 
 Nothing herein shall prejudice the right of the Borrower or any Lender to give any notice or other communication pursuant to this Agreement in any other manner specified in this Agreement. 

Section 8.16 USA PATRIOT Act Notice. Each Lender that is subject to the Act (as hereinafter defined) and
the Agent (for itself and not on behalf of any Lender) hereby notifies the Borrower that pursuant to the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Act”), it is
required to obtain, verify and record information that identifies the Borrower, which information includes the name and address of the Borrower and other information that will allow such Lender or the Agent, as applicable, to identify the Borrower
in accordance with the Act. 
 Section 8.17 Confidentiality. Each of the Agent and the Lenders
agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its and its Affiliates’ respective managers, administrators, trustees, partners, directors,
officers, employees, agents, advisors and other representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information
confidential), (b) to the extent requested by any regulatory authority purporting to have jurisdiction over it or its Affiliates (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to
the extent required by applicable laws or regulations or by any subpoena or similar legal process, provided, however, that, except in the case of disclosure to bank regulators or examiners in accordance with customary banking practices, if legally
permitted written notice of each instance in which Information is required or requested to be disclosed shall be furnished to the Borrower not less than 30 days prior to the expected date of such disclosure or, if 30 days’ notice is not
practicable under the circumstances, as promptly as practicable under the circumstances, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder or any action or proceeding relating to this Agreement or
the enforcement of rights hereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section 8.17, to (i) any assignee of or participant in, or any prospective assignee of or participant in,
any of its rights or obligations under this Agreement or (ii) any actual or prospective party (or its managers, administrators, trustees, partners, directors, officers, employees, agents, advisors and other representatives) to any swap or
derivative or similar transaction under which payments are to be made by reference to the Borrower and its obligations, this Agreement or payments hereunder, (iii) any rating agency, or (iv) the CUSIP Service Bureau or any similar
organization, (g) with the consent of the Borrower or (h) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section or (y) becomes available to the Agent or any Lender or any
of their respective Affiliates on a nonconfidential basis from a source other than the Borrower. 

  
 56 

 For purposes of this Section, “Information” means all information received
from the Borrower or any of its Subsidiaries relating to the Borrower or any of its Subsidiaries or any of their respective businesses, other than any such information that is available to the Agent or any Lender on a nonconfidential basis prior to
disclosure by the Borrower or any of its Subsidiaries, provided that, in the case of information received from the Borrower or any of its Subsidiaries after the date hereof, such information is clearly identified at the time of delivery as
confidential. Any Person required to maintain the confidentiality of Information as provided in this Section 8.17 shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain
the confidentiality of such Information as such Person would accord to its own confidential information. 

Section 8.18 No Fiduciary Duty. The Borrower acknowledges that the Agent, each Lender and their
Affiliates (collectively, solely for purposes of this paragraph, the “Lender Parties”), each Lender Party is acting pursuant to a contractual relationship on an arm’s length basis, and the parties hereto do not intend that any
Lender Party act or be responsible as a fiduciary to the Borrower, its management, stockholders, creditors or any other person. The Borrower and each Lender Party hereby expressly disclaims any fiduciary relationship and agrees they are each
responsible for making their own independent judgments with respect to any transactions entered into between them. The Borrower also hereby acknowledges that no Lender Party has advised nor is advising the Borrower as to any legal, accounting,
regulatory or tax matters, and that the Borrower is consulting its own advisors concerning such matters to the extent it deems appropriate. 
 [Remainder of page intentionally left blank] 

  
 57 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed
and delivered by their respective authorized officers as of the date first written above. 
  

			
	COMPUTER SCIENCES CORPORATION, a Nevada corporation, as the Borrower
		
	By	 	 /s/ Thomas R. Irvin

	Name:	 	Thomas R. Irvin
	Title:	 	Vice President and Treasurer

 [Term Loan Agreement Signature Page] 

 
			
	 THE BANK OF TOKYO-MITSUBISHI UFJ,
 LTD., NEW YORK BRANCH,

	as Agent and a Lender
		
	By	 	 /s/ T. Fennessey

	Name:	 	T. Fennessey
	Title:	 	Managing Director
	
	 BANK OF AMERICA, N.A.,
 as a Lender

		
	By	 	 /s/ Thuy U. Bui

	Name:	 	Thuy U. Bui
	Title:	 	Vice President
	
	 CITIBANK, N.A.,
 as a Lender

		
	By	 	 /s/ James M. Walsh

	Name:	 	James M. Walsh
	Title:	 	Managing Director
	
	 BARCLAYS BANK PLC,
 as a Lender

		
	By	 	 /s/ Michael Mozer

	Name:	 	Michael Mozer
	Title:	 	Vice President

 [Term Loan Agreement Signature Page] 

 SCHEDULE I 
 APPLICABLE LENDING OFFICES 
  

					
	 Bank
	 	 Domestic Lending Office
	 	 Eurodollar Lending Office

	Bank of America, N.A.	 	 2001 Clayton Road., Bldg. B

Concord, CA 94520
 Attention: Prasanna Kumar
Anna
 T: 415-436-3685 ext. 62067
 F:
214-290-9519
 Prasanna.k.anna@bankofamerica.com
	 	 2001 Clayton Road., Bldg. B

Concord, CA 94520
 Attention: Prasanna Kumar
Anna
 T: 415-436-3685 ext. 62067
 F:
214-290-9519
 Prasanna.k.anna@bankofamerica.com

			
	 The Bank of Tokyo-Mitsubishi UFJ, Ltd.,
 New York Branch
	 	 1251 Avenue of the Americas

New York, NY 10020-1104
 Attn: Jaime
Velez
 T: 201-413-8586
 F: 201-521-2304
/ 2305
	 	 1251 Avenue of the Americas

New York, NY 10020-1104
 Attn: Jaime
Velez
 T: 201-413-8586
 F: 201-521-2304
/ 2305

			
	Barclays Bank PLC	 	 745 Seventh Avenue
 New York,
NY 10019
 Attn: Vincent Cangiano /

Gema Dizon
 T: 201-499-2710 / 3729

F: 212-412-7401

xrausloanops1@barclayscapital.com

gemma.dizon@barcap.com
	 	 745 Seventh Avenue
 New York,
NY 10019
 Attn: Vincent Cangiano /

Gema Dizon
 T: 201-499-2710 / 3729

F: 212-412-7401

xrausloanops1@barclayscapital.com

gemma.dizon@barcap.com

			
	Citibank, N.A.	 	 1615 Brett Road, Building #3

New Castle, DE 19720
 Attn: Bank Loan
Syndications
 T: 302-323-5871
 F:
212 994-0961
 glagentoofficeops@citigroup.com
	 	 1615 Brett Road, Building #3

New Castle, DE 19720
 Attn: Bank Loan
Syndications
 T: 302-323-5871
 F:
212 994-0961
 glagentoofficeops@citigroup.com

  

  
 Schedule I-1

 SCHEDULE II 
 LENDERS’ COMMITMENTS 
  

					
	 Lender
	  	Commitment	 
	 The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch
	  	$	75,000,000	  
	 Bank of America, N.A.
	  	$	75,000,000	  
	 Barclays Bank PLC
	  	$	50,000,000	  
	 Citibank, N.A.
	  	$	50,000,000	  
		  	  
	  
	 
	 Total Commitments:
	  	$	250,000,000Manufacturing, Supply and License Agreement

 Exhibit 10.1 
 Confidential Treatment Requested by BioDelivery Sciences International, Inc. 

IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	
	 
	 ***CONFIDENTIAL TREATMENT REQUESTED***
  
 Note: Confidential treatment requested with respect to certain portions hereof denoted
 with “***”

 MANUFACTURING, SUPPLY, AND LICENSE AGREEMENT 

This Manufacturing, Supply, and License Agreement (the “Agreement”) is made as of April 26, 2012 (the “Effective
Date”) by and between Arius Pharmaceuticals, Inc. (a wholly-owned subsidiary of BioDelivery Sciences International, Inc.), a Delaware corporation with an office at 801 Corporate Center Drive, Suite 210, Raleigh, North Carolina 27607 USA
(“BDSI”), and LTS LOHMANN Therapie-Systeme AG, a limited liability company organized and existing under the laws of Germany, having its executive offices and principal place of business at Lohmannstrasse 2, 56626 Andernach, Germany
(“LTS”). BDSI and LTS are sometimes referred to collectively herein as the “Parties” or singly as a “Party.” 
 R E C I T A L S 
 WHEREAS, BDSI or an Affiliate thereof intends to distribute the Product
(as hereinafter defined) or permit the BDSI Licensee, or distributor thereof to distribute the Product; and 
 WHEREAS, LTS is presently engaged
in the production of similar products; and 
 WHEREAS, the Parties have entered into a Process Development Agreement on December 15, 2006
(the “PDA”); and 
 WHEREAS, BDSI desires to contract with LTS for the manufacture and supply of Products and to purchase such
Products from LTS and, contingent, a back-up supplier; 
 WHEREAS, LTS wishes to supply such requirements in return of an adequate compensation,
all upon the terms and conditions hereinafter contained; and 
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual
covenants and agreements contained herein, the Parties hereto, intending to be legally bound, do hereby agree as follows: 
  

	1.	Definitions. 

 In addition
to the capitalized terms defined elsewhere in this Agreement, the following terms used in this Agreement shall have the meaning set forth below. Any capitalized terms not defined herein shall have the meaning as defined in the PDA. 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	1.1	“Active Principle” means fentanyl, which for purposes of the Products to be manufactured by LTS hereunder, shall be as specified in accordance with the
specifications therefor attached hereto as Exhibit A. 

  

	1.2	“Affiliate” means, with respect to a Party: 

  

	 	(a)	Any company or other entity of which such Party as of the effective date: 

  

	 	(i)	directly or indirectly owns more than fifty percent (50%) of the stock or other equity interest entitled to vote for the election of directors of such company or

  

	 	(ii)	otherwise has voting control over such entity; 

  

	 	(b)	Any company or other entity of which such Party has the power to appoint more than half the members of the board of directors or boards legally representing the
undertaking; 

  

	 	(c)	Any entity which, directly or indirectly, has the powers described in paragraphs a. or b. with respect to a Party (a “Parent”); or 

 

	 	(d)	Any entity over which a Parent of a Party has the powers described in paragraphs a. or b. 

 

	1.3	“API” means active pharmaceutical ingredient. 

  

	1.4	“Authority” means the relevant governmental or regulatory body whose approval is required to sell a Product in a particular country of the Territory.

  

	1.5	“Aveva” means Aveva Drug Delivery Systems, Inc. 

  

	1.6	“Back-up Trigger” means ***. 

  

	1.7	“BEMA” means BDSI’s proprietary bioerodible, mucoadhesive multi-layer polymer film technology. 

 

	1.8	“BEMA Fentanyl Product” means the product(s) utilizing the BEMA technology that contain fentanyl as its sole API. 

 

	1.9	“BDSI Licensee” shall mean any Third Party to whom BDSI or any Affiliate thereof has granted rights to use, sell, offer for sale, and/or distribute any
Product, and which may include, but shall not be limited to, Meda AB, KUNWHA Pharmaceutical Co., Ltd., TTY Biopharm Co., Ltd. 

  
 2 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	1.10	“Certificate of Analysis” means a certificate issued by a supplier which states the Specifications for the Product and, if issued by the raw material
supplier, raw material therefor and indicates the final release test results and includes documentation of any batch deviations. “LTS Certificate of Analysis” means a certificate issued by LTS on the finished Product which will indicate
the final release test results and include documentation of any batch deviations. 

  

	1.11	“Commercially Reasonable Efforts” means ***. 

  

	1.12	“Control” or “Controlled” means, with respect to any Patents or other intellectual property, the legal authority or right (whether by ownership,
license or otherwise) of a party to grant a license or a sublicense of or under such Patents or other intellectual property, without breaching the terms of any agreement with, or misappropriating the proprietary or trade secret information of, any
Third Party. 

  

	1.13	“Demonstration Samples” means BEMA-based products, lacking API, used to demonstrate the manner in which the BEMA Fentanyl Product is packaged and used, and
labeled “demonstration samples, for demonstration purposes only,” as such product(s) is(are) further described in the Product Specifications and Packaging Specifications. 

 

	1.14	“European Countries” means the countries specified in Exhibit B attached hereto. 

 

	1.15	“Forecast” means a written forecast describing BDSI’s anticipated requirements with respect to Products for a given time period, including the proposed
delivery schedule with respect to such Products. 

  

	1.16	“GMP” means, as relevant to the Products, the principles and guidelines of good manufacturing practice as contained (a) with respect to any Product
intended for use or sale in the European Union, in either directive 91/356/EEC (medicinal products for human use) or directive 91/412/EEC (medicinal products for veterinary use), as such principles and guidelines are interpreted and expanded in
“The Rules Governing Medicinal Products in the European Community, Volume IV. Good Manufacturing Practice for medicinal Products” and/or amended from time to time, and any reasonably equivalent successors to such guidelines and principles
or (b) with respect to Product intended for use or sale in any other portion of the Territory, any equivalent guidelines or regulations. 

  

	1.17	“Governmental Approval” means all permits, licenses, approvals, and authorizations required by any governmental or regulatory authority as a prerequisite to
the manufacturing, marketing or selling of the BEMA Fentanyl for human therapeutic use in the Territory. 

  

	1.18	“Launch Stocks” shall mean the quantities of stocks of the BEMA Fentanyl Product and Demonstration Samples ordered by BDSI under this Agreement to support the
commercial introduction of the BEMA Fentanyl Product in any country of the Territory. 

  
 3 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	1.19	“Manufacturing Improvement” means any discovery, inventions, know-how, trade secret, technique, methodology, modifications, improvements, works of authorship,
designs, data, or modifications (whether or not protectable under patent, copyright, trade secrecy, or similar laws) with respect to the Process including each of the following resulting from any of the foregoing: any patent applications, and rights
to file patent applications patents issuing thereon, and all continuations, continuations-in-part, reissuances, divisions, extensions, and foreign counterparts resulting from any of the foregoing that are developed or conceived by either Party (or
any Affiliate thereof) as a result of LTS’ manufacture of Products under this Agreement. 

  

	1.20	“Net Sales” means ***. 

  

	1.21	“Order” means a written purchase order for the Products, which order shall include a delivery schedule specifying the requested delivery date and quantity for
each Product ordered. ***. 

  

	1.22	“Packaging Specifications” means the specifications for the packaging of Products, which, with respect to Products supplied for use in clinical trials, shall
be agreed upon by the Parties in each case on short notice and which, with respect to Products supplied for commercial use or sale in the Territory are described in Exhibit C, attached hereto and incorporated herein by reference, as they may be
amended pursuant to this Agreement following qualification and validation, which specifications shall be reasonably consistent with the form of BEMA Fentanyl Product and labeling therefor approved in the applicable Governmental Approval(s) in the
Territory. If and as the Packaging Specifications for Products for commercial use or sale are amended pursuant to this Agreement, the existing Exhibit C shall be amended to reflect such changes, and such amended Exhibit C shall be provided to LTS by
BDSI and shall be deemed to be part of this Agreement. 

  

	1.23	“Patents” means all patents and patent applications, and patents issuing thereon which are necessary or useful for the use, development, sale, or
manufacturing of a Product and all continuations, continuations-in-part, re-issuances, divisions, foreign counterparts, and extensions of any of the foregoing. 

 

	1.24	“Placebo” means a BEMA-based product(s) that does not contain API, intended for use in preclinical testing and clinical studies concerning the BEMA Fentanyl
Product, as such product(s) is(are) further described in the Product Specifications and Packaging Specifications. 

  

	1.25	“Process” means ***. 

  

	1.26	“Product” or “Products” means BEMA Fentanyl Products, Placebos, Demonstration Samples. 

  
 4 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	1.27	“Purchase Price” for each Product is the corresponding amount set forth on Exhibit D, as such amount may be amended from time to time in accordance with this
Agreement ***. 

  

	1.28	“Product Specifications” means the manufacturing specifications, quality and quality control for the applicable Product, which, with respect to Products
supplied for use in clinical trials, shall be agreed upon by the Parties in each case on short notice, and which, with respect to Products supplied for commercial use or sale are described in Exhibit E, attached hereto and incorporated herein by
reference, as they may be amended pursuant to this Agreement following qualification and validation, which specifications shall be reasonably consistent with the form of BEMA Fentanyl Product and labeling therefore approved in the applicable
Governmental Approval(s) in the Territory. If and as the Product Specifications for Products for commercial use or sale are amended consistent with this Agreement, the existing Exhibit E shall be amended to reflect such changes, and such amended
Exhibit E shall be provided to LTS by BDSI and shall be deemed to be part of this Agreement. 

  

	1.29	“QAA” means quality assurance agreement to be concluded between the Parties to allocate the responsibilities with regard to quality aspects.

  

	1.30	“Territory” means all countries world-wide with the exception of the United States of America (U.S.A.), its territories and protectorates, and Canada.

  

	1.31	“Third Party” means any entity other than a Party or any Affiliate of a Party. 

 

	1.32	“Technology”: 

“LTS Technology” shall mean all discoveries, Manufacturing Improvements, inventions, know-how, trade secrets, techniques,
methodologies, modifications, works of authorship, designs and data (whether or not protectable under patent, copyright, trade secrecy or other similar laws), that is conceived, discovered, developed, generated, created, made or reduced to practice
or tangible medium of expression solely by employees or consultants of LTS, or otherwise Controlled by LTS and any Patents Controlled by LTS claiming any of the foregoing. 
 “BDSI Technology” shall mean all discoveries, Product improvements arising from this Agreement, inventions, know-how, trade secrets, techniques, methodologies, modifications, works of
authorship, designs and data (whether or not protectable under patent, copyright, trade secrecy or other similar laws), that is conceived, discovered, developed, generated, created, made or reduced to practice or tangible medium of expression solely
by employees or consultants of BDSI, or Controlled by BDSI and any Patents Controlled by BDSI claiming any of the foregoing. 
  

	1.33	 “Valid Claim” means a claim of any issued, unexpired, granted patent that has not been dedicated to the public, disclaimed, abandoned or held
invalid or unenforceable by a court or other body of competent jurisdiction from which no further appeal can be taken, 

  
 5 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
and that has not been explicitly disclaimed, or admitted by any licensor or owner of such patent in writing to be invalid or unenforceable or of a scope not covering a Product (or its manufacture
or use) through reissue, disclaimer or otherwise. 

  

	2.	Effectiveness; Term. 

This Agreement shall be effective for a period beginning on the Effective Date and, subject to any termination or extension undertaken in
accordance with this Agreement, continue until the *** anniversary of the first commercial sale of the Product by BDSI, an Affiliate thereof, any BDSI Licensee, or any distributor thereof in the Territory (the “Initial Term”). Unless
sooner terminated in accordance with Section 19, this Agreement shall be automatically renewed following the Initial Term for successive terms of *** years each, subject to termination by either Party upon written notice to be given not less
than *** year prior to the end of the Initial Term or to the commencement of any *** renewal term. 
  

	3.	Testing and Registration of the Product. 

  

	3.1	BDSI shall, as between LTS and BDSI, be responsible for obtaining Governmental Approval of the Product for human therapeutic use with the proper health, customs and
other authorities. BDSI shall keep LTS reasonably and regularly informed as to the status of all such approvals and applications therefore, and shall notify LTS in writing promptly upon receipt by BDSI, its Affiliate, or a BDSI Licensee of each
Governmental Approval to market the Product commercially for human therapeutic use in the Territory. BDSI may employ the help of its Affiliates or BDSI Licensee(s) during the process. 

 

	3.2	LTS shall provide to BDSI information regarding LTS’ manufacturing facilities, methods and process controls for the manufacture of the Product, and will reasonably
assist BDSI thereof in compilation of information for the chemistry, manufacturing and control documentation which BDSI reasonably determines in good faith is needed for completion of the regulatory filings. In the event that LTS reasonably
determines that any such information constitutes proprietary, confidential, or trade secret information belonging to LTS, LTS shall, without limitation of BDSI’s rights (or LTS’ obligations) under Sections 4 and 15, be entitled to provide
such confidential information directly to the competent regulatory authority, provided that, in the event LTS elects to provide such information directly, LTS shall do so as quickly as reasonably possible. 

 

	3.3	Upon request, each Party shall provide the other Party with a status update with regard to any audit or inspection conducted by any governmental or other regulatory
authority which relates directly to the Products or the manufacture thereof. 

  
 6 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	4.	Supply. 

  

	4.1	Subject to the terms of this Agreement, LTS shall employ its Commercially Reasonable Efforts to supply Products to BDSI for use or sale in the Territory. Except as
permitted by, and subject to, Section 14, (i) LTS shall be the sole and exclusive supplier of the Products to BDSI for sale in the Territory during the term of this Agreement and BDSI shall purchase solely from LTS all of BDSI’s
requirements for Products to be sold in the Territory and (ii) BDSI shall not manufacture or have manufactured on its behalf any Products for sale in the Territory outside the scope of this Agreement. 

 

	4.2	The manner and style of the labeling, packaging, and trade dress of the Products shall be as described in the Packaging Specifications. ***. LTS shall use
BDSI’s specified labeling (and only such labeling) on the Products. For the avoidance of doubt, BDSI shall be solely responsible for the contents of any product label and LTS shall not be responsible in any manner, including but not limited to
any provision of this Agreement, for any error, mistake, violation of any applicable law, rule, regulation or guideline or any other problem with the content of the label as specified by BDSI unless LTS does not follow label instructions provided by
BDSI. Any *** change or modification to a Product’s label or packaging shall be implemented by LTS as soon as reasonably practicable. BDSI shall reimburse LTS for the reasonable, documented total direct costs of any Product labels or
packaging rendered obsolete by such change and for reasonable, documented costs for the change or modification to a Product’s label or packaging. 

  

	4.3	BDSI may from time to time place binding written purchase orders for batches of BEMA Fentanyl Products, Demonstration Samples, and Placebos to be used for clinical
studies (“Clinical Supply Orders”). BDSI may only place orders in multiples of the full batch sizes set forth on Exhibit F. Such purchase orders shall only be binding upon written confirmation by LTS within *** of receipt, provided that,
notwithstanding foregoing, LTS’ obligation to deliver Product under this Agreement pursuant to orders placed in accordance with this Agreement shall remain unaffected. LTS shall confirm all such orders within *** of receipt. Clinical Supply
Orders shall be placed reasonably, but at least *** in advance of the requested date of delivery subject to the terms of this Agreement. LTS agrees to use Commercially Reasonable Efforts to deliver according to the delivery schedule contained in any
Clinical Supply Order. No terms and conditions contained in any Clinical Supply Order, acknowledgment, invoice, bill of lading, acceptance or other preprinted form issued by either Party shall be effective to the extent they are inconsistent with,
modify or add to the terms and conditions contained herein. 

  

	4.4	 As further depicted in Exhibit G, BDSI shall place Orders for Launch Stocks on a date not less than *** before the first and on a country-by-country
basis each subsequent intended date of commercial launch of the BEMA Fentanyl Product in the Territory (the “Date for Launch”) (notwithstanding that such date may not be capable of determination at the time for the order). BDSI may only
place Orders in multiples of the full batch sizes set forth on Exhibit F. Such Orders shall only be binding upon written confirmation by LTS within *** of LTS’ receipt of such Order, provided that, notwithstanding foregoing,

  
 7 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
LTS’ obligation to deliver Product under this Agreement pursuant to orders placed in accordance with this Agreement shall remain unaffected. LTS shall confirm all such orders within *** of
receipt. LTS shall use Commercially Reasonable Efforts to deliver the BEMA Fentanyl Product and Demonstration Samples in accordance with all Orders made in accordance with this Agreement. 

 

	4.5	Within *** following submission of the initial application for Governmental Approval in the Territory with respect to the BEMA Fentanyl Product, BDSI shall provide LTS
with a non-binding Forecast of BDSI’s requirements for the BEMA Fentanyl Product for the *** period following receipt of the anticipated Governmental Approval. The Forecast shall be updated monthly until the date on which BDSI places an Order
for Launch Stocks. Except as otherwise provided herein, all Forecasts made hereunder shall, except as further described below, be nonbinding and made to assist LTS in planning its production. 

 

	4.6	As further depicted in Exhibit G, all Orders for Products other than Clinical Supply Orders and Orders for Launch Stocks (“Commercial Supplies”) shall be
governed by this Section 4.6: 

  

	 	(a)	BDSI shall, not less than *** before the beginning of each calendar quarter, give LTS: 

 

	 	(i)	Its Order for Commercial Supplies to be delivered to BDSI during that calendar quarter and, 

 

	 	(ii)	a Forecast for the following *** calendar quarters. 

  

	 	(b)	BDSI may only place Orders for Commercial Supplies in multiples of the full batch sizes set forth on Exhibit F. Such Orders shall only be binding upon written
confirmation by LTS within *** of LTS’ receipt of such Order, provided that, notwithstanding foregoing, LTS’ obligation to deliver Product under this Agreement pursuant to orders placed in accordance with this Agreement shall remain
unaffected. LTS shall confirm all such orders within *** of receipt. Notwithstanding the foregoing, BDSI shall have no obligation to deliver Forecasts pursuant to this Section 4.6 until it places an Order for Launch Stocks.

  

	 	(c)	LTS shall not be obligated to accept Orders for a calendar quarter to the extent, in the aggregate, they exceed by more than *** the amounts forecasted for that quarter
in the previous Forecast. However, LTS shall make Commercially Reasonable Efforts, but not be obligated, to also deliver such exceeding quantities. 

  

	 	(d)	LTS shall deliver according to the proposed delivery schedule contained in any Order. 

  
 8 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	(e)	The Parties will discuss delivery and scheduling issues as necessary. 

  

	 	(f)	Each Forecast shall be deemed a binding commitment of BDSI to purchase in the first calendar quarter thereof (i.e. the first quarter following the quarter covered by
the accompanying Order) at least *** of the quantity of Products set forth with respect to such *** calendar quarter. The order quantities for Launch Stocks shall be deemed a binding commitment of BDSI to purchase *** percent *** of such quantities
of Products. 

  

	 	(g)	Shipment by LTS a quantity of the Product that is within plus or minus *** percent *** of the amount specified in BDSI’s Order, and a delivery date that is within
plus or minus *** of such Order’s requested delivery date, shall constitute compliance with LTS’ delivery obligations hereunder. LTS shall only invoice BDSI for actually delivered amounts. 

 

	 	(h)	No terms and conditions contained in any Order, acknowledgment, invoice, bill of lading, acceptance or other preprinted form issued by either Party shall be effective
to the extent they are inconsistent with, modify or add to the terms and conditions contained herein. 

  

	4.7	In the event LTS (i) has properly followed all procedures, processes, and protocols for the manufacture of Product, including those provided in the Product
Specifications or any regulatory approvals or legal requirements, (ii) has used Commercially Reasonable Efforts to manufacture Products that will conform to the Product Specifications, and (iii) reasonably determines that a batch of
Product does not conform to the Product Specifications (“OOS Batch”) and would, if shipped, constitute Defective Product the Parties agree to the following: 

 

	 	(a)	BDSI shall bear the total reasonable, documented *** costs for the first OOS Batch of each *** consecutive batches of Product manufactured under this Agreement
(regardless of size or country destination); 

  

	 	(b)	LTS shall bear such total *** costs for all other OOS Batches in any *** consecutive batch series of batches of Product manufactured under this Agreement; and

  

	 	(c)	 If LTS incurs *** costs for *** or more OOS Batches *** within any *** consecutive batch series of batches of Product in accordance with subsection
(b) above (i.e. before BDSI is obliged to cover again any *** costs under subsection (a)), in accordance with this Section 4.7, then, upon written notice from either Party to the other Party, the Parties shall enter into good faith
discussions about the continuation of the manufacture of the Product at LTS. Should the Parties not reach a definitive agreement on all terms and all conditions reasonably necessary for the continuation the manufacture of Product at LTS in light of
the frequency of OOS Batches or changes to Product Specifications or manufacturing processes 

  
 9 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
required to sufficiently reduce such frequency of OOS Batches, then either Party shall have the right to terminate the Agreement on *** days written notice to the other Party. Notwithstanding
anything to the contrary, the Parties agree that (i) each *** consecutive batch series of batches of Product including one (or more) OOS Batch(e)s referenced in the preceding sentence shall not include any batches of Product included in any
prior or subsequent *** consecutive batch series of Product including any OOS Batch(es) (i.e. no “*** consecutive batch series of batches of Product” may overlap by including the same batch of Product in *** such series for purposes of
this Section 4.7), (ii) the first “*** consecutive batch series of batches of Product” under this Section 4.7 shall begin with the first OOS Batch, and (iii) each subsequent “*** consecutive batch series of batches
of Product” shall begin with the first OOS Batch occurring following the tenth batch of the previous “*** consecutive batch series of batches of Product. 

For purposes of clarification, but not limitation, the rights and obligations of the Parties under this Section 4.7 shall be in
addition to, and without limitation of, any rights or obligations either Party may have in the event of a Back-up Trigger or with respect to any Back-up Supplier. 
  

	4.8	Within *** of the date of delivery of a Defective Product, LTS will replace such Defective Products and deliver them at no additional costs for BDSI as soon as
reasonably possible, provided that (i) BDSI supplies the necessary quantities of Active Principle to LTS according to Section 5 and (ii) if LTS is not able to replace such Defective Products with Products that are not Defective
Products within a reasonable period of time following notification of such Defective Product (and despite reasonably adequate quantities of Active Principle), LTS shall, upon BDSI’s request and instead of the replacement referenced above,
promptly refund any amounts actually paid by BDSI with respect to such Defective Product. “Defective” shall mean any Product not manufactured in accordance with, or otherwise not complying with, the Product Specifications, Packaging
Specifications or GMP, subject to BDSI having had appropriate and correct storage at all times according to the storage specifications, after the Product has been delivered by LTS. 

 

	4.9	BDSI shall, to the extent reasonably possible or feasible, return to LTS, at LTS’ cost, any Products rejected properly in accordance with this Section 4 and
the QAA. The Parties shall jointly agree on the most efficient and cost-effective way of replacement or destruction prior to BDSI taking action. 

  

	4.10	 In addition to any changes to Packaging Specifications effected pursuant to Section 4.2, in the event a Party desires any change to the Product
Specifications, or suppliers of raw materials, such Party shall provide written notice thereof to the other Party, and LTS shall, upon its written confirmation, in accordance with the QAA, and, in the case of such changes proposed or requested by
LTS, BDSI’s written agreement to such change except to the extent such change is permitted without BDSI’s written agreement according to the QAA, implement any such requested change as soon as reasonably possible or, if later,

  
 10 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
the date specified by BDSI for the implementation of such change, provided, however, that such changes will not have any effect or implications on the regulatory approval or status. BDSI shall
reimburse LTS for the reasonable, documented total direct costs resulting from such change to the Product Specifications or a raw material supplier. In case new GMP requirements trigger such a change to Product Specifications or BDSI wishes a change
to the Product Specifications that requires LTS to make additional investments in its facility, LTS shall also have the right, to change the Purchase Price, after discussion with, and subject to written agreement of, BDSI, to reflect such increased
costs. The price caps of Section 7 shall not apply in such case. 

  

	4.11	BDSI shall reimburse LTS for the reasonable, documented total direct cost of any Product ***. LTS shall only be entitled to a reimbursement for raw materials /
packaging materials for the next *** of a Forecast. For avoidance of doubt, in case of such changes implemented by LTS on request of BDSI, BDSI shall remain obligated to compensate LTS for any binding Orders placed by BDSI according to Sections 4.3,
4.4 and/or 4.6. 

  

	5.	Supply of Active Principle. 

  

	5.1	BDSI shall itself or through a Third Party manufacturer provide LTS with such quantities of Active Principle, conforming to the Active Principle Specifications, as are
reasonably sufficient to enable LTS’ to manufacture and supply Products in a timely manner in accordance with this Agreement ***. 

  

	5.2	BDSI shall provide, or require any Third Party manufacturer of Active Principle, to provide all necessary export/import licenses, if any, appropriate Certificates of
Analysis to LTS for each shipment of Active Principle delivered hereunder. BDSI shall promptly advise LTS of any material safety or toxicity problem of which BDSI becomes aware regarding the Active Principle to be provided hereunder or materials
used in the manufacture of the Active Principle to be provided hereunder. 

  

	5.3	LTS shall have the right to audit BDSI, its Affiliates or agreed upon third parties (which approval shall not be unreasonably withheld) as applicable for the
appropriate manufacturing process for Active Principle and current GMP at reasonable times on reasonable notice. 

  

	5.4	In addition, BDSI or its approved vendor, if applicable is and shall continue to be available for governmental inspection if an Authority so requests.

  

	5.5	BDSI acknowledges that LTS’ obligation to supply Product shall be subject to BDSI providing the necessary amounts of Active Principle to LTS according to this
Section 5. LTS shall be deemed not to be in breach of this Agreement if any failure to comply with its obligations arising out of this Agreement is caused by any non-delivery or late delivery or delivery of defective Active Principle.

  
 11 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	5.6	Each party shall promptly advise the other of any safety or toxicity problem of which either party becomes aware regarding the Active Principle or materials used in the
manufacture of the Active Principle. 

  

	6.	Quality; Regulatory. 

  

	6.1	LTS warrants that all Products supplied pursuant to this Agreement shall on the date of delivery have been manufactured in accordance with the Product Specifications,
Packaging Specifications and all legal and regulatory requirements at the place of manufacture (including, but not limited to, those included in applicable Governmental Approvals) and GMP. The Product Specifications may be amended only with the
prior written consent of LTS which shall not unreasonably be withheld. 

  

	6.2	LTS shall, as soon as reasonably possible, provide written notice of any significant changes proposed by LTS to the method of manufacture of the Products.
Product(s)-related changes shall be subject to BDSI’s prior written consent not to be unreasonably withheld. The time and costs for implementing such changes shall be reasonably agreed between the Parties. 

 

	6.3	LTS shall provide BDSI (or its designee) with LTS’ Certificates of Analysis with respect to all deliveries of the Products, as customary in the pharmaceutical
industry and consistent with any applicable legal or regulatory requirements, and with manufacturing and export documents as necessary for 

  

	 	(i)	import and export of the Products and 

  

	 	(ii)	compliance with all applicable regulatory requirements. LTS shall keep complete, accurate and authentic accounts, notes, data and records of the work performed by it
under this Agreement and shall maintain complete and adequate records pertaining to the methods and facilities used by it for the manufacture, processing, testing, packing, labeling, holding and distribution of Products in accordance with the
applicable regulations. 

  

	6.4	LTS shall be responsible for handling and responding to any governmental or regulatory agency inspections with respect to manufacturing of Products during the term of
this Agreement. To the extent available to LTS, LTS shall as soon as is reasonably possible, provide to BDSI copies of any 

  

	 	(a)	request or inquiry made by any regulatory agency with respect to Products or their manufacture or storage and 

 

	 	(b)	 any response thereto or information provided in response with respect to the foregoing, provided that, to the extent reasonably practicable and
permissible under any relevant contracts between LTS and Third Parties, BDSI shall be 

  
 12 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
provided an opportunity to review and comment on any and all such responses. LTS shall use Commercially Reasonable Efforts to 

 

	 	(i)	advise BDSI of any requests by any governmental or regulatory authority(ies) for any inspections with respect to the manufacturing of Products and

  

	 	(ii)	provide BDSI with copies of any relevant correspondence related thereto in due time. 

 

	6.5	LTS and BDSI shall in due time negotiate and agree in good faith upon an appropriate Quality Assurance Agreement (according to EU-GMP Legislation Art. 12 2003/94/EC,
related national laws such as § 9 AMWHV). In the event the terms of this Agreement and the Quality Assurance Agreement conflict, the terms of this Agreement shall govern. In furtherance of LTS’ efforts in quality assurance and subject to a
separate commercial agreement, if executed by the parties, LTS shall also perform any ongoing stability testing. 

  

	6.6	Nothing in this Agreement, however, shall be construed as limiting the right of LTS to develop and/or manufacture for Third Parties any product, other than a Product,
developed by LTS and/or a Third Party independently of BDSI or the BEMA technology, whether or not such product contains the Active Principle, or is used for the same indication as Product, provided that the foregoing shall not be construed as any
license, grant of rights, or covenant not to sue for the benefit of LTS or any Third Party with respect to any of the BDSI Technology or any other patents or intellectual property rights of BDSI. 

 

	7.	Purchase Price; Supply Payment. 

  

	7.1	Payment of the Purchase Price (Exhibit D) shall be made in Euros by BDSI within *** of receipt of 

 

	 	(a)	Products (other than Defective Products) delivered in accordance with this Agreement and 

 

	 	(b)	a written invoice for Products (other than Defective Products) supplied under this Agreement. 

 

	7.2	 The Purchase Price for the Product shall be reviewed by the Parties prior to *** of the Effective Date, and such price may be modified by
written agreement of the Parties to take effect not less than ***. Any price increase sought by LTS shall be substantiated by LTS to BDSI by LTS documenting LTS’ various cost increase factors for the Product, and no price increase proposed or
requested by LTS shall exceed more than *** of the previously-effective Purchase Price. Should LTS, due to increases in LTS’ manufacturing 

  
 13 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
costs for Products or due to increasing raw material costs resulting from unforeseen circumstances beyond LTS’ reasonable control, require a Purchase Price increase of more than *** of the
previously-effective Purchase Price, such increase shall be subject to BDSI’s written agreement not to be withheld unreasonably and BDSI shall have, in addition to the rights set forth above, the right to have the Purchase Price reviewed by an
independent Certified Public Accountant reasonably acceptable to LTS acting in confidence and retained by BDSI at BDSI’s expense, for purposes of confirming such unforeseen circumstances. 

 

	7.3	Payments not made in due time shall from the date of being overdue on until finally paid bear interest at a rate of ***, applying on the specific date when the
payment has become due or on the first business day thereafter. 

  

	7.4	Notwithstanding the foregoing, LTS shall not be obliged to continue manufacturing/ deliveries if BDSI is more than *** in arrears for payments due. In such case, LTS
shall not be obliged to resume manufacturing/deliveries until all open payments are made by BDSI. 

  

	8.	Delivery, Title and Risk. 

  

	8.1	Delivery of the Products shall be effected ***, at which time all risk of loss and damage to the Products shall pass to BDSI, its Affiliates, or a BDSI Licensee,
and BDSI, its Affiliates, or a BDSI Licensee shall carry out all customs and export clearances necessary for the shipment, export, and import of Products out of and/or into any jurisdiction and obtain, at its own expense, any export or import
license or other governmental or regulatory approval required for exportation and/or importation into and/or out of any jurisdiction. 

  

	8.2	BDSI shall ascertain that either BDSI, its Affiliates, or a BDSI Licensee or their designees shall be responsible for final release of the Products to the marketplace
in accordance with the applicable QAA. 

  

	9.	Product Recall. 

  

	9.1	During the term of this Agreement, each Party shall promptly inform the other by telephone and in writing in the event any circumstances occur which may precipitate a
possible or actual recall, withdrawal, or field correction of any Product (a “Product Recall”). LTS shall not be entitled to effect any Product Recall with respect to Products in the Territory without BDSI’s prior written consent,
provided that, notwithstanding the foregoing, LTS may effect any Product Recall required to comply with any regulatory or legal requirements, guidelines, directives, orders, or injunctions if such a Product Recall is not effected within a
commercially reasonable period of time by BDSI or any Affiliate, licensee or distributor thereof. At BDSI’s expense, which shall be reasonable and documented, LTS shall reasonably cooperate with BDSI and follow BDSI’s reasonable
instructions in connection with any Product Recall. 

  
 14 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	9.2	All costs and expenses (including reasonable attorneys’ fees) related to any Product Recall, including any costs of notification, destruction or return, shall be
the sole responsibility of BDSI, and BDSI shall indemnify and hold harmless LTS and its Affiliates for any damages, claims, costs and expenses (including reasonable attorneys’ fees) arising out of any such recall or withdrawal, unless and to
the extent any Product Recall is or must be initiated as a result of LTS’ delivery of Defective Products in which case LTS shall bear all reasonable, documented direct costs and expenses, including reasonable attorney’s fees, and LTS
shall, to the scope and extent of the insurance coverage set forth on Exhibit I, indemnify and hold harmless BDSI and its Affiliates for any damages, claims, costs and expenses (including reasonable attorneys’ fees), arising out of any such
Product Recall, provided that LTS’ liability under this Section 9.2 shall not exceed the insurance coverage amounts set forth on Exhibit I. 

  

	10.	Product Approval Assistance; Additional Process Development Activities. 

 LTS shall, as reasonably requested by BDSI, at BDSI’s cost and expense as quoted by LTS in a commercially reasonable price quotation, reasonably assist BDSI’s or any BDSI Licensee’s efforts
to obtain and maintain any Governmental Approvals. 
  

	11.	Inspections; Audit. 

 LTS
agrees to perform or has performed in accordance with the provisions of this Agreement and ensure the adequacy BDSI’s supply of Products, LTS agrees to allow BDSI or, upon signing of a reasonably proper confidentiality agreement with LTS, an
agent or designee of BDSI, upon reasonable prior notice and at BDSI’s expense, to periodically inspect or audit LTS’ facility(ies), technical, quality assurance and quality control records relating specifically to the supply of Products to
be provided pursuant to this Agreement, such inspection and verification to occur during normal business hours, at BDSI’s sole expense and subject to Section 18 of this Agreement. 

 

	12.	Intellectual Property. 

  

	12.1	LTS acknowledges that LTS shall not have any right to BDSI Technology (or any part thereof) under this Agreement except to the extent necessary to manufacture and
supply Products on behalf of BDSI under this Agreement. Title to the BDSI Technology and any other intellectual property, patents or patent applications of BDSI shall at all times remain vested in BDSI. 

BDSI acknowledges that BDSI shall not have any right to LTS Technology (or any part thereof) under this Agreement except to the extent
agreed upon in this Agreement. Title to the LTS Technology and any other intellectual property, patents or patent applications of LTS shall at all times remain vested in LTS. 

  
 15 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	12.2	No right or license is granted or deemed to be granted hereunder or in connection herewith, by estoppel or otherwise, with respect to the LTS Technology or the BDSI
Technology other than the express licenses set out in this Agreement and the grant of any licenses and/or the utilization of the LTS Technology or the BDSI Technology shall neither transfer to, nor create in favor of the other Party any right of
ownership therein. 

  

	12.3	All Manufacturing Improvements shall be owned by LTS and LTS shall have the sole proprietary rights to any Manufacturing Improvements. BDSI hereby assigns any of its
right, title, or interest in or to all Manufacturing Improvements under this Agreement to LTS. Without limitation of LTS’ rights to LTS’ intellectual property licensed under Section 15, as limited by the licenses granted thereunder,
BDSI shall have the sole proprietary right to the Product and any improvements made to the Product by LTS. LTS hereby assigns any of its right, title, or interest in or to the Product under this Agreement and improvements made to the Product by LTS
to BDSI. Each Party agrees to take any and all actions, and to cause its Affiliates, employees, and contractors to take any and all actions, reasonably requested by the other Party to affect the purposes of the foregoing, including but not limited
to the execution of patent assignments or affidavits. 

  

	13.	Patent Infringement. 

  

	13.1	Each Party will promptly notify the other Party if it receives notice that the Process, the Product, or the manufacture or use of any Product infringes or allegedly
infringes the proprietary rights of any Third Party. Subject to the indemnification procedures set forth herein, the Parties will determine what action, if any, should be taken. 

 

	13.2	Subject to the procedures and requirements set forth in Section 20.5, BDSI shall indemnify, defend, and hold LTS, its managing directors, directors, officers,
employees, Affiliates and agents harmless with regard to any out-of-pocket expenses (such out-of-pocket expenses shall be considered to include royalties and damages, as well as legal expenses and settlement payments) incurred, assessed or sustained
by LTS as a result of a Third Party claim that the Product infringes the intellectual property rights of a Third Party. 

  

	13.3	 Subject to the procedures and requirements set forth in Section 20.5, LTS shall indemnify, defend, and hold BDSI its directors, officers,
employees, Affiliates, agents, licensees, and representatives (collectively, “BDSI Indemnitees”) harmless *** with regard to any out-of- pocket expenses (such out-of-pocket expenses shall be considered to include royalties and damages, as
well as legal expenses and settlement payments) incurred, assessed or sustained by any BDSI Indemnitee as a result of a Third Party claim *** 

  
 16 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
(“BDSI Infringement Claim”)) provided that such indemnification shall be ***. 

  

	14.	Back-up Supplier. 

  

	14.1	Except as contemplated by Section14.2, LTS shall be the sole and exclusive supplier of the Products for sale in the Territory during the term of this Agreement.
Notwithstanding anything to the contrary, and without limitation of BDSI’s rights under Section 14.2, BDSI may in its discretion and at its own cost and responsibility qualify an alternative, back-up to LTS, source of supply (“Back-up
Supplier”) for Products in the Territory during the term of this Agreement; for purposes of clarification, but not limitation, BDSI, any Affiliate thereof, any BDSI Licensee, Aveva, or any other Third Party may constitute a Back-up Supplier.

  

	14.2	The qualification of the Back-up Supplier shall not be construed to give BDSI any right to order Products from the Back-up Supplier for sale in the Territory during the
term of the Agreement except as provided in this Section 14.2. However, BDSI shall have the right, notwithstanding anything to the contrary (including but not limited to the exclusive supply provisions of Section 4.1), to (i) order
and purchase Products from a Back-up Supplier (including, for purposes of clause (b) below, Aveva), and/or have a Back-up Supplier (including, for purposes of clause (b) below, Aveva) manufacture and supply Products on behalf of BDSI, or
(ii) manufacture Products for its own benefit (such right, the “BDSI Back-up Right”) in case a Back-up Trigger has occurred. 

 BDSI shall pay all royalties owed to LTS under this Agreement with respect to any Products procured from any Back-up Supplier and provide LTS in a timely manner with documents showing all quantities
ordered from any Back-up Supplier. BDSI’s failure to comply with the foregoing sentence shall be deemed a material breach of this Agreement. In such a case LTS shall, subject to the provisions of Section 19.3 and BDSI’s opportunity to
cure thereunder, be entitled to terminate this Agreement and all license obligations hereunder. 
  

	14.3	In the situation where LTS is not able to supply Product, or LTS anticipates that it will be unable to supply Product to BDSI in satisfaction of BDSI’s Orders or
Forecasts, LTS shall: 

  

	 	(a)	inform BDSI in a timely manner about such situation and the details causing such situation; and 

  
 17 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	(b)	provide BDSI with a reasonable estimate of the length and extent of production interruption or other issue affecting LTS’ satisfaction of BDSI’s Product
demand. 

 LTS shall inform BDSI immediately when it is again able, after any particular effectiveness of
BDSI’s Back-up Right under Section 14.2(a), to again manufacture and supply Products to BDSI in accordance with this Agreement (the date on which LTS is able to so manufacture and supply Products hereunder, the “Resumption
Date”). 
  

	14.4	Following the Resumption Date, BDSI shall order Products again exclusively from LTS, provided that, if BDSI continues to have obligations to any Back-up Supplier (or
with respect to BDSI’s own manufacture of Products under the Back-up Right) entered into in connection with the exercise of the BDSI Back-up Right having an effect lasting after the Resumption Date, BDSI will be entitled to continue to satisfy
any such obligations to Back-up suppliers and will purchase a minimum portion of *** percent ***, of BDSI’s requirements of Product from LTS pursuant to this Agreement until such time as such obligations have been satisfied, provided that BDSI
shall use reasonable efforts to limit any such obligations to Back-Up Suppliers. 

  

	15.	Grant of Licenses; Release. 

  

	15.1	LTS hereby grants to BDSI a non-exclusive, transferable license, to and under the Process, all Process Improvements (as defined in the PDA), all Manufacturing
Improvements, LTS Technology (as defined herein and in the PDA), any Patents Controlled by LTS covering any of the foregoing, and issued patent *** (including all foreign counterparts thereof) to use, have used, offer to sell, sell, have sold,
import, or have imported Products supplied by or on behalf of LTS under this Agreement. BDSI shall pay to LTS a royalty equal to *** percent (***) of Net Sales of such Product within the Territory, on a country-by-country and Product-by-Product
basis, for so long as a particular Product is covered by a Valid Claim, that has not expired, of the issued patent Controlled by LTS identified as *** (or a foreign counterpart thereof) (the “LTS Patent”) in the country in which such
Product is sold. 

  
 18 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	15.2	Upon any expiration or termination of this Agreement (except termination by in accordance with Section 19.2(a) of this Agreement or termination by LTS in
accordance with Section 19.3 of this Agreement), or in the case of BDSI ordering from a Back-up Supplier or otherwise exercising its Back-up Right as permitted by Section 14, LTS hereby grants to BDSI a non-exclusive, transferable license,
with rights of sublicense, to and under patent *** (including all foreign counterparts thereof) to make, have made, use, have used, offer to sell, sell, have sold, import, or have imported any Product(s)). For the sake of clarity, the license
granted to BDSI above shall terminate in case BSDI has terminated this Agreement in accordance with Section 19.2(a). BDSI shall pay to LTS the following royalties on Products not supplied by or on behalf of LTS under this Agreement:

  

	 	(i)	*** percent (***) of Net Sales of Products sold within the Territory during calendar year ***, on a country-by-country basis, and covered by a Valid Claim, that has not
expired, of the LTS Patent in the country in which such Product is sold; and 

  

	 	(ii)	*** percent *** of Net Sales of Products sold within the Territory on or after ***, on a country-by-country basis, and covered by a Valid Claim, that has not expired,
of the LTS Patent in the country in which such Product is sold. 

 The Parties agree that no royalty shall be due
on any Products sold by BDSI, its Affiliates, any BDSI Licensees, or any distributors of any of the foregoing prior to ***. Notwithstanding anything to the contrary, the rights granted under this Section 15.2 shall, notwithstanding the
definition of “Products” set forth in Section 1.26, include any BEMA-based product that lacks fentanyl and is (i) used to demonstrate the manner in which BEMA Fentanyl Product is packaged or used or (ii) intended for use in
preclinical testing and clinical studies concerning the BEMA Fentanyl Product. 
  

	15.3	So long as BDSI makes all payments as, if, and when due as set forth in Sections 15.1 and 15.2 (subject to and including a *** opportunity to cure such failure to pay
following notice of such failure by LTS to BDSI), LTS does hereby covenant that neither it nor its Affiliates shall commence or maintain against BDSI, its Affiliates, or its or its Affiliates’ officers, directors, employees, agents,
representatives, manufacturers, distributors, funding or other partners, licensees, sublicensees, joint venturers, collaborators or customers, any suit, whether at law or in equity, claiming, with respect to, or relating to infringement (of any kind
or type), violation, or misappropriation of any intellectual property right or any other proprietary rights owned or controlled by LTS or its Affiliates or with respect to which LTS or its Affiliates has any right or interest, by or with respect to
the use, manufacture, import, sale, or offering for sale of any Product in the Territory; this covenant shall be binding upon, and inure to, the benefit of BDSI, their Affiliates, successors, assigns and executors, administrators, personal
representatives and heirs. This covenant shall, subject to BDSI making all payments as, if, and when due as set forth in Sections 15.1 and 15.2 (subject to and including a *** opportunity to cure such failure to pay following notice of such failure
by LTS to BDSI), survive termination or expiration of this Agreement. BDSI’s right to challenge any LTS patents shall remain unaffected; however, in such an event, LTS may terminate this Agreement, including but not limited to the license and
any sublicenses thereof, with immediate effect upon written notice to BDSI. 

  

	15.4	 During the term of this Agreement, BDSI does hereby covenant that neither it nor its Affiliates shall commence or maintain against LTS or its officers,
directors, employees, Affiliates, agents, representatives, manufacturers, distributors, funding or other partners, licensees, sublicensees, joint venturers, collaborators or customers, any suit, whether at law or in equity, claiming, with respect
to, or relating to infringement (of any kind or type), violation, or misappropriation of any intellectual property right or any other proprietary rights owned or controlled by BDSI or its Affiliates or with respect to which

  
 19 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
BDSI or its Affiliates has any right or interest, by or with respect to LTS’ use, manufacture, or sale to BDSI of any Product supplied to BDSI under this Agreement; this covenant shall be
binding upon, and inure to, the benefit of LTS, their Affiliates, successors, assigns and executors, administrators, personal representatives and heirs. LTS’ right to challenge any BDSI patents shall remain unaffected; however, in such an
event, BDSI may terminate this Agreement with immediate effect upon written notice to LTS. 

  

	16.	Assignment of LTS’ Tasks. 

  

	16.1	LTS shall have the right to assign all or any portion of its rights granted under Section 15 and to delegate all or any portion of its obligations under this
Agreement to any Affiliate whilst it remains so, provided that 

  

	 	(a)	such Affiliate is performing LTS’s obligations hereunder, 

  

	 	(b)	prior to the commencement of activities by an Affiliate to perform its obligations hereunder, such Affiliate shall have received all necessary validations, inspections
and regulatory approvals, and 

  

	 	(c)	such assignment and delegation shall not relieve LTS of its obligations hereunder. 

 

	16.2	Any Affiliate with which LTS effects such assignment and delegation shall enjoy all of the rights and be subject to all of the obligations hereby imposed on LTS except
that any assignment of LTS’ rights and delegation of LTS’ obligations under this Agreement shall be non-assignable and shall not contain any right to assign or delegate. 

 

	17.	Royalty Payments. 

  

	17.1	The Parties agree that, notwithstanding anything to the contrary in the PDA, (i) all past, present, and future royalty or similar payment obligations and related
obligations of BDSI and its Affiliates under the PDA (including but not limited to those set forth in Article IX thereof) are hereby waived and terminated and (ii) the only royalty or similar payments due to LTS with respect to BDSI’s, its
Affiliates’, or BDSI Licensees’ manufacture, use, sales, export, or import of Product are those set forth in this Agreement for all such activities occurring after the Effective Date. 

 

	17.2	Except as otherwise provided herein, all royalties and payments due under Section 15 shall be paid within *** of the end of the relevant calendar quarter during
which the applicable Net Sales are received. Each royalty payment shall be accompanied by a statement stating (as applicable) the number, description, and aggregate Net Sales, by country, received during the relevant calendar quarter by BDSI and its
Affiliates and Third Party sublicensees and detailing the calculation of royalties due for such calendar quarter. 

  
 20 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	17.3	All payments due under this Agreement to LTS shall be made by check or bank wire transfer in immediately available funds to an account designated by LTS. All payments
under this Section 17 shall be made in standard European currency the “euro”. With respect to each calendar quarter, whenever conversion of payments from any foreign currency shall be required to calculate the payments due hereunder,
such conversion shall be made at the rate of exchange reported in The Wall Street Journal on the last business day of the applicable calendar quarter. 

 

	17.4	In each country where the local currency is blocked and cannot be removed from the country under such country’s applicable law, royalties accrued in that country
shall be paid to LTS in the country in local currency by deposit in a local bank designated by LTS, unless the Parties otherwise agree. 

  

	18.	Confidential Information. 

  

	18.1	Insofar as a Party provides proprietary or Confidential Information to the other party, it will be referred to herein as the “Disclosing Party”; insofar as a
party receives such proprietary information it will be referred to herein as the “Recipient”; provided that, notwithstanding anything to the contrary, BDSI shall be a Disclosing Party, and LTS a Recipient, with respect to any Confidential
Information concerning the Product or any improvement thereof. A Party’s directors, officers, employees, agents and representatives shall be referred herein as the “Representatives”, and each Recipient shall be liable for any breach
of this Section 18 by its Representatives as though such Representatives were Parties hereto. 

  

	18.2	The Disclosing Party agrees to provide the Recipient with, or allow the Recipient to have access to Confidential Information only upon the following terms and
conditions: 

 “Confidential Information” means all data, information (including schematics, designs,
drawings and specifications), technical information, samples and specimens relating to the Product or components of the Product (including the identity of compounds used therein or therewith), or the use, manufacturing or marketing thereof, or the
Process, or related clinical or regulatory affairs, or the Disclosing Party’s businesses or financial affairs generally (including, without limitation, results of operations, discussions, agreements or arrangements with Third Parties, prices,
processes, pre-clinical and clinical and other test or trial results, products, product concepts, technologies and similar or related non-public information), or those of the Disclosing Party’s Affiliates, clients, customers or other Third
Parties, whether in written, graphic oral or tangible form, (a) furnished to the Recipient by or on behalf of the Disclosing Party, either directly or indirectly, and identified by the Disclosing Party as Confidential Information subject to
this Agreement either in writing or orally (in the case of an oral disclosure, the Confidential Information will be identified as such in writing within *** after such oral disclosure is made), or, with respect to information concerning the Product
or any improvement thereof not first disclosed by the Disclosing Party, (b) generated by the Recipient or obtained from a source other than Disclosing Party. 

  
 21 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 To the extent the Disclosing Party proposes to disclose information not directly related
to the development of the Process or the potential manufacturing of the Product, the Disclosing Party shall first propose the nature of the disclosure and the Recipient may decline such disclosure for any reason or no reason, in its sole discretion.

  

	18.3	The obligations imposed in this Section shall not apply to: 

  

	 	(a)	information that is now in the public domain or subsequently enters the public domain without breach of this Agreement by the Recipient; 

 

	 	(b)	information that the Recipient can demonstrate from its own records to have been known by the Recipient prior to the Disclosing Party’s disclosure (or
Recipient’s generation in the case of Confidential Information concerning the Product or improvements thereof) and was not previously acquired from (or generated on behalf of) the Disclosing Party; or 

 

	 	(c)	information disclosed to the Recipient without obligation of confidentiality by a Third Party lawfully entitled to make such disclosure without breach of any legal or
contractual duty. 

  

	18.4	Any information composed of a combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are
published or available to the general public or in the Recipient’s rightful possession unless the combination itself is published or available to the general public or is in the Recipient’s rightful possession. 

 

	18.5	The Recipient agrees to maintain in confidence all of Disclosing Party’s Confidential Information, not to disclose any of Disclosing Party’s Confidential
Information to any Third Party without the express written consent of the Disclosing Party, and to only use the Disclosing Party’s Confidential Information for the purposes contemplated by this Agreement (including the exercise of any rights
granted hereunder). The Recipient agrees to promptly notify the Disclosing Party in writing of any misuse or misappropriation of Disclosing Party’s Confidential Information that may come to the Recipient’s attention.

  

	18.6	 The Recipient shall take all necessary and reasonable precautions to prevent the disclosure of Disclosing Party’s Confidential Information to any
unauthorized Third Parties. In this regard, the Recipient agrees to disclose Confidential Information only to those of its Representatives (or in the case of BDSI, BDSI Licensees, Aveva, or any other Back-up Supplier) who are directly concerned with
the use and evaluation of such information for the purposes specified in this Agreement and who are bound by obligations of confidentiality at least as stringent as those set forth herein. Upon disclosing Confidential Information to any of its
Representatives, the Disclosing Party 

  
 22 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
shall advise them of the confidential nature of the information, and shall instruct them to take all necessary and reasonable precautions to prevent the unauthorized disclosure thereof. The
Recipient shall remain liable for any breach hereof by any of its Representatives. 

  

	18.7	Notwithstanding the foregoing, Confidential Information may be disclosed to the extent required by applicable laws, regulations, or as ordered by a court or other
regulatory body having competent jurisdiction provided that the Recipient 

  

	 	(a)	uses its Commercially Reasonable Efforts to limit the disclosure and maintain confidentiality to the extent possible and 

 

	 	(b)	provides prior written notice of such disclosure to the Disclosing Party. 

 In addition, BDSI shall have the right to disclose Confidential Information to Authorities and BDSI Licensees in order to obtain marketing authorizations or other regulatory approvals of the Process or
Product under Commercially Reasonable Efforts to maintain the confidentiality of the information, provided that BDSI shall only disclose such Confidential Information to BDSI Licensees who agree to maintain the same standard of confidentiality and
to owe such obligation to BDSI (provided that any breach of such requirements by any Third Party contractor of BDSI shall be deemed a breach of the corresponding obligations of BDSI hereunder). Notwithstanding the foregoing, a party may not file any
patent application or other patent-related filing that will disclose the Confidential Information of the other party without such other party’s prior written consent. 

 

	18.8	Disclosing Party’s Confidential Information shall not be used by Recipient for any purpose other than the manufacturing of a Product, or the use, sale, offering
for sale, or import thereof, as contemplated by this Agreement and thereto related procedures without the express written consent of Disclosing Party, to be given or withheld in the Disclosing Party’s absolute discretion.

 Except as otherwise set forth in this Agreement, in no case shall BDSI be entitled to request any of LTS’
proprietary information concerning the Process or other specific manufacturing know-how unless required for regulatory filing purposes. In such event, BDSI may request such information from LTS and LTS shall either provide such information to BDSI
or, to the extent permitted by applicable law, communicate such information directly to the Authorities or such Third Party without disclosing it to BDSI so long as LTS does so in a timely manner. 

 

	18.9	All Confidential Information disclosed by the Disclosing Party to the Recipient pursuant to this Agreement shall be and remain the property of the Disclosing Party and
all such Confidential Information in fixed form and copies thereof shall be promptly returned or lawfully destroyed upon the Disclosing Party’s request, provided that the Recipient’s legal department or outside counsel shall be entitled to
retain one set of all such information for the sole purpose of monitoring the Recipient’s obligations hereunder. 

  
 23 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	18.10	The obligations of confidentiality and non-use under this Agreement shall apply during the term of this agreement and for a term of the longer of (i) *** after
expiration or termination of this Agreement for any reason or (ii) *** following the disclosure of such Confidential Information hereunder. 

 Each Party will receive and maintain the other Party’s Confidential Information in strict confidence, except as otherwise permitted by this Section 18, and in accordance with all applicable
laws, rules, regulations and confidentiality obligations. 
  

	19.	Termination. 

  

	19.1	Termination by Either Party for Insolvency. Either Party may terminate this Agreement prior to the expiration of the term upon the occurrence of any of the
cessation of operations of the other Party or the bankruptcy, insolvency, dissolution or winding up of the other Party (other than dissolution or winding up for the purposes or reconstruction or amalgamation). 

 

	19.2	Termination for Intellectual Property Loss. 

  

	 	(a)	Each Party shall be entitled to terminate this Agreement upon written notice to the other Party in the event any of BDSI’s rights to BDSI Technology (including but
not limited to any related Patents, know-how, or clinical data) that are reasonably necessary for the manufacture, use, sale, or import of Products in the Territory are, pursuant to any of BDSI’s agreements with Third Parties concerning such
rights, terminated, or transferred or assigned by such Third Party, in whole or in part, in a manner that, renders BDSI unable to have Products manufactured by LTS, or to permit LTS to manufacture Products, under this Agreement without breaching
such agreement(s) or infringing on or conflicting with the intellectual property rights granted, assigned, or transferred by such Third Party to BDSI. 

  

	 	(b)	In case of a Process Infringement Claim (Section 13.3) brought against LTS, BDSI, any Affiliate of BDSI, or any licensee or sublicensee of BDSI or any Affiliate
thereof, the Parties shall without undue delay, discuss possibilities to avoid such claims of alleged infringement. If the Parties cannot, despite using Commercially Reasonable Efforts agree on such options within reasonable time (reasonable time
shall be such time period which would reasonably allow the prospective defendant to prepare and file its defense in a timely manner) or, if sooner, within *** upon receipt by either Party of notice of such a Process Infringement Claim, each Party
shall have the right to terminate the Agreement upon written notice to the other Party with immediate effect. 

  
 24 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	19.3	Termination for Breach. Either Party may, by written notice to the other Party, terminate this Agreement prior to its expiration upon or after the breach of any
material provision of this Agreement by the other Party, if such Party has not cured such breach, if capable of being cured, within *** after written notice thereof by the non-breaching Party. 

 

	19.4	Termination for Supply Failure. In the event a Back-up Trigger occurs more than *** within any *** period, BDSI may, upon written notice to LTS, terminate
this Agreement or render it permanently nonexclusive, enabling BDSI to manufacture Products or have them manufactured on its behalf. Such notice by BDSI shall describe the applicable Back-up Triggers. 

 

	19.5	Effect of Termination. 

  

	 	(a)	In the event of termination of this Agreement, BDSI shall have no further obligation to purchase Products from LTS, and LTS shall have no further obligation to supply
Products to BDSI, provided that BDSI shall purchase any Products (other than Defective Products), and LTS shall supply to Products, remaining in LTS’ possession or control at the time of such termination at the applicable Purchase Price and, as
elected by BDSI 

  

	 	(i)	permit LTS to complete the process of manufacture by LTS of Products in production or scheduled for production at the time of such termination and purchase resulting
Products (other than Defective Products) upon completion of such manufacture at the applicable Purchase Price 

  

	 	(ii)	cause LTS to promptly return to BDSI at BDSI’s costs any Active Principle under LTS’ possession or control, and purchase any raw materials or work-in-process
under LTS’ possession or control or have such raw materials or work-in-process destroyed at LTS’ reasonable, documented costs and expenses thereof. This includes, if so elected by BDSI, the reasonable, documented direct costs of
destruction. LTS shall take such actions as necessary to fulfill and comply with any such election or request made by BDSI under the preceding sentence, including but limited to the sale and/or delivery of any of the foregoing materials.

 Notwithstanding anything to the contrary in this Agreement, BDSI shall remain obligated to take delivery of and
pay for, in accordance with the terms of this Agreement, and LTS shall supply to Products, any Products (other than Defective Products) necessary to fulfill any Order outstanding as of the date of such termination. Neither Party shall otherwise have
any obligation to the other with respect to the supply or purchase of Product or failure to supply or purchase Product following such termination (including any obligation to pay damages for failure to supply or purchase following termination),
provided that, notwithstanding the foregoing, the terms of this Agreement shall apply to any Product supplied to BDSI by LTS following termination in accordance with this Section 19.5. 

  
 25 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	(b)	Except as otherwise provided in this Agreement, expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such
expiration or termination (including but not limited to any obligation of BDSI to pay any amounts due or owing at the time of such cancellation, expiration, or termination). Except as set forth below or elsewhere in this Agreement, the obligations
and rights of the Parties under Sections 3.3, 4.8, 4.9, 6.1, 6.3, 6.4, 6.6, 9, 11, 12, 13, 15 (to the extent provided for in this Agreement), 17, 18, 19, 20, 21.5, 21.6, 21.7, and 22 shall survive expiration or termination of this Agreement.
Further, and notwithstanding anything to the contrary, the licenses granted in Sections 15.1 and 15.2 shall, on a country-by-country basis, survive the expiration of this Agreement or any termination of this Agreement (other than termination of this
Agreement pursuant to Section 19.2(a) or by LTS pursuant to Section 19.3). 

  

	19.6	LTS shall be entitled to terminate this Agreement upon written notice to BDSI in the event any of BDSI’s rights to BDSI Technology (including, but not limited to,
any related Patents, know-how, or clinical data) that are reasonably necessary for the manufacture, use, sale, or import of Products in the Territory are no longer available to BDSI and LTS is, therefore, unable to have Products manufactured by LTS,
or to permit LTS to manufacture Products, under this Agreement without breaching such agreements BDSI might have or infringing on or conflicting with the intellectual property rights previously granted, assigned, or transferred by such Third Party
to BDSI. 

  

	20.	Indemnification. 

  

	20.1	Indemnification by BDSI. BDSI shall indemnify, defend, and hold LTS, its managing directors, directors, officers, employees, Affiliates and agents harmless from
and against all damages, losses or expenses, including reasonable attorney’s fees and expenses, (“Losses”) incurred, assessed or sustained by LTS, arising out of a Third Party claim with respect to or arising out of an injury, claim
or damage resulting from or caused by: 

  

	 	(a)	use of the Product; 

  

	 	(b)	any breach by BDSI of its acknowledgements, representations, warranties, covenants or agreements hereunder; 

 

	 	(c)	an inherent defect in the Product design, elements of the Process BDSI requires LTS to implement that are provided solely as presented by BDSI (without LTS development
input), or Product Specifications and/or Packaging Specifications provided by BDSI, 

  

	 	(d)	any negligence or willful misconduct of BDSI. 

  
 26 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	(e)	any indemnification obligation of LTS under Section 20.3(a) or (b) to the extent exceeding the scope and extent of LTS’ insurance as set forth in
Section 20.4. 

  

	20.2	BDSI’s Insurance Coverage. BDSI shall obtain and use its Commercially Reasonable Efforts to maintain during the term of this Agreement liability insurance
(including but not limited to product liability insurance) as annexed hereto (Exhibit H). 

  

	20.3	Indemnification by LTS. LTS shall indemnify, defend, and hold BDSI, its directors, officers, employees, Affiliates and agents harmless from and against all Losses
incurred, assessed or sustained by BDSI arising out of a Third Party claim with respect to or arising out of an injury, claim or damage resulting from or caused by: 

 

	 	(a)	the Product not having been manufactured according to the Product Specifications, Packaging Specifications, or GMP, or due to any negligence or willful misconduct of
LTS, or 

  

	 	(b)	the breach by LTS of any of its acknowledgements, representations, warranties, covenants or agreements hereunder, 

provided that LTS’ indemnification hereunder with respect to all matters other than willful misconduct shall be subject to the scope
and extent of its liability insurance as set forth in Section 20.4. 
  

	20.4	LTS’ Product Liability Insurance Coverage. LTS shall obtain and use its Commercially Reasonable Efforts to maintain during the term of this Agreement
liability insurance (including but not limited to product liability insurance) as annexed hereto (Exhibit I). Any indemnification obligation owed by LTS shall be limited to the scope and amount of insurance set forth on Exhibit I.

  

	20.5	Procedures and Requirements of Indemnification. 

  

	 	(a)	In no event will an Indemnifying Party have an indemnification obligation hereunder in the event and to the extent that such Losses arose as a result of any Indemnified
Party’s intentional misconduct of this Agreement or other matter subject to indemnification by the Indemnified Party under this Agreement. 

 The Party seeking indemnification under this Section 20 (the “Indemnified Party”) shall give written notice to the Party providing such indemnification (the “Indemnifying Party”)
of the assertion of any claim, or commencement of any suit, action or proceeding in respect of which indemnity may be sought under this Agreement promptly after receipt of notice from a Third Party of the assertion of such claim or the commencement
of such suit, action or proceeding. 
  

	 	(b)	 The Indemnified Party shall tender to the Indemnifying Party (and its insurer) full authority to defend or settle the claim or suit, provided that
(a) neither Party shall, 

  
 27 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
as the Indemnifying Party, enter into any settlement or voluntary disposition of any matter subject to indemnification hereunder in any manner which would materially and adversely affect any
intellectual property rights of the Indemnified Party without the Indemnified Party’s prior written consent and (b) LTS shall not enter into any settlement or voluntary disposition of any matter subject to indemnification hereunder that
would materially and adversely affect the Product (or the manufacture, sale, or use thereof) without BDSI’s prior written consent. The Indemnified Party will be entitled at its own expense to participate in the defence with its own counsel of
any such claim, suit, action or proceeding, and shall provide reasonable cooperation to the Indemnifying Party (and its insurer), as reasonably requested, at Indemnifying Party’s cost and expense. 

 

	 	(c)	The Indemnifying Party shall not be liable for any compromise or settlement of any such claim, suit, action or proceeding effected without its consent, which consent
shall not be unreasonably withheld. 

  

	 	(d)	The Parties agree to cooperate to the fullest extent possible in connection with any third-party claim, suit, action or proceeding for which indemnification is or may
be sought under this Agreement. 

  

	 	(e)	In the event the Indemnifying Party makes any payment pursuant to its indemnification obligations under this Agreement, it shall be subrogated to all rights of the
Indemnified Party to pursue any claim to receive payment or other consideration from any other Third Party which may be liable with respect to such claim, suit, action or proceeding for which indemnification was provided. 

 

	 	(f)	The Indemnified Party shall execute and deliver such instruments and agreements and take such other action as may be required to subrogate the Indemnifying Party to
such Indemnified Party’s rights to receive such payment or consideration. 

  

	20.6	No Indirect, Punitive or Exemplary Damages. Under no circumstances shall either party be liable for indirect, special or consequential damages, lost profits
and/or punitive damages unless covered by an insurance policy or caused by such Party’s intentional misconduct, willful default, or material breach of the confidentiality provisions of this Agreement, provided however that this shall not limit
the Parties obligation to indemnify the other Party with respect to Third Party’s claims. 

  

	21.	Representations and Warranties; BDSI Guarantee. 

  

	21.1	Corporate Power. As of the Effective Date, each Party hereby represents and warrants that such Party is duly organized and validly existing under the laws of the
jurisdiction of its organization and has full power and authority to enter into this Agreement and the transactions contemplated hereby and to carry out the provisions hereof. 

  
 28 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	21.2	Due Authorization. As of the Effective Date, each Party hereby represents and warrants that such Party is duly authorized to execute and deliver this Agreement
and to perform its obligations hereunder. 

  

	21.3	Binding Obligation. As of the Effective Date, each Party hereby represents and warrants that this Agreement is a legal and valid obligation binding upon it and
is enforceable in accordance with its terms, except that the enforcement of the rights and remedies created hereby is subject to bankruptcy, insolvency, reorganization and similar laws of general application affecting the rights and remedies of
creditors and that the availability of the remedy of specific performance or of injunctive relief is subject to the discretion of the court before which any proceeding therefore may be brought. As of the Effective Date, the execution, delivery and
performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any law or regulation of any court, governmental body or
administrative or regulatory agency having authority over it. 

  

	21.4	Legal Proceedings. Except as set forth on Schedule 21.4 or with respect to any similar litigation based on the intellectual property rights referenced in
Schedule 21.4 or any foreign equivalents thereof (the “Existing Claims”), or to the extent any Existing Claims or related circumstances could cause any of the circumstances described below (or otherwise cause to BDSI to violate the
representation and warranty set forth below), as of the Effective Date, each Party hereby represents and warrants to the other Party that there is no action, suit or proceeding pending against or affecting, or, to the knowledge of either Party or,
in the case of BDSI, also the BDSI Parent, threatened against or affecting that Party, or any of its assets, before any court or arbitrator or any governmental or regulatory body, agency or official that would, if decided against either Party, have
a material adverse impact on the business, properties, assets, liabilities or financial condition of that Party (that are not already reflected in that Party’s respective financial statements as filed with the Securities and Exchange Commission
(or foreign equivalent thereof) or otherwise made public or provided to the other Party) and which would reasonably be anticipated to have a material adverse effect on that Party’s ability to consummate the transactions contemplated by this
Agreement. 

  

	21.5	LTS Warranties. 

  

	 	(a)	LTS represents and warrants to BDSI that all Product supplied hereunder shall have been manufactured in accordance with the Product Specifications, Packaging
Specifications, GMP, and all applicable regulatory or legal requirements 

 The warranty provided in this
subsection (a) does not apply to any non-conformity of any Product resulting from: 
  

	 	(A)	alteration, misuse, negligence, mishandling or storage in an improper environment in each case by any Party other than LTS or its Affiliates, contractors, employees, or
other agents or representatives, or 

  
 29 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	(B)	use, handling, storage or maintenance, by any Party other than LTS or its Affiliates, contractors, employees, or other agents or representatives, other than in
accordance with the Product Specifications, or 

  

	 	(C)	use, handling, storage or maintenance of the Product by BDSI, the BDSI Licensee or any Third Party, subsequent to BDSI (or its designee) taking delivery of the Product
from LTS, that is not in accordance with applicable regulatory approvals for the Product and the applicable laws and regulations relating to the handling, distribution or use of the Product. 

 

	 	(b)	LTS represents and warrants to BDSI that to the best of LTS’ knowledge as of the Effective Date: 

 

	 	(i)	LTS may manufacture the Product for BDSI, without the need to obtain consents or approvals from any Third Party, 

 

	 	(ii)	to LTS’ knowledge as of the Effective Date, no claim of infringement by the LTS Technology has been made by any Third Party, and 

 

	 	(iii)	all employees of LTS are by law required to assign any inventions to LTS and LTS will only engage such contractors, which agree to be under the same obligation.

  

	21.6	BDSI Warranties. BDSI represents and warrants to LTS that: 

  

	 	(a)	BDSI acknowledges that the Product Specifications are determined by the results and the quality of the development and manufacturing carried out solely by or on behalf
of BDSI and are being provided to LTS under the terms of this Agreement, and LTS shall be entitled to disclaim any responsibility with regard to any defect in the Product Specifications (except in respect of any part of the Product Specifications
based on the explicit written contribution, proposal, or request of LTS), 

  

	 	(b)	to BDSI’s knowledge as of the Effective Date, taking into account the rights and licenses granted to BDSI under this Agreement, and except with respect to any
intellectual property rights that may be the subject of any Existing Claims (including any foreign equivalents thereof), BDSI owns, controls, or has licensed all intellectual property rights necessary for the manufacture, marketing, distribution and
sale of the Product in the Territory, subject to the rights of any of BDSI’s licensees with respect to such rights, and, therefore, 

  

	 	(c)	to BDSI’s knowledge as of the Effective Date, and except with respect to the Existing Claims or any intellectual property rights that may be the subject of any
Existing Claims (including any foreign equivalents thereof), the BDSI Technology 

  
 30 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	(i)	includes all rights and licenses necessary for LTS to manufacture the Product in the Territory, and 

 

	 	(ii)	does not infringe the proprietary rights of any Third Party in the Territory; 

 

	 	(d)	BDSI has the right, under any intellectual property owned, licensed, or otherwise controlled by BDSI, to have LTS manufacture Product in the Territory on BDSI’s
behalf as contemplated by this Agreement without the need to obtain consents or approvals from any Third Party with respect to such intellectual property; 

  

	 	(e)	to BDSI’s knowledge as of the Effective Date, and except with respect to the Existing Claims, no claim of infringement in the Territory by the BDSI Technology has
been made by any Third Party and there are no potential claims of patent infringement that may reasonably be so made with respect to the manufacture, use, sale, or import of Product in the Territory. 

 

	 	(f)	BDSI has full and exclusive rights to any inventions made by its employees under this Agreement and all contractors of BDSI are obliged to so assign such rights
pursuant to their relationship with BDSI. 

  

	 	(g)	BDSI, its Affiliates, BDSI Licensees, their affiliates, or any sublicensees of any of the foregoing shall be responsible for the registration of the Product with the
proper health, customs and other Authorities as applicable. 

  

	21.7	Limitation on Warranties. EXCEPT TO THE EXTENT EXPLICITLY PROVIDED HEREIN, NOTHING HEREIN SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY BY ONE PARTY TO THE
OTHER PARTY THAT THE INTELLECTUAL PROPERTY RIGHTS OF EITHER PARTY ARE NOT INFRINGED BY ANY THIRD PARTY, OR THAT THE MANUFACTURE, USE, OR SALE OF PRODUCTS DOES NOT INFRINGE ANY INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. OTHER THAN AS SET FORTH
ABOVE, NEITHER PARTY MAKES ANY WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF MERCHANTABILITY IN RESPECT OF ANY PRODUCT.

  

	21.8	 BDSI Guarantee. For any period of time following the Effective Date during which BDSI is an Affiliate of BioDelivery Sciences International,
Inc. a Delaware corporation (“BDSI Parent”), BDSI Parent hereby fully and unconditionally guarantees to LTS BDSI’s compliance with, and performance of BDSI’s obligations under, this Agreement. With the exception of the rights
expressly granted to LTS in this Section 21.8, nothing expressed or implied from this Section 21.8 is intended to or shall be construed to give to any person or entity other than LTS any legal or equitable rights, remedy or claim under or
in respect of this Section 21.8, and this Section 21.8 is intended to be and is for the sole and exclusive benefit of LTS. No person or entity, other than LTS, is an intended

  
 31 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
beneficiary of this Section 21.8 in any respect whatsoever. For clarity, the foregoing shall not be interpreted as limiting the ability of any successor or permitted assign of LTS to
exercise LTS’ rights pursuant to this Section 21.8. 

  

	22.	Miscellaneous. 

  

	22.1	Assignment. This Agreement shall not be assignable by either party hereto, in whole or in part, in fact or by operation of law, without the prior written consent
of the other, except that either party may assign this Agreement in whole or in part to one or more of its Affiliates (but only for as long as it remains so) and which may now or hereafter be organized, provided that the assigning party shall remain
fully liable under this Agreement for its own performance and the performance of its assignees. Notwithstanding the foregoing, BDSI may assign this Agreement without such consent to 

 

	 	(a)	any person or entity to which BDSI transfers all or substantially all of its assets or business related to the Product, or with which BDSI is consolidated or merged, or

  

	 	(b)	any Affiliate of BDSI or other person or entity that owns a majority of the voting stock of BDSI, 

provided that, notwithstanding the preceding clause (a) of this Section 22.1, any assignment or transfer of this Agreement by
BDSI during the term of this Agreement to any third party that is engaged, as a principal and substantial portion of its business, in the commercial manufacture of thin film-based pharmaceutical products for third party pharmaceutical companies (and
not for sale of finished pharmaceutical products to the retail or wholesale pharmaceutical market for its own benefit) shall require the prior written consent of LTS, such consent not to be unreasonably withheld. 

 

	22.2	Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or breached this Agreement for failure
or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including, but not limited to, fire, floods, embargoes, epidemic,
disease, terrorism, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, failure of public utilities, common carriers or suppliers, acts of God or acts, omissions
or delays in acting by any statute, ordinance or governmental or regulatory authority or the other Party, or for any other reason which is completely beyond the reasonable control of the Party (collectively a “Force Majeure”); provided
that the Party whose performance is delayed or prevented shall continue to use good faith diligent efforts to mitigate, avoid or end such delay or failure in performance as soon as practicable. 

  
 32 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 The parties shall use their Commercially Reasonable Efforts to promptly avoid or remove
any such cause and shall resume performance under this Agreement as soon as feasible whenever such cause is removed; provided, however, that the foregoing shall not be construed to require either party to settle any dispute with any Third Party, to
commence, continue or settle any litigation, or to incur any unusual or extraordinary expenses; provided, further that if such cause continues for more than ***, either party may terminate this Agreement by written notice to the other Party
without any further remedies. 
  

	22.3	Governing Law; Dispute Resolution. 

  

	 	(a)	Any controversy or claims arising out of or relating to either Party’s performance under this Agreement, the Parties’ inability to agree on any provision to
be agreed upon or the interpretation or effectiveness of this Agreement shall upon the written request of either Party be referred to the Project Manager at LTS and the Vice President for Product Development of BDSI for resolution. The LTS Project
Manager and the Vice President for Product Development of BDSI shall promptly meet, in person or by telephone, and in good faith attempt to resolve the controversy, claims or issues referred to them. If no resolution has been achieved within
*** of such request, the chief executive officers of BDSI and LTS or their designees shall discuss the matter in good faith and use commercially reasonable efforts to resolve the dispute. If such chief executive officers or their designees
cannot resolve the matter within *** of such request, either Party shall be free to commence proceedings to resolve the dispute in accordance with the following arbitration procedure. All disputes arising out of or in connection with this
Agreement shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce (“ICC”) by one or more referees or arbitrators appointed in accordance with said Rules of Arbitration. Any Party to this Agreement
shall also have the right to have recourse to, and shall be bound by, the Pre-Arbitral Referee Procedure of the ICC in accordance with its Rules for a Pre-Arbitral Referee Procedure, including without limitation any order of a single referee for
preliminary injunction. Any arbitration pursuant to this Section 3 shall be conducted in the English language and shall be held in Toronto (Ontario, Canada). The decisions of the referee or arbitrator(s) shall be rendered to the Parties in
writing, and shall be final and binding. The costs and expenses of the referee or arbitrator(s) shall be borne equally by the Parties, but each Party shall bear its own expenses incurred in the proceedings. The referee or arbitrator(s) shall have no
authority to award punitive damages. 

  

	 	(b)	This Agreement shall be governed by and construed in accordance with the laws of Switzerland (Canton Zurich) regardless of the laws that might otherwise govern under
applicable principles of conflicts of laws thereof. In no event shall choice of law analysis lead to the application of any laws other than the laws of Switzerland. 

  
 33 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	(c)	IN THE EVENT THAT ANY DISPUTE OR CLAIM OF ANY SORT ARISING OUT OF THIS AGREEMENT SHOULD BE COMMENCED BY EITHER PARTY, EACH OF THE PARTIES WAIVES IRREVOCABLY ANY RIGHT
THAT SUCH PARTY MAY HAVE TO DEMAND OR REQUEST A TRIAL BY JURY. 

  

	 	(d)	Notwithstanding anything to the contrary, either Party may seek injunctive, equitable, or similar relief from a court of competent jurisdiction as necessary to enforce
its rights, under this Agreement or otherwise, without the requirement of arbitration. 

  

	22.4	Waiver. Except as specifically provided for herein, the waiver from time to time by either of the Parties of any of their rights or their failure to exercise any
remedy shall not operate or be construed as a continuing waiver of same or of any other of such Party’s rights or remedies provided in this Agreement. The rights and remedies provided shall be cumulative and not exclusive of any rights or
remedies provided by law. 

  

	22.5	Severability. In case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining
provisions shall not in any way be affected or impaired thereby. Any provision of this Agreement held invalid or unenforceable in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.

  

	22.6	Notices. All payments, notices, reports, statements and other communications provided for herein shall be dated and in writing and shall be deemed to have been
duly given 

  

	 	a.	on the date of delivery, if delivered personally, by e-mail or by facsimile machine, receipt confirmed, 

 

	 	b.	on the following business day, if delivered by a nationally recognized overnight courier service, with receipt acknowledgement requested, or 

 

	 	c.	three business days after mailing, if sent by registered or certified mail, return receipt requested, postage prepaid, in each case, to the Party to whom it is directed
at the following address (or at such other address as any Party hereto shall hereafter specify by notice in writing to the other Parties hereto): 

  

			
	If to BDSI:	 	    Arius Pharmaceuticals, Inc.
		 	801 Corporate Center Drive, Suite 210
		 	Raleigh, North Carolina 27607 USA
		 	Attn: Chief Executive Officer
		 	Telephone: (+1) + 919 582 9050
		 	Facsimile: (+1) + 919 582 9051

  
 34 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

			
	If to LTS:	  	LTS LOHMANN Therapie-Systeme AG
		  	General Counsel
		  	Postfach 15 25
		  	56605 Andernach
		  	 Germany
 Telephone: (+49) +
26 32 99- 2230
 Facsimile: (+49) + 26 32 99-25 30

  

	22.7	Independent Contractors. It is expressly agreed that LTS and BDSI shall be independent contractors and that the relationship between the two Parties shall not
constitute a partnership or agency of any kind. Neither LTS nor BDSI shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior
written consent of the other Party. 

  

	22.8	Rules of Construction. The Parties hereto agree that they have been represented by counsel during the negotiation and execution of this Agreement and, therefore,
waive the application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the Party drafting such agreement or document. Whenever the context hereof shall so
require, the singular shall include the plural, the male gender shall include the female gender and neuter, and vice versa. 

  

	22.9	Publicity. BDSI and LTS shall consult with each other before issuing any press release with respect to this Agreement or the transactions contemplated hereby and
neither shall issue any such press release or make any such public statement without the prior consent of the other, which consent shall not be unreasonably withheld; provided, however, 

 

	 	(a)	that a Party may, without the prior consent of the other Party, issue such press release or make such public statement as may upon the advice of counsel be required by
law or the rules and regulations of the Securities and Exchange Commission of the US, the Nasdaq or any other stock exchange and 

  

	 	(b)	if it has used reasonable efforts to consult with the other Party prior thereto, such consent shall be deemed to have been given if the recipient of the press release
or public statement fails to respond to the other Party within *** after the recipient’s receipt of such press release or public statement. No such consent of the other Party shall be required to release information which has previously been
made public. 

  

	22.10	 Entire Agreement; Amendment. This Agreement (including the Exhibits attached hereto) sets forth all of the covenants, promises, agreements,
warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes and terminates all prior agreements and understandings between the Parties. There are no covenants,
promises, agreements, warranties, 

  
 35 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

	 	
representations, conditions or understandings, either oral or written, between the Parties other than as set forth herein. No subsequent alteration, amendment, change or addition to this
Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. To the extent there is any conflict or inconsistency between this Agreement and the PDA, the terms of this
Agreement shall, notwithstanding anything to the contrary in the PDA, supersede those of the PDA. 

  

	22.11	PDA-Related Provisions. The Parties hereby agree that, upon execution of this Agreement by the Parties, and notwithstanding anything to the contrary in the PDA,
the requirements of Section 6.1 of the PDA (Commercialization of Results/ Exclusivity) shall have been satisfied. 

  

	22.12	Headings. The captions contained in this Agreement are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the
several Articles or Sections hereof. 

  

	22.13	Invalidity. If any provision of this Agreement or the application thereof is adjudicated to be invalid or unenforceable, such invalidity or unenforceability
shall not affect other provisions of this Agreement which can be given effect without the invalid and unenforceable provision or application, and to this end, the provisions of this Agreement shall be severally. The parties shall co-operate in good
faith in amending this Agreement in such an event in order to replace any provision hereof so held invalid or unenforceable with a valid provision which is as similar as possible in substance to the invalid or unenforceable provision, and to
overcome any difficulties thereby occasioned and thus restore the economic balance of this Agreement. 

  

	22.14	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. Signatures to this Agreement may be transmitted via facsimile and such signatures shall be deemed to be originals. 

 [Signature page to follow.] 

  
 36 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 IN WITNESS WHEREOF, LTS, BDSI, and, solely for purposes of Section 21.8, BDSI
Parent have executed this Manufacturing, Supply, and License Agreement, in duplicate originals, by their respective officers hereunto duly authorized, the day and year first above written. 

 

									
	ARIUS PHARMACEUTICALS, INC.	 		 	 LTS LOHMANN THERAPIE SYSTEME AG

					
	By:	 	 /s/ Mark A. Sirgo
	 		 	By:	  	 /s/ K. Haczkienic

	Name:	 	Mark A. Sirgo	 		 	Name:	  	K. Haczkienic
	Title:	 	President and CEO	 		 	Title:	  	Head of Board of Directors
				
	BIODELIVERY SCIENCES INTERNATIONAL, INC.	 		 		  	
					
	By:	 	 /s/ Mark A. Sirgo
	 		 		  	
	Name:	 	Mark A. Sirgo	 		 		  	
	Title:	 	 President and CEO
	 		 		  	

  

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 Exhibit A – Active Principle Specifications 

*** 

  

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 Exhibit B – European Countries 

*** 

  

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 Exhibit C – Packaging Specifications 

*** 

  

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 Exhibit D – Purchase Price 

*** 

  

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 Exhibit E – Product Specifications 

*** 

  

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 Exhibit F – Batch Sizes 

*** 

  

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 Exhibit G – Launch Stocks, Commercial Orders 

*** 

  

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 Exhibit H – BDSI Insurance Requirements 

*** 

  

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 Exhibit I – LTS Insurance Requirement 

*** 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 Schedule 21.4 

Existing Claims 
 On November 2, 2010, MonoSol Rx, LLC (“MonoSol”) filed an action against BDSI Parent and its ONSOLIS® film (a BEMA-based product incorporating fentanyl) commercial partners in the Federal District Court of New Jersey (“DNJ”) for alleged patent infringement.
The litigation is captioned MonoSol RX, LLC v. Biodelivery Sciences International, Inc., Meda Pharmaceuticals Inc. and Aveva Drug Delivery Systems, Inc., U.S.D.C. D. N.J., Civil No. 10-cv-5695 (the “Litigation”). BDSI Parent was
formally served in this matter on January 19, 2011. MonoSol claims that its manufacturing process for ONSOLIS®
film, which has never been disclosed publicly and which BDSI, BDSI Parent, and our partners maintain as a trade secret, infringes its patent (United States Patent No. 7,824,588). MonoSol’s complaint includes a claim of false marking. Of note,
the BEMA technology itself is not at issue in the case, but rather only the manner in which ONSOLIS , which incorporates the BEMA technology, is manufactured. MonoSol seeks unspecified damages, attorney’s fees and an injunction preventing
future infringement of MonoSol’s patents. 
 BDSI Parent strongly refutes as without merit
MonoSol’s assertion of patent infringement, which relates to BDSI Parent’s and BDSI’s confidential, proprietary manufacturing process for ONSOLIS® film. On February 23, 2011, BDSI Parent filed its initial answer in this case. In such answer, BDSI Parent stated its position that BDSI Parent’s and BDSI’s
products, methods and/or components do not infringe MonoSol’s patent because they do not meet the limitations of any valid claim of MonoSol’s patent. Moreover, in BDSI Parent’s answer, BDSI Parent stated its position that
MonoSol’s patent, which is the subject of the case, is actually invalid and unenforceable for failure to comply with one or more of the requirements of applicable U.S. patent law. For these and other reasons, BDSI Parent intends to defend this
case vigorously, and anticipates that MonoSol’s claims will be rejected. 
 BDSI Parent has engaged in voluntary and court
mandated settlement discussions with MonoSol, but to date has been unable to reach any settlement with them. These discussions are part of the normal course of such an action but do not alter BDSI Parent’s or BDSI’s view of
non-infringement and invalidity of the subject patents. 
 During the third quarter ending September 30, 2011, a case management
conference was held on July 13, 2011 and a mandatory settlement conference before the magistrate judge was held on September 8, 2011. 
 On September 12, 2011, BDSI Parent filed a request for inter partes re examination in the United States Patent and Trademark Office (“USPTO”) of MonoSol’s US patent No 7,824,588
demonstrating that all claims of the patent were anticipated by or obvious in the light of prior art references, including several prior art references not previously considered by the USPTO. On September 16, 2011, BDSI Parent filed in court a
motion for stay pending the outcome of the reexamination proceedings. 

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 On September 26, 2011, MonoSol filed a second amended complaint, which added two
additional patents not previously asserted — US Patent No. 7,357,891 (the “891 patent”), and US Patent No. 7,425,292 (the “292 patent”), both directed to methods of making film products — and on
October 4, 2011 MonoSol filed an opposition to the motion for stay. BDSI Parent filed an answer to the second amended complaint denying infringement and asserting challenges to the validity of the two newly-asserted patents. The court conducted
a status conference on October 25, 2011, at which it denied the motion to stay without prejudice, set November 18, 2011 as the date for MonoSol to file supplemental initial disclosures and its infringement contentions pursuant to the DNJ
Local Patent Rules, and the first week in January as the date for defendants to serve their non infringement and invalidity contentions. The court stated that it would conduct a status conference immediately thereafter and invited defendants to
renew their motion to stay based on developments in the USPTO and otherwise. On November 18, 2011, MonoSol served its contentions asserting infringement of selected claims from the three asserted patents. Defendants served their
non-infringement contentions and invalidity contentions with respect to all three asserted patents on January 3, 2012. Notably, on November 10, 2011, the United States Patent & Trademark Office (“USPTO”) granted BDSI
Parent’s Request for Inter Partes Reexamination of MonoSol’s asserted United States Patent No. 7,824,588, effectively placing this patent into reexamination before the USPTO. On the same day, the USPTO issued an Office action
rejecting all 191 claims over prior art. 
 BDSI Parent filed a Request for Ex Parte Reexamination of MonoSol’s
asserted United States Patent No. 7,425,292 on January 20, 2012, and a Request for Ex Parte Reexamination of MonoSol’s asserted United States Patent No. 7, 357,891 on January 20, 2012. On February 13, 2012, the
USPTO granted BDSI Parent’s Request for Ex Parte Reexamination of the ‘292 patent. On the same day, the USPTO issued an office action rejecting all 22 claims of the ‘292 patent. On March 1, 2012, the USPTO granted BDSI
Parent’s Request for Ex Parte Reexamination of the ‘891 patent. On the same day, the USPTO issued an office action rejecting all 9 claims of the ‘891 patent. 

BDSI Parent and the other defendants had renewed their motion for stay of court proceedings, and on March 7, 2012, the court entered
an order staying the court case pending the outcome of the proceedings on the reexaminations in the USPTO. 
 As expected, in
the ‘891 Patent and ‘292 Patent Ex Parte Reexamination proceedings, MonoSol amended the claims several times and made multiple declarations and arguments in an attempt to overcome the rejections made by the US Patent Office. These
amendments, declarations and other statements regarding the claim language significantly narrowed the scope of their patents. In the case of the ‘891 Patent, not one of the original claims survived reexamination and five separate
amendments were filed. Additionally, arguments and admissions made by MonoSol prevent it from seeking a broader construction during any subsequent litigation by employing arguments or taking positions that contradict those made during
prosecution. Our original assertion that our products and technologies do not infringe on MonoSol’s original patents are only strengthened by the significant narrowing of the claims in

 Confidential Treatment Requested by BioDelivery Sciences International, Inc.

 IRS Employer Identification No. 35-208985 
 Confidential treatment requested with respect to certain portions hereof denoted with 
 “***” 
  

 
both patents. A Reexamination Certificate for the ‘292 Patent in its amended form was issued on July 3, 2012. A Reexamination Certificate for the ‘891 Patent in its amended
form was mailed August 21, 2012. In the ‘588 Patent, the USPTO on July 20, 2012 issued a second Office action closing prosecution. The Action rejects all claims as anticipated or obvious for a second time. It also rejects
the amended claims proposed by MonoSol as unclear and lacking support. 
 It is BDSI Parent’s and BDSI’s position that
they will continue to defend this case vigorously, and they anticipate that MonoSol’s court claims will ultimately be rejected. All claims of MonoSol’s three asserted patents currently stand rejected or significantly narrowed by the USPTO.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]